dbgap_rnaseq_sample	dbgap_dnaseq_sample	dbgap_subject_id	cohort	used_manuscript_analyses	manuscript_dnaseq	manuscript_rnaseq	manuscript_inhibitor	consensus_sex	inferred_sex	reportedRace	reportedEthnicity	inferred_ethnicity	centerID	CEBPA_Biallelic	consensusAMLFusions	ageAtDiagnosis	age_high	isRelapse	isDenovo	isTransformed	specificDxAtAcquisition_MDSMPN	nonAML_MDSMPN_specificDxAtAcquisition	priorMalignancyNonMyeloid	priorMalignancyType	cumulativeChemo	priorMalignancyRadiationTx	priorMDS	priorMDSMoreThanTwoMths	priorMDSMPN	priorMDSMPNMoreThanTwoMths	priorMPN	priorMPNMoreThanTwoMths	dxAtInclusion	specificDxAtInclusion	ELN2017	dxAtSpecimenAcquisition	specificDxAtAcquisition	ageAtSpecimenAcquisition	timeOfSampleCollectionRelativeToInclusion	specimenGroups	diseaseStageAtSpecimenCollection	specimenType	rnaSeq	exomeSeq	totalDrug	analysisRnaSeq	analysisExomeSeq	analysisDrug	cumulativeTreatmentTypeCount	cumulativeTreatmentTypes	cumulativeTreatmentRegimenCount	cumulativeTreatmentRegimens	cumulativeTreatmentStageCount	cumulativeTreatmentStages	responseToInductionTx	typeInductionTx	responseDurationToInductionTx	mostRecentTreatmentType	currentRegimen	currentStage	mostRecentTreatmentDuration	vitalStatus	overallSurvival	causeOfDeath	X..Basophils.in.PB	X..Blasts.in.BM	X..Blasts.in.PB	X..Eosinophils.in.PB	X..Immature.Granulocytes.in.PB	X..Lymphocytes.in.PB	X..Monocytes.in.PB	X..Neutrophils.in.PB	X..Nucleated.RBCs.in.PB	ALT	AST	albumin	creatinine	fabBlastMorphology	hematocrit	hemoglobin	karyotype	LDH	MCV	otherCytogenetics	plateletCount	platelet_high	surfaceAntigensImmunohistochemicalStains	CD7.Pos.	CD33	totalProtein	wbcCount	wbccount_High	FLT3.ITD	allelic_ratio	NPM1	RUNX1	ASXL1	TP53	variantSummary	SF3B1_Mutation	SRSF2_Mutation	U2AF1_Mutation	ZRSR2_Mutation	Splicing_Mutation_either_or_SF3B1_SRSF2_U2AF1_ZRSR2	AML_MDS_wSplicingMachinery_Mutation	Found	IDH2	TET2	DNMT3A	SF3B1_Mut	platelet_high.1	Inv16_Pos	ASXL1_Mutated	TP53_Mutated	RUNX1_Mutated	FLT3_ITD_Mutated	wbccount_High.1	HighInflammation	High_AtypicalBcell	IL18R1_Expression	IL18RAP_Expression	IL1R1_Expression	IL2RB_Expression	IL4R_Expression	CXCL6_Expression	CLEC5A_Expression	IL18R1_high	IL18RAP_high	IL1R1_high	IL2RB_high	IL4R_high	CXCL6_high	CLEC5A_high	Inflammation_Scores						
BA2452R	BA2452D	2157	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			34	#REF!	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	36	574	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)"	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Salvage	43	Dead	595	Dead-Unknown	1	90	30	0	NA	46	30	8	NA	43	11	2.8	0.92	M4	25.5	9.1	"46,XY,add(17)(p13)[19]/46,XY[1]"	123	85	Normal	14	FALSE	"partial CD7, CD13, CD33, CD38, dim CD45, dimCD58, CD117, CD123, and HLA-DR"	TRUE	TRUE	5.8	0.6	FALSE	positive	0.960784314	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	1.816067625	2.436852961	0.872750258	4.332317747	4.264750825	1.124399465	-0.229320236	no	no	no	yes	no	yes	no	0.279352153						
BA2480R		2374	Waves1+2	yes	no	yes	no	Male	Male	Asian	NON-HISPANIC	Asian	1			56	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	309	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	8	"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|3+7 (Cytarabine, Daunorubicin)|Azacitidine|3+3 plus Sorafenib|Clofarabine|Clofarabine, Cytarabine"	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Consolidation	64	Dead	1735	Dead-Disease	0	77.5	75	1	NA	16	1	4	NA	NA	NA	NA	NA	NOS	26.3	9.3	"46,XY[4]"	NA	87.8	Normal	9	FALSE	"CD13, CD33, partial CD56, CD58, CD64, dim CD117, CD123and partial/dim cMPO positive"	FALSE	TRUE	NA	7.9	FALSE	positive	2.448275862	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	2.338827778	3.937987222	6.654599047	5.579354969	5.041039969	-1.138252503	2.688451126	no	yes	yes	yes	no	no	no	0.62561048						
BA3037R		2391	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1			55	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	55	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	707	Dead-Disease	0	88		0	NA	6	0	1	NA	19	26	3.4	0.88	M1	28.2	9.6	"46,XX[20]"	678	99.9	Normal	19	TRUE	"partial CD7, CD13, CD25, CD33, partial CD34, dim CD45, CD117, CD123, and partial HLA-DR positive"	TRUE	TRUE	6.8	17.9	FALSE	positive	NA	positive				FLT3-ITD|NPM1|WT1 (8000/10000 copies (High))					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	2.49376655	3.772117493	1.8714754	3.225490031	6.749627317	0.716051259	-1.636140113	no	yes	no	no	yes	yes	no	0.515793481						
BA2236R	BA2236D	2446	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			54	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	349	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	7	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine"	5	Consolidation|Salvage|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Decitabine	Re-induction	160	Dead	1378	Dead-Disease	3	71	83	2	NA	5	10	4	NA	35	31	3.9	0.81	M4	33.7	11.7	"47,XY,+21[17]/47,idem,t(10;22)(q22;q13)[cp3]/46,XY[1]"	438	100.6	80% Trisomy 21	119	TRUE	"CD13, CD33, CD38, CD58, dim CD64, CD117, and CD123"	FALSE	TRUE	7.1	33.8	TRUE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.753543555	3.620911573	0.598455727	4.574779733	5.596997549	-1.412061693	3.922874998	no	yes	no	yes	no	no	no	0.601911945						
BA2865R		2271	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1			50	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"7+3 (Cytarabine, Idarubicin)|ATRA (Tretinoin)|HiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	27	Bone Marrow Transplant	"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Sibling	-1	Alive	3129	Alive	0	90	82	0	NA	1	0	2	NA	19	30	2.8	0.86	M0 	26.4	9.1	"46,XX,t(11;17)(q13;q21)[20]"	1165	97.7	"While the chromosome 17 breakpoint is clearly within band 17q21 by metaphase chromosome analysis, these results suggest that it is not within the RARA gene"	8	FALSE	"dim CD4, CD13, dim CD15, dim CD33, CD38, CD58,CD64, CD117, CD123, dim HLA-DR, and cMPO"	FALSE	TRUE	5.3	84.1	TRUE	negative	0	positive		CAS		"FLT3 (A680V)|NPM1 (W288fs*12 )|WT1 (5000/10,000 copies)"					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.854913955	1.766538076	-1.367205179	1.883679389	4.97212947	-0.670700712	1.488141969	no	no	no	no	no	yes	no	0.282228058						
BA2003R	BA2003D	2491	Both	no	no	no	no	Female	Female			AdmixedAsian	3			57	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	58	215	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Dead	257	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	positive	2.125	positive				FLT3-ITD|NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	TRUE	TRUE	2.301550208	4.385585013	4.521531936	0.83513308	5.90273863	0.846900161	2.913586334	no	yes	yes	no	no	yes	no	0.601859182						
BA2068R	BA2068D	2469	Waves1+2	yes	yes	yes	yes	Female	Female	Black	NON-HISPANIC	Black	2			64	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Induction	5	Alive	1112	Alive	1.4	76	0	0.1	NA	94.3	1.5	2.7	NA	22	20	3.6	0.48		32.6	10.9	"46,XX[14]"	184	NA	"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],"	32	TRUE	"CD4(few +), CD7(-), CD11b(-), CD13(-), CD14(-), CD15(partial +), CD16(-), CD34(-), CD36(-), CD38(+), CD45(+), CD56(few +), CD64(-), CD117(partial +), HLA-DR(-), MPO(+) and TdT (+)"	TRUE	FALSE	7.5	1.5	FALSE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	3.153795923	3.633583208	0.411929265	4.846678463	3.909462302	-1.436271149	-0.824696888	yes	yes	no	yes	no	no	no	0.49639547						
BA2104R	BA2104D	2378	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			83	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Colon Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	83	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	9	Dead-Disease	0		90	0	NA	9	7	4	NA	242	341	1.9	2.48	M5	17.6	6.2	"47,XY,+8[6]/46,XY[13] (Specimen Source: Blood)"	2037	94.5	trisomy 8 (Specimen Source: Blood)	14	TRUE	"CD11b, CD13, dimCD14, CD15, dim CD16, CD33,     CD56,     CD58, CD64, CD123, and HLA-DR positive"	FALSE	TRUE	3.6	82	TRUE	negative	0	positive				FLT3-D835 (bone marrow)|NPM1 (An insertion mutation is present in exon 12 (near the C-terminus) of NPM.)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	1.500750377	3.993051187	2.754855677	2.865464441	6.958955598	-0.654487552	2.405879253	no	yes	yes	no	yes	yes	no	0.799098298						
BA2449R		2081	Waves1+2	yes	no	yes	yes	Female	Female	White	NON-HISPANIC	White	1		RUNX1-RUNX1T1	7	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	7	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	y	y	n	y	1	Standard Chemotherapy	1	"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)"	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	9	Standard Chemotherapy	"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)"	Re-induction	-1	Dead	158	Dead-Treatment	0	85	30	0	NA	42	0	27	NA	18	19	3.9	0.41	M1	27.7	9.4	"46,XX,t(8;21)(q22;q22)[19]/46,XX[1]"	747	90.5	"91.5% AML/ETO fusion, t(8;21)"	71	TRUE	"CD13, CD33, CD34, CD56, CD71, CD117, HLA-DR, MPO-positive"	TRUE	TRUE	7.3	4.8	FALSE	negative	0	negative				KIT (D816V; MAF 50%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.233074617	2.521438608	2.724935193	2.246470288	6.054486595	0.43652254	6.704229774	no	no	no	no	yes	yes	yes	0.340102977						
BA2802R	BA2802D	2005	Both	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			52	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	"Mixed phenotype acute leukaemia, T/myeloid, NOS"	NonInitial	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	"Mixed phenotype acute leukaemia, T/myeloid, NOS"	53	234	Post-Transplant|Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	"7+3 (Cytarabine, Idarubicin)|Sunitinib|HAM (Cytarabine, Mitoxantrone)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Decitabine|Busulfan, Cyclophosphamide"	5	Salvage|Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	80	Dead	404	Dead-Disease	0	50		0	NA	9	2	29	NA	32	34	3.7	0.68		34	11.1	"45~48,XY,+5,add(5)(q11.2)x2,t(7;7)(q22;q36),+11,add(13)(q13),-22[cp9]/45~47,sl,-add(5)(q11.2),der(11)t(11;12)(p11.2;q13),-12[cp6]/46,sl,t(Y;18)(p11.2;q21),der(9)t(9;17)(p13;q11.2),-17[2]/46,XY[3]"	167	102.8	Deleted 5q	152	TRUE	"partial CD7, CD13, CD33, CD34, partial CD56, CD58, HLA-DR, and partial MPO-positive CD117, CD123,"	TRUE	TRUE	6.7	14	FALSE	negative	0	negative			TP53 (p.V216M; 66.9%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	4.46988803	4.858323673	3.058336328	4.85971091	6.03404287	-0.206871603	2.911273211	yes	yes	yes	yes	no	yes	no	0.566460258						
BA2235R	BA2235D	2407	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			60	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	104	Alive	2801	Alive	0	80		0	NA	11	13	23	NA	32	50	2.9	0.64	M2	41.1	13.4	"46,XX[20]"	660	86.1	normal	228	TRUE	"partial CD7, partial CD11b, CD13, CD33, dim CD45, CD58,     partial CD64, partial CD117, CD123, dimHLA-DR,  MPO positive"	TRUE	TRUE	7.4	53.9	TRUE	negative	0	positive				DNMT3A (p.Q696fs*9; MAF 40% )|IDH1 (p.R132H; MAF 40%)|NPM1 (p.W288fs*12; MAF ~40%)|PTPN11 (p.G503A; MAF 40%)					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.923101348	3.787096119	1.628561585	4.185154904	6.377832333	-1.370552466	3.488623678	no	yes	no	yes	yes	no	no	0.606144873						
BA3006R	BA3006D	2239	Waves1+2	yes	yes	yes	yes	Female	Female			White	3			33	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	33	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|HAM (Cytarabine, Mitoxantrone)"	4	Allogeneic - Sibling|Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Sibling	-1	Dead	439	Dead-Treatment	NA	70.8		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"46,XX[7] "	NA	NA		NA	NA	"increased CD117 positive, partial CD34 positive myeloblasts,   representing approximately 91% of the leukocytes, consistent with acute myeloid leukemia"	FALSE	FALSE	NA	NA	NA	positive	4	positive				FLT3-ITD|NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	FALSE	2.761737646	1.348487816	5.920769628	0.655067771	6.019124465	-0.021355424	0.007648135	no	no	yes	no	no	yes	no	0.405408148						
BA2239R	BA2239D	2326	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			66	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	74	Alive	2756	Alive	0	90		0	NA	14	61	1	NA	19	14	2.4	1.13	M5	23.9	7.9	"46,XY[20]"	387	103.6	normal	122	TRUE	"CD11b, dim/partial CD13, CD14, CD33, CD38, CD58, CD64,     partial CD117, dim/partial CD123, and HLA-DR positive"	FALSE	TRUE	6.3	28	TRUE	negative	0	positive				CREBBP (p.Q2208H; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|NPM1 (W288fs*>9; MAF 50%)|WT1 (rs16754; MAF 50%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	0.410246244	2.123061449	1.206592604	3.341022731	6.675586551	-1.737451065	6.356703151	no	no	no	no	yes	no	yes	0.694817682						
BA2782R	BA2782D	2235	Waves1+2	yes	yes	yes	no	Male	Male			White	3			53	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	752	Dead-Treatment	NA	73	32	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA	"atypical monocytic cells expressing weaker than   normal CD13 and CD33, with increased promonocytes/monoblasts representing approximately 44% of the leukocytes, (and increased atypical CD117 positive, CD34 negative myeloblasts showing weak expression   of aberrant CD7 and representing approximately 14% of the leukocytes)"	TRUE	TRUE	NA	22.79	TRUE	negative	0	positive				NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	1.016825413	2.902452582	1.841768401	2.596764032	6.680157598	-2.69590525	4.275700856	no	no	no	no	yes	no	no	0.841701166						
BA2909R	BA2909D	2509	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NON-HISPANIC	Asian	1		RUNX1-RUNX1T1	8	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	8	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)"	2	Induction|Intensification	Complete Response	Standard Chemotherapy	11	Standard Chemotherapy	"COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)"	Intensification	62	Alive	2662	Alive	0	30		0	NA	33	17	20	NA	NA	NA	NA	0.53	M2	29.3	10.3	"46,XY,t(8;21)(q22;q22)[5]/46,idem,der(7)t(7;8)(q22;q11.2)[13]/46,XY[2]"	NA	93.5	t(8;21) (34%) | t(8;21) and der(7)t(7;8) (56%) | Missing D7S486 signal (70%)	109	TRUE	"dim CD7, CD13, CD33, CD34, CD38, partial CD56,CD58, CD117, CD123, dim HLA-DR, and MPO"	TRUE	TRUE	NA	19.5	FALSE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.16243646	5.358145436	3.673523703	4.148754191	7.113624892	-0.023417433	8.32412391	yes	yes	yes	yes	yes	yes	yes	0.67302201						
BA2653R	BA2653D	2191	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1	mono		42	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute megakaryoblastic leukaemia	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)"	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Re-induction	4	Dead	273	Dead-Disease	0	70		0	NA	43	6	38	NA	36	28	3.5	0.81	M7	34.8	12		762	85.2	"Extra signals were observed for BCR (22q11.2), PML (15q22), MLL (11q23),     RUNX1T1 (8q21.3) and RUNX1 (21q22) in roughly 45-60% of interphase cells.     These results suggest the presence of a hyperdiploid clone."	13	FALSE	"CD7, CD13, CD33, CD58, partial CD61, CD71, and Factor 8 positive"	TRUE	TRUE	6.8	7.9	FALSE	negative	0	negative				CEBPA (p.V119?M120insV; MAF 30% )					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.03785813	6.935583178	2.166424144	5.687960815	7.136714052	2.747269925	3.229681125	yes	yes	no	yes	yes	yes	no	0.783529552						
BA2947R		2506	Waves1+2	yes	no	yes	yes	Male	Male	White	NON-HISPANIC	White	1		RUNX1-RUNX1T1	14	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	1	"COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)"	1	Induction	Complete Response	Standard Chemotherapy	133	Standard Chemotherapy	"COG-AAML0531 (Cytarabine, Daunorubicin, Etoposide, L-Asparaginase, Mitoxantrone +/- Gemtuzumab)"	Induction	133	Alive	2487	Alive	0	62	64	0	NA	28	1	7	NA	15	9	4.1	0.58	M2	18.5	6.3	"45,X,-Y,t(8;21)(q22;q22)[4]/45,idem,del(9)(q12q22)[13]/46,XY[3]"	486	105.8	RUNX1T1/ RUNX1 fusion and t(8;21) (94%)	63	TRUE	"CD13, CD33, CD34, dim CD45, partial CD56, CD58, dim CD117, HLA-DR, MPO, and partial TdT-positive"	FALSE	TRUE	7.9	13.3	FALSE	negative	0	negative				TP53 (p.S366A; MAF 50% )					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	1.619820405	2.893539278	-2.32040487	3.112175422	6.400748588	-1.212051012	7.056474872	no	no	no	no	yes	no	yes	0.489287083						
BA2032R	BA2032D	2022	Waves1+2	yes	yes	yes	yes	Female	Female			White	2			64	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	"Crenolanib|MEC, plexifor, GCSF|Sorafenib|7+3 (Cytarabine, Idarubicin) plus LBH|Clofarabine, Cytarabine"	4	Salvage|Induction|Experimental|Re-induction	Refractory	Standard Chemotherapy	21	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	124	Dead	455	Dead-Disease	NA	81	94	NA	NA	6	NA	NA	NA	87	47	2.8	0.53		27.2	9.7	"46,XX,t(3;11)(q21;p11.2),t(15;15)(q15;q22)[19]/46,XX,t(2;14)(q21;q11.2)[2]"	743	NA	"nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2 (5'MLL con 3'MLLx2)[198],(PML,RARA)x2[199],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	11	FALSE	"CD7(partial +), CD15(partial +), CD33(bright +), CD34(partial +), CD45(+), and CD117(variably +). (80% population of variably-sized cells)"	TRUE	TRUE	5.2	26	TRUE	positive	15.66666667	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	5.337218856	1.982276333	5.748225876	3.64476359	6.667811052	2.445112797	1.097609056	yes	no	yes	no	yes	yes	no	0.558480086						
BA2106R	BA2106D	2055	Waves1+2	yes	yes	yes	yes	Female	Female			White	4			35	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	37	1	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI"	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Re-induction	53	Dead	761	Dead-Disease	NA	92	97	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	"46,XX[5]"	NA	NA		NA	NA	"CD45, DIM CD64, DIM CD13, DIM CD33, CD15, CD38, MPO, CD11C, DIM CD4, DIM PARTIAL CD19, CD117, AND HLA-DR"	FALSE	TRUE	NA	140	TRUE	negative	0	positive				FLT3-D835|IDH1|NPM1					no		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	1.368503796	0.741906919	-1.303085909	2.128709626	3.333194398	1.054184415	-0.821921733	no	no	no	no	no	yes	no	0.251968687						
BA2939R		2055	Waves1+2	no	no	no	no	Female	Female			White	4			35	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	37	160	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cyclophosphamide, Etoposide, TBI"	5	Allogeneic - Sibling|Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Re-induction	53	Dead	761	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	"46,XX[5]"	NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	2.141679992	2.080985544	-0.492659737	3.596142745	3.347740082	0.725196498	-0.249756304	no	no	no	no	no	yes	no	0.282270342						
BA2525R	BA2525D	2543	Waves1+2	yes	yes	yes	yes	Female	Female			White	4			72	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"Azacitidine, Lenalidomide|Temozolomide, Vorinostat"	2	Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"Temozolomide, Vorinostat"	Re-induction	-1	Dead	420	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX,del(5)(q31q35),inv(7)(p15q32),del(12)(q?15)[2]/45~46,idem,add(3)(q27),-9,-del(12)(q?15),+add(12)(q13),-16,-17,+mar1,+mar2x2[cp16]/46,XX[2]"	NA	NA		NA	NA		NA	NA	NA	NA	NA	positive	0.538461538	positive			TP53	TP53					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	TRUE	NA	FALSE	TRUE	6.870847832	7.072510297	0.340080739	7.378746611	7.106932866	-2.850011737	2.501327532	yes	yes	no	yes	yes	no	no	0.593000289						
BA2546R	BA2546D	2259	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|Decitabine|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Consolidation	-1	Dead	228	Dead-Treatment	1.8	51		0.9	NA	41.2	37.7	11.4	0	20	20	3.2	1.37	M4	33.7	11	"42~45,XY,del(4)(q31q35),del(5)(q13q35),add(9)(q21),add(13)(p11.2),-16,-21[cp15]/40~46,sl,+9,-add(9)(q21),-15,+der(16)t(15;16)(q11.1;p13.3),-18,+mar[cp5]"	NA	92.6	Extra MLL signal (5%) | 5q deletion (95%) | Abnormal 9q (33%) | Partial deletion of RUNX1 (34%)	24	TRUE	"CD13, CD33, CD34, CD56, CD58, dim CD64, CD117 and partial HLA-DR."	FALSE	TRUE	7.1	5.23	FALSE	negative	0	negative			TP53 (p.X307_splice; 46.6%)|TP53 (p.R273S; 40.4%)	"TP53 (Intron 7, 5' splice site mutation; MAF 40%)|TP53 (p.R273S; MAF 40%)"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	4.074385753	4.637752326	4.091937332	4.841081905	5.843920428	-0.173595676	6.662326941	yes	yes	yes	yes	no	yes	yes	0.735491748						
BA2910R	BA2910D	2261	Waves1+2	yes	yes	yes	yes	Female	Female			White	2			79	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	79	0	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	"7+3 (Cytarabine, Idarubicin)|Crenolanib"	2	Induction|Experimental	Complete Response	Standard Chemotherapy	4	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	14	Dead	124	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA		NA	NA	NA	NA	NA	positive	0.470588235	positive				FLT3-ITD (High level (>50%))|NPM1 (Positive for insertion mutation in exon 12)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	FALSE	4.194089346	2.333922722	2.391874654	3.428475056	6.160031709	2.239092599	-0.827405877	yes	no	no	no	yes	yes	no	0.50329059						
BA3178R		2789	Waves3+4	yes	no	yes	no	Male	Male				3		MLLT3-KMT2A	71	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	71	7	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)"	3	Consolidation|Induction|Re-induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	"CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)"	Re-induction	-1	Dead	179	Dead-Disease	NA	84.2	93	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5a	NA	NA	"49,XY,+8,+8,t(9;11)(p22;q23),+der(9)t(9;11)"	NA	NA	"8q22 (RUNX1T1): gain of two copies present  11q23 (MLL): rearrangement present (95% RUNX, 91% MLL)"	NA	NA	"CD4+, CD33+, CD117+, HLA-DR+ myeloblasts"	FALSE	TRUE	NA	93.46	TRUE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	0.370450274	0.827628838	-0.392107614	2.324649572	4.711215377	-2.063108614	-1.463854919	no	no	no	no	no	no	no	0.359656043						
BA3029R	BA3029D	2079	Waves1+2	yes	yes	yes	no	Male	Male			White	2			62	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide"	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	Dead	568	Dead-Unknown	0	81	59	0	NA	0	0	10	NA	34	15	4	NA		30.2	10.7	"46,XY"	NA	NA		17	TRUE	"CD2(-), CD4(dim +), CD10(-), CD11b(-), CD13(+), CD14(-), CD15(variably +), CD16(-), CD33(bright +), CD34(-), CD36(-), CD38(+), CD45(moderately +), CD56(-), CD64 (partial +), CD117(variably +), HLA-DR(-), MPO(+), TdT(-)."	FALSE	TRUE	6	1.8	FALSE	positive	10.11111111	positive				"CCND3 (Foundation, P203S; MAF 8%)|CHEK2 (Foundation; T367fs*15; MAF 9%)|DNMT3A (Foundation, R882H; MAF 9%)|FLT3 (Foundation, Y591_V592INSVDFREYEYDLKWEFPRENLEFD; MAF 13%)|NPM1 (Foundation; W288fs*10+;MAF 8%)"					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	3.847392747	3.294414242	4.526233338	5.156329382	5.997243165	0.95732621	-0.540513338	yes	no	yes	yes	no	yes	no	0.483484389						
BA2735R	BA2735D	2079	Waves1+2	no	no	no	no	Male	Male			White	2			62	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	254	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Crenolanib|Clofarabine, Cytarabine|Busulfan, Cyclophosphamide"	5	Consolidation|Induction|Experimental|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	24	Targeted Therapy - Kinase Inhibitor(s)	Crenolanib	Experimental	141	Dead	568	Dead-Unknown	NA			NA	NA	NA	NA	NA	NA	23	26	2.9	NA		27.9	9.6	"45,XY,der(12;16)(q10;p10)[2]/46,XY[18]"	NA	NA	"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2) [200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x1(5'CBFB con 3'CBFBx1)[31/200]"	30	FALSE		NA	NA	5	27.4	TRUE	positive	5.666666667	positive				CCND3 (P203S; MAF unlisted)|CHEK2 (T367fs*15; MAF unlisted)|DNMT3A (R882H; MAF unlisted)|FLT3-ITD|NPM1 (W288fs*10+; MAF unlisted)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	6.815699908	6.385505936	5.096709014	2.632459474	6.677802347	1.929655182	1.471277842	yes	yes	yes	no	yes	yes	no	0.593742526						
BA2069R	BA2069D	2179	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1		MLLT3-KMT2A	55	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Decitabine"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Salvage	4	Dead	246	Dead-Disease	1.4	75	23	8.5	NA	11.4	8.5	34	0.2	62	31	3.8	1.44	M5	38.1	12.2	"46,XY,t(9;11)(p22;q23)[20]"	497	87.6	MLL rearrangement and t(9;11) (86%)	32	TRUE	"CD11b, partial CD13, CD33, CD38, CD56, CD58, CD64, partial CD117, CD123, and HLA-DR+ "	FALSE	TRUE	7.9	10.21	FALSE	positive	1.083333333	positive				No gene mutations found in the 43 genes tested					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	0.020492332	1.582482866	0.884640282	2.897727105	5.660519196	-4.162213222	1.706922136	no	no	no	no	no	no	no	0.49858318						
BA2634R	BA2634D	2047	Waves1+2	yes	yes	yes	yes	Male	Male			White	3			74	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with maturation	75	0	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Etoposide, Mitoxantrone"	3	Hypomethylating/Low Dose Cytarabine|Salvage|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Salvage	-1	Dead	415	Dead-Disease	NA	60.1		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"46,XY,add(1)(p34),del(7)(q22),del(20)(q11.2)[20]"	NA	NA	"normal, no evidence of RUNX1T1/RUNX1 transloc or 11q23 or 16q22"	NA	NA	"Increased CD34 positive myeloblasts, representing approximately 55% of the leukocytes"	FALSE	FALSE	NA	NA	NA	positive	1.941176471	negative									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	TRUE	TRUE	6.383067824	6.534480568	3.062997067	5.715903043	6.301423724	-1.367205179	4.554520229	yes	yes	yes	yes	yes	no	yes	0.667183732						
BA2937R	BA2937D	2212	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			61	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|Hydroxyurea|Busulfan, Cyclophosphamide"	5	Allogeneic - Sibling|Salvage|Induction|Re-induction|Symptom Control	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Sibling	-1	Dead	213	Dead-Treatment	0	25	20	13	NA	6	12	55	0.9	45	34	3.1	0.8		31.1	9.8	"42~44,XY,t(1;10)(q12;q21),-5,-7,-11,add(13)(p11.1),der(18)t(11;18)(q14;q21.1),add(20)(q12),+1~3mar[cp4]/41~44,sl,add(4)(q23)[cp9]/41~44,sl,del(4)(q21q?27)[cp5]/41~42,"	NA	88.9	Monosomy 5 (52%) | 5p deletion (39%) | Monosomy 7 (48%) | Abnormal 7q arm (48%)	243	TRUE	"CD13, CD33,CD34, CD38, dimCD56, CD58, CD117, and HLA-DR+"	FALSE	TRUE	6.4	96.64	TRUE	negative	0	negative			TP53 (p.R248Q; 96.4%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	5.765687009	6.385991643	3.921638856	3.922044406	6.468245227	0.635764115	6.649159646	yes	yes	yes	yes	yes	yes	yes	0.76612443						
BA2019R	BA2019D	2365	Waves1+2	yes	yes	yes	no	Male	Male			HispNative	3			39	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	T lymphoblastic leukaemia/lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	39	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	7	"Nelarabine|POMP (Prednisone, Methotrexate, 6-MP, Vincristine)|3+7 (Cytarabine, Daunorubicin)|HyperCVAD|Azacitidine|GCLAC (GCSF, Clofarabine & Cytarabine)|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)"	5	Hypomethylating/Low Dose Cytarabine|Salvage|Induction|Maintenance|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"GCLAC (GCSF, Clofarabine & Cytarabine)"	Re-induction	-1	Dead	169	Dead-Disease	NA	59.3	28	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,t(10;11)(p13;q14)[11]/45,sl,-Y[7]/46,sdl1,t(1;8)(q12;p21)[2]"	NA	NA	Normal	NA	NA	"Increased atypical myeloblasts (partial CD34+, weak CD7+, partial CD61+), representing approximately 91% of the leukocytes, consistent with persistent acute myeloid leukemia."	TRUE	FALSE	NA	1.7	FALSE	negative	0	negative			TP53 (p.R282W; 72.5%)						no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	3.911949968	2.623482227	1.990437336	3.137136059	5.337919529	-3.286356894	1.382955476	yes	no	no	no	no	no	no	0.515085149						
BA2412R	BA2412D	2260	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			85	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	86	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	169	Dead	333	Dead-Disease	0			0	NA	17	44	39	0	15	9	3.5	0.9	M5	25.7	8.2		175	88		18	TRUE		NA	NA	6.9	13.22	FALSE	negative	0	negative			TP53 (p.R248W; 72.2%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	4.451365321	5.972010448	3.448025032	5.716694706	6.879120863	1.539016813	6.065967418	yes	yes	yes	yes	yes	yes	yes	0.879809304						
BA2418R	BA2418D	2405	Waves1+2	yes	yes	yes	no	Female	Female			White	2			47	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	2	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	"Crenolanib|MEC (Cytarabine, Etoposide, Mitoxantrone)"	2	Salvage|Experimental			NA	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Salvage	4	Dead	934	Dead-Unknown	0	84	72	0	NA	28	0	0	NA	10	17	2.8	0.56		14.5	5.3		291	NA		10	TRUE		NA	NA	5.1	1.2	FALSE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	3.440981737	2.888840019	1.964440872	5.193067466	5.499811476	0.061899566	-2.713314441	yes	no	no	yes	no	yes	no	0.372084619						
BA2294R	BA2294D	2499	Waves1+2	yes	yes	yes	yes	Female	Male			HispNative	4		RUNX1-RUNX1T1	62	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Induction	-1	Alive	239	Alive	NA	52	57	NA	NA	NA	6	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,t(8;21)(q22;q22)[14]"	NA	NA		NA	NA	"CD34, PARTIAL CD38, CD33, CD13, CD64, PARTIAL CD11C, PARTIAL CD19, HLA-DR, PARTIAL CD15, CD117, AND MPO"	FALSE	TRUE	NA	12.9	FALSE	negative	0	negative				NRAS					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	3.168114613	4.187944625	-0.973688092	5.015316954	6.272022849	0.068042127	7.265037787	yes	yes	no	yes	yes	yes	yes	0.629133063						
BA2814R	BA2814D	2539	Waves1+2	yes	yes	yes	yes	Male	Male			White	3		MLLT3-KMT2A	62	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"7+3 (Cytarabine, Idarubicin)|Fludarabine, TBI|MiDAC|FATE Trial RIC (Fludarabine, Melphalan, Rabbit ATG) |ODSH (2 O, 3-O Desulfated Heparin) "	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, TBI"	Allogeneic - Matched Unrelated Donor	-1	Dead	979	Dead-Disease	NA	93	58	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5a	NA	NA	"47,XY,+8,t(9;11)(p21;q23)[9]/46,XY[11]"	NA	NA	"8q22 (RUNX1T1): gain present  11q23 (MLL): rearrangement present (83.5% 11q23, 84.5% 8q22)"	NA	NA	"Large population of promonocytes/monoblasts that represent approximately 88% of the leukocytes, consider acute monoblastic leukemia."	FALSE	FALSE	NA	14.66	FALSE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.348487816	1.139679676	3.23020313	1.949289437	6.369828867	-2.671580925	2.228584264	no	no	yes	no	yes	no	no	0.547471103						
BA2631R	BA2631D	2369	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			60	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	114	Alive	2769	Alive	0.8	30	55	4.5	NA	19.7	8.3	15.9	0.3	49	23	3.5	1.22	M2	30.6	10.6	"46,XY[21]"	536	95.6	Normal	141	TRUE	"CD7, CD13, CD33, partial CD34, CD38, CD58, CD117, CD123,HLA-DR, and MPO positive"	TRUE	TRUE	7.2	11.93	FALSE	negative	0	positive				CEBPA (p. Q83fs*27 (c.245?246insTGTTCCA); MAF 50%)|FLT3 ( p.N841I; MAF 12%)|FLT3 (p.I836delI; MAF 25%)|NPM1 (p.W288fs*>9; MAF 40%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.054788152	2.739328747	-0.261236045	3.964635524	5.3404797	-0.625770429	6.179899465	no	no	no	yes	no	yes	yes	0.467968197						
BA2485R		2540	Waves1+2	yes	no	yes	no	Male	Male	Multiracial	HISPANIC	HispNative	1			56	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	n	n	y	n	n	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Consolidation|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	111	Alive	1389	Alive	0.8	95		0	NA	25.6	0	0	0.7	27	16	3.4	0.97	M1	11.1	3.7	"46,XY[20]"	314	95.7	Normal	20	FALSE	"CD13, CD33, CD38, partial CD56 (7%), CD58, CD117, CD123, and partial MPO positive"	FALSE	TRUE	7.1	13.26	FALSE	positive	NA	positive				FLT3-ITD (Internal tandem duplication; MAF: 40%)|IDH2 (p.R140Q; MAF: 50%)|NPM1 (p.W288fs*9; MAF: 40%)					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	3.768072434	0.478564734	0.965478501	1.452270628	4.575134679	-1.813378709	-0.883218417	yes	no	no	no	no	no	no	0.264187353						
BA2455R	BA2455D	2373	Waves1+2	yes	yes	yes	no	Male	Male			White	4			72	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	33	Dead-Disease	NA	94	71	NA	NA	NA	0	NA	NA	NA	NA	NA	NA	M5	NA	NA	"48,XYY,+8[21]"	NA	NA		NA	NA	"CD38, CD56, CD13(dim), CD64, CD11c, CD4, CD56, HLA-DR, and CD15"	FALSE	FALSE	NA	24.2	TRUE	negative	0	positive				FLT3-D835|NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	0.764705649	2.134894412	2.13094475	3.687560228	5.863798374	-1.471201234	0.95732621	no	no	no	no	no	no	no	0.605926081						
BA2325R	BA2325D	2492	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1			74	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"3+7 (Cytarabine, Daunorubicin)"	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"3+7 (Cytarabine, Daunorubicin)"	Induction	6	Alive	29	Alive	0.9	60	9	0	NA	11.4	44.7	35.1	7.1	17	28	2.6	0.79	M4	28.1	9.4	"46, XX,t(2;16)(p23;p13.3)(13) "	645	98.3		71	TRUE	"CD13, CD14, CD16, CD33, CD64 and HLA-DR"	FALSE	TRUE	6.2	35.91	TRUE	negative	0	positive				NPM1 (p.W288fs*>9 (C-terminal frame-shift); MAF 44%)|PTPN11 (p.E76Q; MAF 40%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.728098026	4.852632498	3.5765847	4.271957484	6.67173083	-0.093173525	6.021607404	no	yes	yes	yes	yes	yes	yes	0.859723913						
BA2871R	BA2871D	2273	Waves1+2	yes	yes	yes	no	Female	Female			White	3			80	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	80	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Unknown	1	Bevacizumab	1	Unknown			NA	Unknown	Bevacizumab	Unknown	-1	Dead	10	Dead-Disease	NA	84		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"44-47,XX,del(5)(q13q33),der(14;18)(q10;q10),-20,-21,+1-4mar[cp15]"	NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	negative			TP53 (p.R306*; 28.8%)|TP53 (p.X187_splice; 21.9%)						no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	TRUE	5.555868047	6.16270218	2.747269925	8.416089831	6.311620981	-3.363664044	3.885891201	yes	yes	yes	yes	yes	no	no	0.754419174						
BA2125R	BA2125D	2562	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			71	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|Azacitidine, Lenalidomide|Decitabine"	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"Azacitidine, Lenalidomide"	Re-induction	28	Dead	295	Dead-Disease	0	46	49.1	0	NA	20.5	8	17	0.9	32	39	3.3	0.73	M2	20.7	6.4	"42~45,XX,add(5)(q13),der(17)add(17)(p11.2)add(17)(q11.2),-18,-22[cp6]/43~44,sl,add(13)(q32),add(14)(q11.2),+mar[cp12]/43~44,sl,add(14)(q11.2),-21, "	685	79	5q deletion (85%) | Loss of RARA on 17q21 (46%)	11	FALSE	"partial CD7, CD13, partial CD33, CD34, partial CD38, CD58, CD117, dim/partial CD123, partial TdT, HLA-DR positive."	TRUE	TRUE	6.6	12.87	FALSE	negative	0	negative			TP53 (p.V173M; 77.4%)	SUZ12 (V186D)|TP53 (V173M; MAF 80%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	4.235093564	4.113058746	3.615338297	4.788201595	6.115037183	-4.318740899	4.52552363	yes	yes	yes	yes	yes	no	yes	0.608785627						
BA2603R	BA2603D	2314	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			63	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	2438	Alive	1.7	29	14	0.8	NA	9.4	28.2	49.6	1.6	18	26	2.8	0.74	M4	21.2	7.3	"46,XX[20]"	514	101.4	Normal	57	TRUE	"CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and MPO positive (Myeloid blast phenotype) | CD11b, variable CD13, CD14, CD33, dimCD56, CD64, HLA-DR-positive (Monocytic phenotype)"	FALSE	TRUE	6.1	63.75	TRUE	negative	0	positive				CREBBP (p.V319I; MAF 50%)|DNMT3A (p.R882H; MAF 50%)|DNMT3A (p.T138I; MAF 50%)|NPM1 (p.W288fs*12; MAF 50%)|NRAS (p.Q61H; MAF 40%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.777728307	4.800439135	2.616268835	2.55995121	6.889932081	-1.276942076	6.933559364	no	yes	no	no	yes	no	yes	0.563621081						
BA2822R	BA2822D	2227	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			37	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	38	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	2	"7+3 (Cytarabine, Idarubicin)|Azacitidine"	2	Induction|Maintenance	Refractory	Standard Chemotherapy	6	Supportive/Palliative Care	Azacitidine	Maintenance	-1	Dead	207	Dead-Disease	0		95	0	NA	0.9	0	0	0.1	17	56	1.8	0.6		23	7.9	"48~54,XY,add(2)(p13),+5,add(5)(q13),del(5)(q13),+10,+11,+13,+13,del(13)(q32),+14,-15,-16,del(17)(p12),-20,+21,+21,+22,+mar[cp9]/49~52,sl,-del(17)(p12)[cp8]/51~54,sl"	NA	86.8	Extra chromosome 5 (98%) | 5q deletion (98%) | Monosomy 16 (93%) | Extra copies of chromosome 21 (63%) | Monosomy 17 (99%) | Extra chromosome 11 (99%)	20	TRUE	"CD10, CD13, CD33, CD34, CD56 and HLA-DR positive"	FALSE	TRUE	5.3	38.47	TRUE	negative	0	negative			TP53 (p.R273H; 90.9%)	"NRAS (p.G13D, MAF 46%)|TP53 (p.R273H, MAF 96%)"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	3.678111865	1.78647363	1.567397786	1.695502181	4.817948795	-0.358388936	4.500292914	yes	no	no	no	no	yes	yes	0.366045378						
BA2594R	BA2594D	2554	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			72	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Other malignant neoplasm without specification of site	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Decitabine	3	Consolidation|Induction|Maintenance	Unknown	Standard Chemotherapy	38	Standard Chemotherapy	Azacitidine	Maintenance	36	Dead	252	Dead-Disease	0	55	46	0	NA	27.8	27	20.6	0	32	31	2.2	1.37	M4	20.6	6.6	"43~44,X,-Y,t(3;11)(p21.3;p11.2),del(5)(q11.1;q31.1),add(12)(p11.2),-21[cp17]/44~45,idem,-t(3;11),+9[cp4]"	435	85.8	Previous FISH results were consistent with the deleted 5q and trisomy 9	33	TRUE	"CD13, CD33, CD34, partial CD56,variable CD117, dim CD123, and dim HLA-DR+"	FALSE	TRUE	5.9	20.82	FALSE	negative	0	negative			TP53 (p.H193R; 90.7%)	TP53 (p.H193R; MAF 92%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	5.208309749	5.790454551	4.566214579	4.400700402	6.884920678	1.273501254	6.550271563	yes	yes	yes	yes	yes	yes	yes	0.682889244						
BA2474R	BA2474D	2029	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			46	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC"	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Re-induction	4	Dead	1373	Dead-Disease	0	80		1.6	NA	9.9	14.9	10.7	0	52	28	2.5	0.77	M4	25.2	8.4	"46,XX[20]"	550	88.1	Normal	107	TRUE	"dim CD11b, CD13, CD33, partial CD34, dim CD45, dim CD64, CD117, CD123, and dim HLA-DR+"	FALSE	TRUE	6.3	57.23	TRUE	negative	0	positive				DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PTPN11 (p.E76Q; MAF 40%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	2.261333777	3.322963546	0.349158084	3.673523703	5.93252196	-1.565142279	4.931220233	no	no	no	no	no	no	yes	0.614384507						
BA2065R	BA2065D	2029	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1			46	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	424	Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	"7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC"	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Re-induction	4	Dead	1373	Dead-Disease	0	70	59	3.5	0.9	17.7	0	13.3	0	184	77	2.8	0.72	M4	37	12.6	"46,XX[20]"	NA	94.4	Normal	138	TRUE	"CD13, CD33, partial CD34, partial CD38, dim partial  CD64, CD117 and CD123 positive"	FALSE	TRUE	5.7	16.95	FALSE	negative	0	positive				DNMT3A (p.R882C; MAF 39%)|NPM1 (p.W288fs*>9 ; MAF 39%)|PTPN11 (p.E76Q; MAF 41%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.742431412	1.295814481	-0.404193883	3.212667677	5.603072247	-0.871720723	2.331714407	no	no	no	no	no	yes	no	0.55872906						
BA2737R		2241	Waves1+2	yes	no	yes	yes	Female	Female			White	2		RUNX1-RUNX1T1	57	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea"	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	"Decitabine, Hydroxyurea"	Supportive/Palliative Care	-1	Dead	138	Dead-Unknown	0	76	79	0	NA	9	5	4	NA	45	41	3.2	NA		28.6	9.6	"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1] "	NA	NA	"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	64	FALSE	"CD2(-), CD4(+), CD5(equivocal), CD7(-), CD11b(+), CD13(-), CD14(partial +), CD15(+), CD16(-), CD33 (bright +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56(+), CD64(+), CD117(partial +), HLA-DR(+)"	TRUE	TRUE	6.3	19.5	FALSE	negative	0	negative	RUNX1 (Y414*; MAF 16%)			CREBBP (MYST3-CREBBP fusion; MAF unlisted)|RUNX1 (Y414*; MAF 16%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	2.356536176	2.586312112	-0.863064	4.069641909	5.659007204	-1.539633623	4.273087929	no	no	no	yes	no	no	no	0.567942866						
BA2463R		2241	Waves1+2	no	no	no	no	Female	Female			White	2		RUNX1-RUNX1T1	57	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	58	111	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	n	y	y	n	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|Decitabine, Hydroxyurea"	4	Consolidation|Induction|Re-induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	"Decitabine, Hydroxyurea"	Supportive/Palliative Care	-1	Dead	138	Dead-Unknown	0	N/A	58	0	NA	14	3	19	NA	24	116	3.7	NA		21.4	7.7	"46~47,XX,t(1;11)(p34;p15),der(8)del(8)(p11.2p23)t(1;8)(q21;q24.3),add(9)(q34),del(9)(q13q22),add(16)(p13.3),+1~2mar[cp11] /47~48,idem,+13[cp2]/47~48,idem,-13,der(21)t(8;21)(q13;p12),+2~3mar[cp6]/46,XX[1]"	NA	NA	"nuc ish(D5S721,D5S23,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200], (5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[199],(RUNX1T1x3,RUNX1x2)[69/200]/(RUNX1T1x2,RUNX1x3)[7/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	10	FALSE	"CD2(-), CD4(+), CD7(-), CD11b(partial +), CD13(partial +), CD14(partial +),CD15(variably +), CD16(-), CD33(variably +), CD34(-), CD36(+), CD38(variably +), CD45(variably +), CD56 (variable +), CD64(partial +), CD117(-), HLA-DR(+)."	TRUE	TRUE	6	11.2	FALSE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	0.23878428	2.293575033	0.417200903	2.996165962	4.458296907	-2.539470233	3.238076097	no	no	no	no	no	no	no	0.604764593						
BA2110R	BA2110D	2305	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Fludarabine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC"	4	Consolidation|Salvage|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Fludarabine	Consolidation	4	Dead	439	Dead-Disease	0.1	70		0.1	1.7	8.3	85.2	4.6	0.2	16	13	2.7	0.87	M4	30.4	9.6	"46,XX[20]"	506	101.7	Normal	112	TRUE	"CD11b, partial CD13, partial CD14, dim CD15, partial      CD16, CD33, CD38, CD58, CD64, partial CD123 and HLA-DR positive"	FALSE	TRUE	7.4	58.86	TRUE	positive	NA	positive				DNMT3A ( p.R882H; MAF 50%)|FLT3-ITD (MAF 10%)|FLT3-N676K (MAF 12%)|NPM1 (p.W288fs*12; MAF 50%)|PTPN11 (p.F71L; MAF 14%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	2.321125304	2.984199528	1.332427638	3.309577828	6.644646271	-0.437848975	5.236379786	no	no	no	no	yes	yes	yes	0.796803233						
BA2220R	BA2220D	2394	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			23	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mediastinum mass	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	23	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) "	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	Dead	318	Dead-Disease	3.2	3	30	2.1	NA	25.8	1.1	36.6	43.4	32	131	3	0.91	M6b	17.9	5.7	"48,XY,add(6)(p22),der(7)t(7;19)(p11.1;p12),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp20]"	16499	95.2	Low-level tetraploidy or near-tetraploidy (5%)	24	FALSE		NA	NA	5.6	40.76	TRUE	negative	0	negative			TP53 (p.G245S; 83.1%)	NRAS (p.G12C; MAF 86%)|TP53 (p.G245S; MAF 87%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	3.694815097	2.989978183	2.263488224	4.178644794	5.088705654	0.282808392	3.706178281	yes	no	no	yes	no	yes	no	0.510560757						
BA2720R	BA2720D	2394	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			23	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Mediastinum mass	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	24	163	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	"Trametinib|HAEP (Cytarabine, Etoposide, Cisplatin) "	3	Consolidation|Induction|Experimental	Complete Response	Standard Chemotherapy	8	Targeted Therapy - Kinase Inhibitor(s)	Trametinib	Experimental	197	Dead	318	Dead-Disease	0	5	10	0	2.9	36.2	1.5	47.8	NA	30	146	3.4	0.82	M6b	25.5	7.9	"48,XY,add(6)(p22),der(7)t(7;19)(p11.2;p12),del(9)(p13p22),i(13)(q10)x2,add(14)(q24),+mar1,+mar2[cp2]/46~48,sl,add(17)(p1?3),add(22)(q13)[cp9]/46~48,sl,add(21)(p11.2)[cp6]/47~48,sl,add(1)(p36.1)[cp2]/48,sl,t(2;17)(p21;p11.2)[1]"	NA	98.5	Low-level tetraploidy or near-tetraploidy	48	TRUE	"A CD34 positive blasts population comprises approximately 4% of cellular gated events. Approximately 3% of cells are lymphocytes composed of 28% B cells, 45% T cells and 27% NK cells. | T cells are present in a CD4:CD8 ratio of about 1.1:1 and do not demonstrate aberrant antigen expression. A monoclonal B cell population is not identified."	FALSE	FALSE	6.1	11.28	FALSE	negative	0	negative			TP53 (p.G245S; 89.1%)	NRAS (p.G12C; MAF 97%)|TP53 (p.G245S; MAF 96%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	2.993923877	4.603307764	3.185942568	5.45014856	5.897651351	0.144506183	2.746048812	yes	yes	yes	yes	no	yes	no	0.624151388						
BA2772R	BA2772D	2397	Waves1+2	yes	yes	yes	no	Male	Male			HispNative	2			61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	5	Standard Chemotherapy	HiDAC	Consolidation	5	Alive	71	Alive	1	81	68	NA	NA	5	2	2	NA	85	52	3.1	0.85		28.8	10.1	"46,XY[20]"	1205	NA	"nuc ish(D4Z1,D10Z1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200]"	20	FALSE	"CD2(-),CD4(partial dim +), CD7(-), CD11b(few +), CD13(+), CD14(-), CD15(partialCD22(-), CD25(appears partial dim +), CD33(bright +), CD34(few +), CD36(-), CD38(variable +), CD45(moderately +), CD56(-), CD64(partial +), CD79a(-), CD117(+), CD123(partial +), HLA-DR(partial +), MPO(+), TdT(-)."	TRUE	TRUE	6.2	152.75	TRUE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.814322082	1.825951595	1.564264587	1.934965274	5.36365752	-0.157247813	6.77834046	no	no	no	no	no	yes	yes	0.459999623						
BA3296R	BA3296D	2684	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			18	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	B lymphoblastic leukaemia/lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid sarcoma	18	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy|Post-Transplant	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	3	"GCLAM (G-CSF, Cladribine, Cytarabine, and Mitoxantrone) |Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|Radiation"	2	Re-induction|Allogeneic - Matched Unrelated Donor			NA	Bone Marrow Transplant	"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)"	Allogeneic - Matched Unrelated Donor	-1	Dead	336	Dead-Treatment	0.6	0.5	0	0.4	NA	15.6	6.3	75.6	0	32	27	4.6	0.78		44	15.5	"46,XY[20] "	NA	89.4	"MLL (11q23):  88% of cells had a 0r1g1f split signal pattern consistent with rearrangement|9p21: 76% of cells were missing both signals for 9p21, consistent with homozygous deletion of 9p21|ETV6 (12p13): 68% of cells had an extra signal for ETV6 (Solid Tissue/Skin)"	291	TRUE	"CD43, CD68, CD163 (weak) and lysozyme positive (Solid Tissue/Skin)"	FALSE	FALSE	7.5	13.67	FALSE	negative	0	negative				EP300 (p.P318A (possible germline polymorphism); MAF 41%)|FAM5C (p.R353C (possible germline polymorphism); MAF 44%)|NOTCH2 (p.E366V; MAF 65%)|PHF6 (p.T12fs*23 (5 bp insertion with frame-shift); MAF 40%)|PTPN11 (p.D61V (confirmed somatic); MAF 39%) (Solid Tissue/Skin)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	5.441385132	8.056263834	5.857723741	5.251094901	8.302553922	2.671289769	7.390433207	yes	yes	yes	yes	yes	yes	yes	0.750469031						
BA2619R	BA2619D	2184	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			62	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone)|MEC (Cytarabine, Etoposide, Mitoxantrone)"	2	Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"HAM (Cytarabine, Mitoxantrone)"	Salvage	7	Dead	167	Dead-Other	6.1	22	17.4	5.2	16.5	31.3	1.7	21.8	0.2	13	11	3.2	0.78	M2	29.5	9.5	"59~62,XX,+X,+1,+2,del(5)(q13q34),+6,+8,+8,+9,+11,+11,i(11)(q10),+12,+14,+16,+19,+22,+mar[cp19]/46,XX[1]"	444	101.4	"Trisomy 9 (88%) | Missing ERG1 signal (75%) | 2 small red/2 \normal\\ red pattern with the PML probe (79%) | Trisomy 11 and i(11q) (92%) | Tetrasomy 8 (87%) | Trisomy 16 (81%)\\\"""""	34	TRUE	"CD13, CD34, CD58 and CD117"	FALSE	FALSE	7	10.75	FALSE	negative	0	negative			TP53 (p.R280T; 41.1%)|TP53 (p.X33_splice; 37.9%)	"GATA1 (p.N160S; MAF:40%)|NRAS (p.G12D; MAF 11%)|TP53 (Intron 4, 3' Splice site (C.97-1G>A); MAF 26%)|TP53 (p.R280T;  MAF 36%"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	3.926178741	5.335031781	4.200237724	4.930522504	6.704229774	-0.054271382	5.276160194	yes	yes	yes	yes	yes	yes	yes	0.586831322						
BA2856R	BA2856D	2376	Waves1+2	yes	yes	yes	no	Male	Male			White	3			55	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|ODSH (2 O, 3-O Desulfated Heparin) "	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	129	Alive	1022	Alive	NA	37	20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	283	TRUE	"Increased atypical CD117 positive myeloid blasts (weak CD7  positive, HLA-DR negative), representing 18% of the total  leukocytes, consistent with a myeloid neoplasm"	TRUE	FALSE	NA	16.11	FALSE	negative	0	positive				NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.579059055	5.814821246	5.23139219	4.582631802	6.695805771	1.132098452	1.469167148	yes	yes	yes	yes	yes	yes	no	1.010542149						
BA2377R	BA2377D	2385	Waves1+2	yes	yes	yes	yes	Male	Male			White	2		MLLT3-KMT2A	35	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(9;11)(p22;q23); MLLT3-MLL	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide, Thymoglobulin"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Cyclophosphamide, Thymoglobulin"	Allogeneic - Matched Unrelated Donor	-1	Alive	1156	Alive	NA	86		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,der(4)t(4;9;11)(p14;p22;q23),der(9)del(9)(p13p22)t(4;9;11),der(11)t(4;9;11)[19]/46,XY[1].isht(4;9;11)(5'MLL-,3'MLL+;5'MLL-,3'MLL-;5'MLL+,3'MLL-)[1] "	NA	NA	"nuc ish(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL sep 3'MLLx1)[189/200],(PML,RARA)x2 [200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[198]"	NA	NA	"CD2(-), CD4(+), CD7(-), CD11b(+), CD13(partial +), CD14(-), CD15(+), CD16(-), CD33(+), CD34(-), CD36(partial +), CD45(+), CD56(variably +), CD64(+), CD117(partial +), CD79a(-), HLA-DR(+), MPO(-), Tdt(-)"	TRUE	TRUE	NA	NA	NA	positive	2.448275862	positive		ASXL1 (p.D943Qfs*6; 38.5%)		ASXL1 (D943fs*6; MAF 25%)|FLT3-D835 (BMA)|KMT2A (MLL-AF9 fusion)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	TRUE	NA	FALSE	TRUE	-0.305832616	1.54697322	5.630561549	2.683474124	6.481205729	-3.4062923	-1.21830795	no	no	yes	no	yes	no	no	0.566377116						
BA3023R	BA3023D	2149	Waves1+2	yes	yes	yes	no	Female	Female			HispNative	4			27	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	HiDAC|SWOG S1203 (7+3 +/- Vorinostat)	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	137	Alive	791	Alive	NA	69	68	NA	NA	NA	1	NA	NA	NA	NA	NA	NA	M2	NA	NA	"48,XX,+3,+10[2]/46,XX[18]"	NA	NA		NA	NA	"CD34, CD38, CD13, CD33, CD11C, CD19, PARTIAL CD4, HLA-DR, PARTIAL CD15, CD117, PARTIAL CD61, AND PARTIAL CD7"	TRUE	TRUE	NA	5.1	FALSE	negative	0	positive				NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	2.59279126	2.619556586	3.34723699	4.93436696	5.825802632	0.357962098	2.711168133	no	no	yes	yes	no	yes	no	0.637166625						
BA2275R	BA2275D	2199	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			57	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Brain Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	10	Standard Chemotherapy	Decitabine	Induction	10	Dead	35	Dead-Unknown	0	45		0.9	27.8	18.2	12.2	40.9	0	32	19	2	0.83	M2	26.9	9.1	"44~48,XY,-5,del(7)(q22),+11,idic(11)(p11.2)x2,-12,der(13)t(1;13)(p13;p12),add(17)(q25),der(18)t(12;18)(q13;q11.2),-22,+2mar[cp14]/44~47,sl,-9,+16[cp3]/46~47,sl,der(1)t(1;3)(q21;q21),der(3)t(1;3)(q21;q21)ins(3)(3;?)(p21;?),-idic(11)(p11.2)[cp4]/46,XY[1]"	NA	97.1	"EGR1/5p; 88% , consistent with monosomy 5  | D7S486; 96% , consistent with deletion 7q  | BCR; 84% of cells had three signals for BCR (22q11.2)| MLL; 28% of cells had three intact signals for MLL, while another 76% of cells had four intact signals. "	77	TRUE	"CD13, CD33, CD34, CD71, CD117, dim CD123 and HLA-DR+"	TRUE	TRUE	6.7	5.92	FALSE	negative	0	negative			TP53 (p.R248Q; 95.8%)	TP53 (p.R248Q; MAF 80%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	4.876587899	6.527793851	5.069165817	3.037956318	7.237197009	2.417576281	7.043446336	yes	yes	yes	no	yes	yes	yes	0.588919879						
BA2901R	BA2901D	2529	Waves1+2	yes	yes	yes	yes	Male	Male			White	2			68	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Melanoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)"	4	Consolidation|Induction|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Azacitidine	Maintenance	-1	Alive	1203	Alive	0	79	54	NA	NA	10	42	30	NA	8	26	4	NA		20.8	6.8	"46,XY "	NA	NA	IGH-MYEOV and IGH-CCND1 rearrangement; MAF unlisted	61	TRUE	"CD2(-), CD4(equivocal), CD7(partial +), CD11b (equivocal), CD13(+), CD14(-), CD15(-), CD16(equivocal), CD33(-), CD34(bright +), CD36(-), CD38(dim +), CD45(+), CD56(equivocal), CD64(-), CD117(+), CD123(equivocal), HLA-DR(dim +), MPO(partial +), TdT(-) (Population 1 of 4 (0.02% of total events), consists of small myeloblasts) | CD2(-), CD4(equivocal), CD7(-), CD11b (-), CD13(partial +), CD14(-), CD15(partial +), CD16(-), CD25(-), CD33(variably +), CD34(-), CD36(-), CD38(moderately bright +), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(partial +), MPO(partial +), TdT(-) (Population 2 of 4 (3.8% of total events), consists of immature myeloid cells) | CD13(partial +), CD14(partial +), CD36(variably +), CD45(variably +), CD56(partial +), HLA-DR(partial +), MPO(partial +) (Population 3 of 4 (61% of total events), consists of monocytes) | CD19(-), CD20(-), CD38(bright +), CD45(-), CD56(+), surface Ig(-), intracellular kappa(+), intracellular lambda(-) (Population 4 of 4 (0.34% of total events), consists of plasma cells)"	TRUE	TRUE	7.1	41.4	TRUE	negative	0	positive				DNMT3A (R882C; MAF 50%)|NPM1 (W288fs*10+; MAF 34%)|NRAS (G13D; MAF 44%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.611627168	4.801796871	4.836545994	4.208327586	6.730506765	-0.56909391	6.507482447	no	yes	yes	yes	yes	yes	yes	0.871672419						
BA2195R	BA2195D	2013	Waves1+2	yes	yes	yes	yes	Female	Female			Black	4	N/A		68	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	CPX-351 (Liposomal Cytarabine + Daunorubicin)	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Dead	70	Dead-Disease	NA	33	37	NA	NA	NA	8	NA	NA	NA	NA	NA	NA		NA	NA	"42~45,XX,-18[cp14]/43~45,idem,+2~3mar[cp3]/47,XX,+8[cp2]/45,X,-X[1]"	NA	NA		NA	NA	"CD34+ BLAST POPULATION, 33%, EXPRESSING PARTIAL CD38, PARTIAL CD4, PARTIAL CD11C, HLA-DR, CD117, PARTIAL CD13, PARTIAL CD33, PARTIAL CD15, AND MPO"	FALSE	TRUE	NA	29.1	TRUE	negative	0	negative	RUNX1 (p.S322Nfs*277; 9.7%)		TP53 (p.I195T; 22.2%)|TP53 (p.P151R; 54.8%)	CEBPA (Triple positive)|IDH2					no		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	TRUE	TRUE	3.454564138	6.646311693	5.319763325	4.657598538	6.45847747	-0.883218417	6.091280648	yes	yes	yes	yes	yes	yes	yes	0.856118635						
BA2354R	BA2354D	2050	Waves1+2	yes	yes	yes	yes	Male	Male	Asian	NON-HISPANIC	Asian	1		RUNX1-RUNX1T1	37	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	37	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"3+7 (Cytarabine, Daunorubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Etoposide, Mitoxantrone|Busulfan, Cyclophosphamide"	4	Salvage|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	0	Alive	1348	Alive	0.8			0	7.5	17.5	0	37.5	0.4	22	13	3	0.89	M2	15.8	5.5	"45,X,-Y,t(8;21)(q22;q22)[20]"	411	100.6	"RUNX1T1/RUNX1:  94% of cells had the dual fusion signal pattern consistent with RUNX1T1/RUNX1 fusion and t(8;21), as seen on metaphase analysis."	42	TRUE	"dim CD7, CD13, dim CD33, CD34, CD38, CD56, dim partial      CD64, CD117, dim CD123, HLA-DR, MPO, dim TdT positive"	TRUE	TRUE	7	8.15	FALSE	negative	0	negative				EZH2 (p.F445fs*3; MAF 30% )|KIT (p.N822K (exon 17); MAF 5% )|KIT (p.Y418_D419insFL (exon 8); MAF 29%)|TET2 (p.G1160E; MAF 49% )					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	4.805356331	5.253852829	3.956413745	3.204027111	6.208728417	-1.231423649	7.777132138	yes	yes	yes	no	yes	no	yes	0.422869383						
BA2893R	BA2893D	2455	Waves1+2	yes	yes	yes	yes	Female	Female			White	3			59	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Azacitidine, Sorafenib|Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC"	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Azacitidine, Sorafenib"	Hypomethylating/Low Dose Cytarabine	-1	Dead	254	Dead-Disease	NA	51.5	72	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA	"Large population of CD117 positive myeloblasts (predominantly CD34 negative, HLA-DR negative), representing approximately 71% of the leukocytes consistent with acute myeloid leukemia."	FALSE	FALSE	NA	89.17	TRUE	positive	1	positive				NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.233852064	1.560156281	4.79382003	2.241208066	5.563644509	1.512424753	3.678111865	no	no	yes	no	no	yes	no	0.382094824						
BA2054R	BA2054D	2058	Waves1+2	yes	yes	yes	no	Female	Female			White	3			49	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	49	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Matched Unrelated Donor	-1	Alive	1168	Alive	NA	54	3	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	"46,XX,del(17)(p11.2)[15]/46,XX[5]"	NA	NA	consistent with karyotype (68% del 17p13)	NA	NA	"Most of the atypical cells (data not shown) are myeloid blasts that express CD117, partial CD7 (about 30% positive), CD13, CD33, HLA-DR, weak CD4, and partial CD15 (about 50% positive), but do not express CD34, CD14(MO2), or CD64. (The monocytic cells (percentages shown) are atypical in that they express weaker than normal CD13, with brighter than normal and more uniform than normal CD15, with phenotypically normal expression of bright CD33, bright CD64, CD4, and HLA-DR, and include approximately 80% that are phenotypically consistent with promonocytes/monoblasts, based on the lack of CD14(MO2).)"	TRUE	TRUE	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	3.213182977	5.416466741	3.536801956	2.200430448	6.801788717	-0.3326533	5.773314205	yes	yes	yes	no	yes	yes	yes	0.604482896						
BA2902R	BA2902D	2144	Waves1+2	yes	yes	yes	no	Male	Male			Asian	4			83	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	83	1	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"Azacitidine|Decitabine, Midostaurin"	2	Hypomethylating/Low Dose Cytarabine|Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"Decitabine, Midostaurin"	Induction	-1	Dead	47	Dead-Disease	NA	78		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[13]"	NA	NA		NA	NA	"ABNORMAL CD34-NEGATIVE BLAST POPULATION, 65%, EXPRESSING MYELOPEROXIDASE, CD117, CD13, CD33, AND CD56, AND SHOWING PARTIAL EXPRESSION OF CD38, CD64(DIM), CD11c(DIM), CD4(DIM) AND HLA-DR"	FALSE	TRUE	NA	NA	NA	positive	1.083333333	positive				FLT3-ITD|NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	TRUE	TRUE	2.98881255	3.233922826	3.031621114	5.0328937	5.185832737	1.846329256	0.843813627	yes	no	yes	yes	no	yes	no	0.655437583						
BA2870R	BA2870D	2364	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			77	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Azacitidine|Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	6	Dead	16	Dead-Disease	0	95	9	0	0.9	53	0	28.7	0.8	10	16	4	1.02	M5	25.8	8.6	"47,XX,+1,add(1)(p22)[15]/47,XX,+1,i(1)(q10)[5]"	601	97	"1p36/1q25: 81% of cells had three signals for 1q25 and two for 1p36, consistent with the larger clone above (ie. the clone with add(1)(p22). Another 13% of cells had four signals for 1q25 and two signals for 1p36, consistent with the smaller clone above (ie. the clone with the i(1)(q10))."	8	FALSE	"CD4, CD11b, CD15, CD33, CD38, CD58, CD64, CD123 and partial HLA-DR positive"	FALSE	TRUE	8.2	3.65	FALSE	negative	0	positive				FLT3-V491L (p.V491L; MAF 9%)|NPM1 (p.W288fs*12; MAF ~50% )|PTPN11 (p.S502L; MAF 44%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	0.845322357	1.216274304	-0.470048586	3.309577828	4.377846905	-3.077199316	0.608034603	no	no	no	no	no	no	no	0.338106563						
BA2789R	BA2789D	2141	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			66	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|MiDAC|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Matched Unrelated Donor	2	Dead	1715	Dead-Other	0	95	90.2	0	2.5	4.9	0.8	1.6	0.6	19	23	3	0.5	M1	18.9	6.1		501	100.5	Normal	10	TRUE	"CD13, CD33, dim CD71, CD117, CD123, and MPO"	TRUE	TRUE	6.4	66.67	TRUE	negative	0	positive				IDH2 (p.R140Q; MAF 46%)|NPM1 (p.W288fs*9; MAF 42%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.010052081	1.34249067	-0.891707138	2.624190487	3.657744187	-1.955393393	1.564264587	no	no	no	no	no	no	no	0.253400297						
BA2722R	BA2722D	2244	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			82	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	82	0	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	122	Dead	35	Dead-Disease	7.6			4.2	8.5	28	6.8	12.7	0.1	24	22	3.1	0.96		31.5	11	"43~46,XX,add(2)(q11.2),-4,del(5)(q23),add(7)(q32),+8,add(11)(q23),-16,del(17)(p12),-18,+22[cp19]/46,XX[1]"	1304	86.8		21	TRUE		NA	NA	7.3	17.63	FALSE	negative	0	negative			TP53 (p.P151S; 96.9%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	4.179020839	5.980544427	4.277230765	2.492492077	7.078454149	-0.015069307	6.680708328	yes	yes	yes	no	yes	yes	yes	0.608153001						
BA2806R	BA2806D	2285	Waves1+2	yes	yes	yes	yes	Male	Male	Unknown		White	2			42	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Bu/Cy/ATG|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	Bu/Cy/ATG	Allogeneic - Matched Unrelated Donor	-1	Alive	1016	Alive	NA	81	85	NA	NA	4	7	4	NA	89	50	3	0.94		27.8	9.5		945	95.5		39	FALSE	"partialCD4, partial/dimCD7, partialCDllb, CD13, partialCD15, partialCD22, partialCD25, brightCD33, partialCD34, CD38, CD45, CD117, partialCD123, HLA-DR, partialMPO, partialTdT"	TRUE	TRUE	5.7	48.03	TRUE	positive	0.960784314	positive		ASXL1 (p.G645Vfs*58; 8.0%)		FLT3-ITD|NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.94605022	1.612255669	2.079500717	3.241245784	5.258927463	-1.228223179	3.656354228	no	no	no	no	no	no	no	0.410767061						
BA2523R	BA2523D	2225	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	4			46	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	"HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|SWOG S1203 (7+3 +/- Vorinostat)|MEC, Lenalidomide|Etoposide, Cytarabine"	4	Consolidation|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"GCLAC (GCSF, Clofarabine & Cytarabine)"	Salvage	-1	Alive	874	Alive	NA	90		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	"46,XY[20]"	NA	NA		NA	NA	"MPO, HLA-DR, CD11c,CD13, CD33, DIM CD7, PARTIAL CD64, PARTIAL CD4, AND LACKING CD34"	TRUE	TRUE	NA	NA	NA	negative	0	positive				DNMT3A|IDH1|NPM1|NRAS					no		Found	TRUE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	1.070285281	-0.204556344	0.962688765	2.121525013	5.45304162	-2.067474047	0.521473783	no	no	no	no	no	no	no	0.252489154						
BA3027R	BA3027D	2324	Waves1+2	yes	yes	yes	yes	Female	Female			White	5			53	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Ovarian cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	53	33	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|GCLAC (GCSF, Clofarabine & Cytarabine)"	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	29	Standard Chemotherapy	"GCLAC (GCSF, Clofarabine & Cytarabine)"	Re-induction	17	Dead	72	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"53~55,XX,+1,+2,der(5)t(5;13)(q13;q12),+6,add(7)(q32),+8,+11,-13,+14,i(17)(q10),+19,+19,+21,+mar[cp7]/46,XX[7]"	NA	NA	Gain of 8 (4/301 cells); Gain of 8q22/21q22 (7.7/301 cells); Gain 11q23 (5/200 cells)	NA	NA		NA	NA	NA	NA	NA	negative	0	negative			TP53 (p.S215R; 15.2%)						no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	TRUE	4.931563456	6.397384984	5.033235873	6.786833539	7.074051678	1.875020429	5.904762398	yes	yes	yes	yes	yes	yes	yes	1.099556977						
BA2441R	BA2441D	2250	Waves1+2	yes	yes	yes	yes	Male	Male	White	HISPANIC	HispNative	1			50	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)"	2	Salvage|Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Salvage	4	Dead	99	Dead-Disease	0	76	93	0	0	6.1	1.7	1.8	0	7	10	2.2	0.44	M0	18.8	6.3	"43~47,XY,del(1)(q42),r(2)(p2?3q37),t(3;5)(q27;q31),del(4)(q31),+del(5)(q31),add(5)(q11.2),-7,del(11)(q23),add(12)(p13),-22,+mar[cp11]/43~46,idem,add(14)(q24)[cp8]"	NA	85.8	deleted 5q and three short arm signals; monosomy 7 and the metaphase karyotype; no evidence for MLL deletion or rearrangement	14	TRUE	"CD7, CD11b, CD13, dim CD33, CD34, CD38, CD58, CD117 and HLA-DR+"	TRUE	TRUE	5.9	50.74	TRUE	negative	0	negative			TP53 (p.R273H; 53.6%)|TP53 (p.G105D; 52.9%)	"NRAS ( p.Q61K; MAF 37%)|TP53 (p.G105D, MAF 60%)|TP53 (p.R273H; MAF 44%)"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	3.347740082	1.063462797	0.686505344	2.721241501	3.615338297	-3.709646114	2.028375843	yes	no	no	no	no	no	no	0.448196229						
BA2514R	BA2514D	2409	Waves1+2	yes	yes	yes	yes	Female	Female			Black	2			67	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Acute Myeloid Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	67	0	Post-Chemotherapy|Post-Transplant|Post-DLI|Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea"	3	Salvage|Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	449	Dead-Disease	0	24	6	0	NA	77	10	7	NA	29	37	4.1	0.89		30.1	9.9	"46,XX[20]"	511	NA	"nuc ish(DXZ1x2)[182]//(DXZ1,DYZ3)x1[18]. nuc ish(D5S2064,D5S630,EGR1)x2[197],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2 [200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2) [200]"	288	TRUE	"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD33(variably +), CD34(+), CD36 (-), CD38(+), CD45(+), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+)"	TRUE	TRUE	8	3.3	FALSE	negative	0	negative			TP53 (p.R283C; 47.5%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	3.516455317	5.7056619	4.22250535	3.057668158	6.314924756	2.425270274	6.718374775	yes	yes	yes	no	yes	yes	yes	0.614293192						
BA2695R	BA2695D	2409	Waves1+2	no	no	no	no	Female	Male			Black	2			67	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Acute Myeloid Leukemia	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	254	Post-Chemotherapy|Post-DLI|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)|Targeted Therapy - Other|Bone Marrow Transplant	4	"AG-120|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea"	3	Salvage|Experimental|Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	-1	Dead	449	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	18	25	4.1	NA		20.4	6.8	"47,XX,+11[5]/48,idem,+19[15] "	NA	NA	"nuc ish(DXZ1x2)[181]//(DXZ1,DYZ3)x1[19] nuc ish(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x3(5'MLL con 3'MLLx3)[176/200],(PML,RARA)x2[196], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[199]"	24	TRUE		NA	NA	7.4	27.5	TRUE	positive	1.325581395	negative			TP53 (p.R283C; 45.1%)	FLT3-ITD|IDH1 (R132G)|IDH1 (p.R132G; MAF 51%)|KMT2A (MLL-PTD (exons 2-10))|TP53 (p.R283C; MAF 49%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	TRUE	3.040172106	3.63913648	5.000667997	4.873422525	6.209205633	-1.942942469	6.57456923	yes	yes	yes	yes	yes	no	yes	0.78152644						
BA2479R		2362	Waves1+2	yes	no	yes	no	Female	Female			White	5			71	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	71	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	n	y	n	n	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	115	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	115	Alive	1044	Alive	NA	65		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA		96	TRUE	"positive for CD33, CD13, CD117, and myeloperoxidase; negative for CD34 and HLA-DR"	FALSE	TRUE	NA	1.6	FALSE	negative	0	positive				ASXL1 (p.A1312V; MAF 33.6%)|IDH1 (p.A1312V; MAF 32.1%)|NPM1 (p.L258fs; MAF 31.1%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	5.133332979	6.44756726	2.277454383	8.643556921	7.605103304	0.030874783	-0.268163697	yes	yes	no	yes	yes	yes	no	0.732410104						
BA2123R	BA2123D	2000	Waves1+2	yes	yes	yes	no	Male	Male			White	2			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	Decitabine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	214	Dead	269	Dead-Treatment	NA	10	1	0	NA	80	2	17	NA	24	27	4.3	1.48		20.4	7.2	"46,XY[20]"	275	93.3	"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[199](RUNX1T1, RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	23	TRUE	"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(partial dim +), CD16(-), CD33 (bright +), CD34(partial +), CD36(-), CD38(variably +), CD45(+), CD56(-), CD64(-), CD117(+), HLA-DR (+), GLy-A(-), MPO(partial +), TdT(-)."	TRUE	TRUE	6.9	1.6	FALSE	negative	0	positive				DNMT3A (W297*; MAF 44%)|FLT3-D835 (D835Y; MAF 6%)|GATA2 (P161A; MAF 51%)|NPM1 (W288fs*10+; MAF 26%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	0.388417745	2.702257125	3.332681415	4.022859936	4.866048033	-2.053730838	2.326749366	no	no	yes	yes	no	no	no	0.471111662						
BA2836R	BA2836D	2242	Waves1+2	yes	yes	yes	yes	Male	Male			White	2			59	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	107	Dead	430	Dead-Unknown	0	35	27.4	0	NA	36.8	6.6	29.2	NA	13	25	2.9	1.4		23.6	7.6	"46,XY[20]"	383	NA	"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	35	TRUE	"CD2(-), CD7(-), CD11b(-), CD13(+), CD14(-), CD15(- to partial dim +), CD16(-), CD25(-), CD33(+ to slightly bright +), CD34(partial +), CD36(equivocal), CD38(slightly dim and variable), CD45(dim +), CD56(-), CD64(-), CD117(+), CD123(+), HLA-DR(+), MPO(+), TdT(-)."	TRUE	TRUE	6	3.6	FALSE	negative	0	positive				CEBPA (H224fs*97; MAF 7%)|CEBPA (Y181*; MAF 15%)|IDH2 (R140Q; MAF 35%)|NPM1 (W288fs*10+; MAF 26%)|POT1 (splice site 1164-1G>A; MAF 48%)|SRSF2 (P95R; MAF 37%)		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	2.84794513	3.988974495	1.408184558	4.704530812	5.351555208	0.170321229	3.596599359	no	yes	no	yes	no	yes	no	0.64528824						
BA2714R	BA2714D	2366	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			60	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)"	3	Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	Dead-Disease	0	90	61	1	4	47	10	1	0.1	30	26	2.4	1.17	M4	14	4.6	"46,XY[20]"	612	104.5	Normal	80	TRUE	"dim CD4, dim CD7, dim CD11b, CD13, CD33, variable CD34, CD38, CD58, variable CD64, CD117, CD123, dim HLA-DR, MPO, and dim TdT"	TRUE	TRUE	5.8	70.84	TRUE	negative	0	positive				FLT3-V491L (p.V491L; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)|SF3B1 (p.K666Q; MAF 47%)|WT1 (p.Y395fs*51; MAF 49%)	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.488141969	1.018229942	-0.155093445	3.117239626	6.229043006	-1.982860036	1.532974469	no	no	no	no	yes	no	no	0.628516903						
BA3317R	BA3317D	2366	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1			60	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	769	Post-Chemotherapy|Relapse	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)"	3	Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	167	Standard Chemotherapy	Azacitidine	Salvage	6	Dead	870	Dead-Disease	0	80	45	1.8	0	49.6	0	3.5	0.9	31	20	3	0.85	M4	26.2	9.3	"46,XY,t(3;4)(p21;q21)[20]"	261	99.6	Normal	44	TRUE	"CD13, CD34, dim CD33, CD38, CD58, CD71, CD117, CD123, partial TdT, and partial MPO+ "	TRUE	TRUE	6.1	3.42	FALSE	negative	0	positive				FLT3 (p.N841T; MAF 43%)|NPM1 (p.W288fs*12; MAF 41%)|SF3B1 (p.K666Q; MAF 48%)|WT1 (p.Y395fs*51; MAF 44%)	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.130716438	1.087265128	-0.416155586	3.594713283	3.842193862	-0.638748848	0.364990869	no	no	no	no	no	yes	no	0.336926047						
BA2036R	BA2036D	2445	Waves1+2	yes	yes	yes	yes	Female	Female			White	3			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Dead	21	Dead-Treatment	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA	"Large population of atypical myeloblasts (CD56 positive,  weak CD117 positive, CD34 negative, HLA-DR negative),  representing approximately 87% of the leukocytes,  consistent with acute myeloid leukemia"	FALSE	FALSE	NA	NA	NA	negative	0	positive				KMT2A (p.Ile3572Ser (NM_001197104.1); MAF 44.1%)|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.4%)|TET2 (p.His724fs; MAF 43.5%)					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	6.24227196	3.999561505	2.718149952	4.777689554	6.610065685	-0.940696846	1.074138718	yes	yes	no	yes	yes	yes	no	0.522214484						
BA2410R	BA2410D	2495	Waves1+2	yes	yes	yes	no	Female	Female			White	2			57	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin) plus Crenolanib"	1	Induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin) plus Crenolanib"	Induction	-1	Dead	81	Dead-Treatment	NA	55	47	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA	"It reveals 0.23% CD34 (+) myeloid blasts with the following immunophenotype: CD2(-), CD7(-), CD13(+), CD15(-/few +), CD33 (bright +), CD36(few +), CD38(partial +), CD45(+), CD64(-), CD117(+), HLA-DR(-), MPO (partial +). (A limited/targeted immunophenotypic analysis could be performed on this paucicellular specimen.) | CD2(-), CD4(partial dim +), CD7(-), CD11b(-), CD13(variably +), CD15(-/few +), CD33(bright +), CD34(-), CD36(- /few +), CD38(+), CD45(+), CD56(-), CD64(few +), CD117(+), and HLA-DR(-) (There is also a 16% population of medium-sized cells with the following immunophenotype)"	TRUE	TRUE	NA	26.5	TRUE	positive	NA	positive				ASXL1 (E981G; MAF 49%)|DNMT3A (F290fs*24; MAF 40%)|FLT3-ITD (MAF 18%)|JAK2 (N322I; MAF 51%)|NPM1 (W288fs*10+; MAF 38%)					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	1.67574341	3.09979908	2.38904504	4.106337586	5.216385714	2.061119916	4.464478356	no	no	no	yes	no	yes	yes	0.501041864						
BA2139R	BA2139D	2342	Waves1+2	yes	yes	yes	yes	Female	Female			White	3			48	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|Cytarabine|TBI, VP-16"	4	Consolidation|Induction|CNS|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"TBI, VP-16"	Allogeneic - Matched Unrelated Donor	-1	Alive	939	Alive	NA	86	77	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5b	NA	NA	"46,XX "	NA	NA		NA	NA	"Large population of atypical monocytic cells (weaker than  normal CD33, partial loss of CD13) including  promonocytes/monoblasts representing approximately 50% of  the leukocytes suggestive of acute monoblastic or monocytic  leukemia. | Large population of atypical monocytic cells (weaker than normal CD33, partial loss of CD13) including promonocytes/monoblasts representing approximately 50% of the leukocytes"	FALSE	TRUE	NA	81	TRUE	positive	0.785714286	positive				DNMT3A (p.Arg882Cys; MAF 47.1%)|FLT3-ITD|NPM1 (p.Trp288fs (NM_002520.6); MAF 27.9%)					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	2.628089617	3.820360948	3.514045267	2.746048812	6.928331113	-1.598667209	3.255227085	no	yes	yes	no	yes	no	no	0.752192043						
BA2986R	BA2986D	2110	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			48	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	56	0	Residual Disease|Post-Chemotherapy|Post-DLI|Post-Transplant	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	7	"7+3 (Cytarabine, Idarubicin)|HiDAC|Donor Lymphocyte Infusion|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|Cytarabine, Mitoxantrone|Busulfan, Cyclophosphamide"	5	Allogeneic - Sibling|Consolidation|Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Re-induction	5	Dead	3069	Dead-Disease	0	62	5	0	0	83.2	1.8	0	0	28	21	2.5	0.8		24.1	8.3	"46,XX,t(1;11)(q44;q13),del(6)(p23)[9]/46,idem,t(17;20)(q25;q11.2)[11]"	290	94.5	"All probe results were within normal laboratory limits.      *Note: while it was not disrupted, MLL (11q23) was observed on the end of      the derivative chromosome 1 on available metaphase cells, reflecting the      t(1;11)."	53	TRUE	"dim CD2, CD13, CD33, CD34, CD38, CD117, dim CD123, dim      HLA-DR, and TdT positive"	FALSE	TRUE	6.5	1.46	FALSE	negative	0	negative				BCOR (p.A1262S; MAF 45% )|DNMT3A (p.R882H; MAF 15% )|GATA1 (c.-12C>T; MAF 35%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	4.791024581	6.6047618	0.450991498	8.270316657	4.964400321	-3.144296937	0.78292856	yes	yes	no	yes	no	no	no	0.572024108						
BA2970R	BA2970D	2327	Waves1+2	yes	yes	yes	yes	Male	Male	Black	NON-HISPANIC	Black	2			63	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Ruxolitinib|Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	103	Dead	8	Dead-Disease	1	9	15.4	2.9	NA	20.2	16.3	42.3	NA	NA	NA	NA	0.6		22.7	7	"46,XY[20]"	1086	NA	"nuc ish(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[199], (5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	126	TRUE	"CD34(+), CD7(partial +), CD13(+), CD33(+), CD38(partial +), CD45(moderately +), CD56 (+), CD117(+), HLA-DR(variably +), other myeloid and lymphoid antigens(-)."	TRUE	TRUE	NA	73.4	TRUE	positive	9	positive		ASXL1 (p.W898*; 42.1%)		ASXL1 (Foundation; W898*; MAF 47%)|KRAS (Foundation; A59T mutation; MAF 47%)|KRAS (Foundation; G13C; MAF 3%)|SUZ12 (Foundation; W617*; MAF 49%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	2.536142514	7.455713454	5.079761292	3.176785506	5.268147981	1.476380914	7.100069657	no	yes	yes	no	no	yes	yes	0.780282338						
BA2093R	BA2093D	2343	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			51	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|SWOG S1203 (7+3 +/- Vorinostat)|Bu/Cy/TBI"	5	Consolidation|Salvage|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Salvage	62	Dead	628	Dead-Disease	0	90		0	0	85.8	1.9	8.5	0	25	25	3	0.93	M0	25.1	8.2	"60~61<3n>,XYY,-1,-2,-3,-4,-5,del(5)(q13q33),-6,-7,+8,-9,+11,-12,+13,-15,-16,-17,-18,+21,+22[cp15]/70~73,idem,+Y,+1,+2,+5,+del(5)(q13q33),+6,+9,+11,+12,+20,+20[cp4]/46,XY[1]"	634	81.8	"EGR-1/ D5S23, D5S721: 60/100 cells (60%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the first clone, above; 38 cells (38%) had a 2 red/ 4 green signal pattern, consistent with two copies of the deleted 5q in the second clone."	77	TRUE	"partial CD7, CD13, dim partial CD22, CD33, CD3,  partial CD56, dim CD71, CD117, dim CD123, and dim HLA-DR "	TRUE	TRUE	6.5	0.5	FALSE	negative	0	negative			TP53 (p.X187_splice; 40.1%)|TP53 (p.X125_splice; 28.4%)	"NRAS (p.G13D; MAF ~40%)|TP53 (Splice site (3' splice site mutation, intron 5); MAF 42%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 44%)"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	2.009941064	1.568363935	-0.926284489	3.464121446	3.823409871	-1.485040412	0.438311265	no	no	no	no	no	no	no	0.443610137						
BA2425R	BA2425D	2532	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			68	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|3+7 (Cytarabine, Daunorubicin)|MiDAC"	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Mismatched Unrelated Donor	-1	Dead	314	Dead-Disease	2.6		49	5.1	6.8	36.8	0.9	14.5	0.2	18	16	2.8	0.67		21.9	7.5	"43-45,XX,del(5)(q16q33),der(7)t(7;12)(q11.1;q12)ins(7;?)(q11.1;?),-12,der(21;22)(q10;q10),+mar[cp20]/46,XX[1] "	821	88.7		8	FALSE	"CD13, CD33, CD34, CD71, CD117, dimCD123, HLA-DR, and dim CD 64 positive (Peripheral Blood)"	TRUE	TRUE	7.2	11.01	FALSE	negative	0	negative			TP53 (p.L130Pfs*19; 33.3%)	TP53 (p.I254N; MAF 40%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	3.473964059	4.612567835	2.140114298	4.706965601	6.353994761	1.245055059	5.434037796	yes	yes	no	yes	yes	yes	yes	0.690668503						
BA2905R	BA2905D	2019	Waves1+2	yes	yes	yes	no	Male	Male			White	5	N/A		77	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	77	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Other	3	AG-221|Azacitidine|Decitabine	3	Hypomethylating/Low Dose Cytarabine|Experimental|Maintenance			NA	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	38	Dead-Disease	NA	70	72	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,+11[8]/46,XY[12]"	NA	NA	35% gain of 11q23	174	TRUE	"CD34, CD117, HLA-DR, CD13, and CD33. A subset of the myeloblasts showed aberrant co-expression of CD34 and myeloperoxidase.  A subset of the myeloblasts showed aberrant expression of CD56."	FALSE	TRUE	NA	33.1	TRUE	negative	0	negative				ASXL1 (p.G642fs; MAF 32.1%)|CEBPA (p.K90fs; MAF 39.1%)|EZH2 (p.F246fx; MAF 91.4%)|IDH2 (p.R140Q; MAF 49.2%)|RUNX1 (p.L29S; MAF 52.9%)|STAG2 (p.D884fs; MAF 89.8%)|TET2 (p.P1723S; MAF 48.4%)|TET2 (p.Y867H; MAF 50.3% )					no		Found	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	TRUE	TRUE	TRUE	2.412118063	6.262496751	3.166388755	3.39561115	5.581951198	0.692902997	4.782928817	no	yes	yes	no	no	yes	yes	0.622080612						
BA2304R	BA2304D	2010	Waves1+2	yes	yes	yes	yes	Female	Female			White	3		MLLT3-KMT2A	52	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	52	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Melphalan, ATG, Methotrexate"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Melphalan, ATG, Methotrexate"	Allogeneic - Matched Unrelated Donor	-1	Alive	804	Alive	NA	51		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA	"46,XX,t(9;11)(p22;q23)[5]"	NA	NA	11q23 (MLL): rearrangement present (89.5%)	NA	NA	"The monocytic cells (percentages shown) are  atypical in that they express partial CD56 (about 50%  positive), but otherwise demonstrate phenotypically normal  expression of CD13, bright CD33, bright CD64, CD15, HLA-DR,  and partial myeloperoxidase (Flow cytometric analysis of the bone marrow aspirate  specimen indicates that 4% of the CD45 positive leukocytes  are lymphocytes, 89% are monocytic cells, and 7% are  myeloid cells.) | CD10, CD11b, CD13,  CD16, CD33, and CD64 (Myeloid (phenotypically normal))"	FALSE	TRUE	NA	NA	NA	negative	0	negative				KRAS (p.Gly13Asp; MAF 38.9%)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	1.05672614	2.799233832	3.454052776	2.845540902	6.650696125	-0.730775878	4.95124374	no	no	yes	no	yes	yes	yes	0.77260004						
BA2386R	BA2386D	2292	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown		White	2			52	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Salvage	-1	Dead	633	Dead-Disease	0	83	48.6	0	NA	9.4	0.9	40.2	NA	21	47	3.3	0.55	M1	25.3	8.3	"46,XX[20]"	NA	NA	"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	48	TRUE	"CD2(-), CD4(dim +), CD7(-), CD11b(-), CD13(+ and dim +), CD14(-), CD15(+), CD16(-), CD25(-), CD33(slightly bright +), CD34(-), CD36(-), CD38(variably +), CD45(+), CD56(small subset +), CD64(-), CD117(dim and variably +), CD123(variably +), HLA-DR(+), TdT(-), MPO(+)."	TRUE	TRUE	6.6	22.1	TRUE	negative	0	positive				FLT3 (Foundation; A680V; MAF 6%)|FLT3 (Foundation; Y842C; MAF 2%)|KDM6A (Foundation; P738fs*2;MAF 31%)|NPM1 (Foundation; W288fs*10+; MAF 25%)|TET2 (Foundation; Q742*; MAF 45%)|TET2 (Foundation; R1712fs*6;MAF 44%)					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	4.292298686	5.321640442	3.567071468	3.060581114	5.151740137	-0.222304756	3.768072434	yes	yes	yes	no	no	yes	no	0.612757387						
BA3400R	BA3400D	2292	Waves3+4	no	no	no	no	Female	Female	Unknown			2			52	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	616	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone)"	Salvage	-1	Dead	633	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	"46,XX[20]"	NA	NA	"nuc ish(D4Z1,D10Z1)x2[200],(RUNX1T1,RUNX1)x2[200],(ABL1,BCR)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(ETV6,RUNX1)x2[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	NA	NA		NA	NA	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	5.478733315	4.919675605	1.035973365	5.747018905	5.724413092	0.502611742	3.731102732	yes	yes	no	yes	no	yes	no	0.598717371						
BA2201R	BA2201D	2291	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			68	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	23	Bone Marrow Transplant	"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Matched Unrelated Donor	-1	Dead	861	Dead-Other	0.9	86		0	0	2.6	20.8	0.9	0.2	20	28	2.9	1.49	M5	33	10.8	"46,XY[20]"	1211	95.9	Normal	83	TRUE	"Variable CD13, variable CD14, CD33, variable CD64, CD117, CD123, and partial HLA-DR positive"	FALSE	TRUE	7.2	134.36	TRUE	positive	NA	positive				FLT3-ITD (MAF 91%)|IKZF1 (p.Q156H; MAF 45%)|NPM1 (p.W288fs*; MAF 49%)|SF3B1 (p.K666Q; MAF 50%)	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	0.623156646	1.307417208	0.138726037	2.520079577	6.369828867	-0.697873876	4.802496495	no	no	no	no	yes	yes	yes	0.606173375						
BA2113R	BA2113D	2088	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Unknown	Standard Chemotherapy	9	Standard Chemotherapy	Decitabine	Induction	9	Dead	25	Dead-Disease	1.8	41		0.9	0	79.6	0.9	14.2	0	21	19	2.7	0.98	M2	27.7	9.4	"45~46,XX,add(1)(q42),del(5)(q31q35),del(6)(q13),del(9)(q13q34),del(17)(p13),i(21)(q10)[cp12]/46~47,idem,+mar[cp6]/46,XX[2]"	404	88.5	"EGR1 (5q31): 73% of cells were missing a signal for EGR1 (5q31), consistent with the deletion seen on metaphase analysis.  TP53 (17p13.1): 71% of cells were missing a signal for TP53 (17p13.1), consistent with the deletion seen on metaphase analysis.  RUNX1 (21q22): 77% of cells had three signals fo"	6	FALSE	"CD13, dimCD33, CD34, CD38, CD58, partial CD64, CD117, CD123, and HLA-DR positive."	FALSE	TRUE	7.6	1.61	FALSE	negative	0	negative			TP53 (p.R248Q; 53.3%)	TP53 (p.R248Q; MAF 56%)|U2AF1 (p.Q157P; MAF 41%)			yes		yes	yes	Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	2.127913771	2.974501064	2.022587049	5.186215225	6.028194684	-2.335407551	4.002469856	no	no	no	yes	no	no	no	0.580979316						
BA2155R	BA2155D	2402	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown		White	2	bi		72	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated CEBPA	73	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine"	4	Hypomethylating/Low Dose Cytarabine|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Azacitidine	Hypomethylating/Low Dose Cytarabine	112	Dead	565	Dead-Disease	0	81	94	0	NA	51	3	2	NA	11	16	4.5	0.99	M0	28.2	9.6	"46,XX,der(3)t(3;17)(q29;q21)[19]/46,XX,t(3;21)(q26.2;q22)[2]"	NA	NA	"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1, D7S522)x2[199],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200], (PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	10	FALSE	"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(variably +), CD14(-), CD15(partial +), CD16(-), CD19 (-/few dim +), CD25(-), CD33(partial +), CD34(partial +), CD36(-), CD38(bright and variably +), CD45(+), CD56(variably +), CD64(-), CD117(variably +), CD123(-/few +), MPO(+), TdT(-/few dim +) (87% pop of med to large size cells) | HLA-DR(partial +)"	TRUE	TRUE	6.9	35	TRUE	negative	0	negative			TP53 (p.X187_splice; 30.4%)	CEBPA (Foundation; M1fs*60; MAF 34%)|CEBPA (Foundation; N307_V308insVETQQK; MAF 36%)|TP53 (Foundation; splice site 560-2insA; MAF 44%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	3.939719808	3.136004266	0.953128031	3.716958369	3.045215638	0.013944418	2.788235783	yes	no	no	no	no	yes	no	0.458905233						
BA2020R	BA2020D	2065	Waves1+2	yes	yes	yes	no	Male	Male			HispNative	3			51	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Sibling	-1	Alive	762	Alive	NA	78.5	71	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA	"CD13, partial CD15, CD33, CD117,  myeloperoxidase, and partial HLA-DR (\atypical cells with dim CD45\\ - 45% of leukocytes) | CD13,  bright CD33, and bright CD64 (Monocytic (19% of leukocytes)) | CD13, CD33, and CD64, with  a left shift (increased percentage that lack CD10, CD11b,  and CD16) (Myeloid (19% of leukocytes))\\\"""""	FALSE	TRUE	NA	12	FALSE	positive	NA	positive				FLT3-ITD (c.1775_1816dup; MAF 3%)|IDH2 (R140Q; MAF 42.3%)|NPM1 (c.860_863dup; MAF 14.5%)|PTPN11 (c.1507G>A; MAF 4%)|PTPN11 (c.1508G>A; MAF 15.4%)					no		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	0.128934221	0.891711786	-0.370236433	3.031621114	5.716289484	-2.590271627	3.367191354	no	no	no	no	no	no	no	0.382654818						
BA2226R	BA2226D	2014	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			53	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	SWOG S1203 (7+3 +/- Vorinostat)	1	Induction	Complete Response	Standard Chemotherapy	153	Standard Chemotherapy	SWOG S1203 (7+3 +/- Vorinostat)	Induction	153	Alive	1833	Alive	0	93	80	0	1.7	19.3	20.2	13.2	0.6	47	37	3.1	0.79	M5	26.8	8.8	"46,XX[20]"	977	92.1	Normal	36	FALSE	"Blast immunophenotype: partial CD11b, CD13, CD33, CD38, CD58, partial CD64, partial CD117 and a subset with MPO - Blast/promonocyte immunophenotype: CD11b, CD13, partial CD14, CD15, CD33, CD38, CD58 and CD64"	FALSE	TRUE	6	42.34	TRUE	negative	0	positive				FLT3-D835 (p.D835Y; MAF: 40%)|NPM1 (p.W288fs*12; MAF 40%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.875020429	3.280126954	2.359977024	3.747592183	6.660673206	-0.43050765	7.799569219	no	no	no	no	yes	yes	yes	0.646223759						
BA2376R	BA2376D	2513	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	6	Alive	1891	Alive	0.4	68		0.1	3	17	62.6	16.9	0.1	29	17	3.7	1.51	M5	27.7	8.9	"46,XY[20]"	296	104.9	Normal	74	TRUE	"dim CD4, CD11b, partial CD14, CD15, dim CD33, CD38, CD56, CD58, CD64 and HLA-DR positive"	FALSE	TRUE	8	16.84	FALSE	negative	0	positive				DNMT3A (p.S714C; MAF 35%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13V; MAF 6%)|PTPN11 (p.A72V; MAF 10%)|TET2 (p.Q876*; MAF 6%)					no		Found	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	1.397328316	2.08727892	3.239117622	4.203319895	6.67058413	-2.104319609	4.359065242	no	no	yes	yes	yes	no	no	0.721662075						
BA2200R	BA2200D	2371	Waves1+2	yes	yes	yes	yes	Male	Male			White	3			59	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Relapse|Post-Chemotherapy	Relapse	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"Azacitidine, Sorafenib|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)"	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Azacitidine, Sorafenib"	Re-induction	-1	Dead	256	Dead-Disease	NA	93.2	47.5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,t(3;4)(p21;q25)[3]/46,XY[17]"	NA	NA		NA	NA	"CD4, CD7, CD11b, CD13,  CD33, partial CD34, CD117, HLA-DR, partial weak TdT and  partial CD64"	TRUE	TRUE	NA	42.91	TRUE	positive	NA	positive				DNMT3A (c.2251T>C; MAF 36.9% (33.1% on 3/13/15))|FLT3-ITD (c.1759_1800dup; MAF 24% (39% on 3/13/15))|NPM1 (c.860_863dup; MAF 9.9% (24% on 3/13/15))					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.174073432	3.418072141	4.318511396	1.569304273	5.901576141	-0.741570412	2.118428903	no	no	yes	no	no	yes	no	0.425318321						
BA2121R	BA2121D	2356	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1		RUNX1-RUNX1T1	36	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Hydroxyurea"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	103	Alive	552	Alive	0	25	38	0	3.4	29.1	2.6	23.9	0	32	39	2.3	0.7	M2	21	7.5	"45,X,-Y,t(8;2;21)(q22;p21;q22)[20]"	NA	104.5	RUNX1T1/RUNX1: (92%)	29	FALSE	"CD13, CD33, partial CD34, CD64, CD19 dim, CD71, CD117 partial, HLA-DR, dim CD123, CD58 and MPO"	TRUE	TRUE	6.7	24.98	TRUE	negative	0	negative				CBL (p.E369_Y371delinsH; MAF 31%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	2.541549483	4.700314162	3.287993363	4.257193785	6.646840272	0.471360863	8.070649986	no	yes	yes	yes	yes	yes	yes	0.566436266						
BA2944R	BA2944D	2577	Waves1+2	yes	yes	yes	yes	Male	Male			White	3		RUNX1-RUNX1T1	23	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"7+3 (Cytarabine, Idarubicin)|Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)"	2	Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine, Cyclophosphamide, Thymoglobulin (Bu/Flu/Cy/ATG)"	Allogeneic - Matched Unrelated Donor	-1	Alive	747	Alive	NA	88		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	"46,XY,add(6)(q23),del(7)(q33),t(8;21)(q22;q22)[2]/46,sl,add(17)(p11.1)[5]/46,sdl1,add(16)(p11.2)[2]/46,sdl2,add(3)(q21)[8]/46,sdl3,add(20)(q11.2)[3]"	NA	NA	62% t(8;21) (RUNX1T1;RUNX1) translocation present	NA	NA	"CD13, CD33, CD34, CD38, CD117, HLA-DR, cMPO, CD19 and partial CD56"	FALSE	TRUE	NA	NA	NA	negative	0	negative				BRCA2 (c.6275_6276delTT; MAF unlisted)|BRCA2 (c.6859A>T; MAF unlisted)|FLT3-ITD (MAF unlisted)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	2.42106071	0.891711786	-1.583657597	4.328596221	5.961806565	-4.162213222	1.468121529	no	no	no	yes	no	no	no	0.393593678						
BA2033R	BA2033D	2432	Waves1+2	yes	yes	yes	yes	Male	Male			White	5			71	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	71	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Lenalidomide|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Hypomethylating/Low Dose Cytarabine	-1	Dead	11	Dead-Disease	NA	60	14	NA	NA	NA	7	NA	NA	NA	NA	NA	NA		NA	NA	"45,XY,add(3)(p10),add(5)(q11.2),psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter)[1]/44,sl,-add(3)(p10), +der(3;13)(q10;q10)[2]/48,sdl1,+8,+14,+21,+22[8]/42-44,sl,-add(3)(p10),add(4)(p15),-7,-8, add(12)(p11.2),+mar,+1-2r[cp7]/80-82 < 4n > ,slx2,-2,add(4)(q22)x2,-6,+8,+8,add(8)(p23)x2, (dic(8;11)(p12;p11.2)x2,-psu dic(9;?;6)(6qter- > 6p22::?::9p22- > 9qter),-10,der(10;17)(q10;q10), der(12;13)(p10;q10),der(14;17)(q10;q10),-16,-17,-18,add(20)(p11.2)[cp4])"	NA	NA	"FISH assays were positive for loss of 5q31 sequences in 85.5% of cells, positive for findings consistent with trisomy 8 in 49% of cells, and positive for findings consistent with monosomy 7 in around 8% of cells."	17	FALSE	"Flow cytometry was negative for increased myeloblasts. The flow showed a mild increase in   immature monocytic cells, but not to the degree seen in the marrow smears. This is likely   attributable to hemodilution of the sample received for flow cytometry. (Aberrant CD56, unusually dim CD38 - but only 3-4% assayed cells are myeloblasts)"	FALSE	FALSE	NA	21.6	TRUE	negative	0	negative			TP53 (p.P151H; 97.9%)	TET2 (p.G355D; MAF 33.8%)|TP53 (p.P19H; MAF 8.9%)					no		Found	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	4.225970129	6.894419142	6.077366518	6.100634402	7.151585592	3.901365441	6.489028524	yes	yes	yes	yes	yes	yes	yes	0.996228436						
BA2224R	BA2224D	2202	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			62	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	263	Dead	424	Dead-Disease	0	21	2.5	1.7	0	68.3	1.7	25	0	22	9	3.2	0.81	M2	20.6	6.8	"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]"	NA	100.5	EGR1 (73.5%) ;  TP53: (85.5%)	174	TRUE	"CD7, CD34, CD117, HLA-DR, CD13, CD33, dim CD123, variable CD15 and subset MPO"	TRUE	TRUE	5.8	3.74	FALSE	negative	0	negative			TP53 (p.G266V; 65.7%)	JAK2 (p.V617F; MAF 1.5%)|SF3B1 (p.G742D; MAF 35%)|TP53 (p.G266V; MAF 55%)	yes				yes	yes	Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	5.060341068	6.274267782	3.12161169	7.243011976	6.38934322	-0.845075814	5.311827986	yes	yes	yes	yes	yes	yes	yes	0.622442946						
BA2470R	BA2470D	2202	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			62	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	412	Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	Decitabine|Hydroxyurea	2	Induction|Re-induction	Complete Response i	Standard Chemotherapy	-1	Standard Chemotherapy	Hydroxyurea	Re-induction	263	Dead	424	Dead-Disease	0.9			0	0	7.8	1.7	4.3	0.1	18	21	2.8	1.43	M2	25	8.2	"46,XY,del(5)(q22q35),del(12)(q24.1q24.1),add(17)(p11.2)[19]/46,XY[1]"	564	102.5	EGR1 (73.5%) ;  TP53: (85.5%)	139	TRUE		NA	NA	6.6	46.79	TRUE	negative	0	negative			TP53 (p.G266V; 91.4%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	5.533871004	5.096709014	1.106864199	2.542878314	4.752010161	-1.689535676	4.045934855	yes	yes	no	no	no	no	no	0.52420226						
BA2978R	BA2978D	2411	Waves1+2	yes	yes	yes	yes	Female	Female	Declined	HISPANIC	HispNative	1		RUNX1-RUNX1T1	14	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	DLI|Standard Chemotherapy|Bone Marrow Transplant	8	"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|COG-AAML1031 (IT/IV Cytarabine, Daunorubicin, Etoposide, Mitoxantrone +/- Bortezomib or Sorafenib)|Donor Lymphocyte Infusion|HiDAC|Azacitidine|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Busulfan, Cyclophosphamide|Clofarabine, Cytarabine"	4	Allogeneic - Sibling|Salvage|Induction|Re-induction	Complete Response	Standard Chemotherapy	189	Bone Marrow Transplant	Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)	Allogeneic - Sibling	-1	Alive	2083	Alive	NA	18		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"46,XX,t(8;21)(q21.3;q22)[17]/49,sl,+4,+15,+der(21)t(8;21)[2]/53,sdl,-4,+13,+18,+19,+20,+21[4]"	NA	NA	"All twenty-three metaphase cells examined were abnormal, with t(8;21), leading to RUNX1/RUNX1T1 fusion.   Two subclones, comprising 6 cells total, had an additional copy of the der(21)."	NA	NA	"CD13, CD33, CD34, CD38, CD56, CD58, dim/partial CD64, CD117, CD123, HLA-DR and MPO"	FALSE	TRUE	NA	NA	NA	negative	0	negative				FBXW7 (p.G79S; MAF 50%)|KIT (p.D816Y; MAF 45%)|NRAS (p.G12D; MAF 45%)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	6.758313238	7.224594469	4.096766246	2.152706008	6.755974895	-0.77780812	7.798009391	yes	yes	yes	no	yes	yes	yes	0.674198966						
BA2829R	BA2829D	2238	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			53	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	7	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea"	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	49	Dead	168	Dead-Disease	0	9		1.7	0.9	6.1	8.8	43	0.4	38	29	3.4	0.71		27	9.1	"46,XY,add(3)(p24)[cp4]/46,XY[14]"	321	95.1	normal	170	TRUE	"CD117 (Initial diagnosis on 7/27/2015 BMBX: CD7, dim CD11b, CD13, CD33, partial CD34, CD58, CD117, CD123, dim MPO, and HLA-DR positive)"	TRUE	TRUE	6.7	16.65	FALSE	positive	NA	positive				CBL (p.I423N; MAF <0.5%)|DNMT3A (p.R882C; MAF 0.9%)|FLT3-ITD (MAF 2.9)|NPM1 (p.W288fs*12; MAF 0.7%)|TET2 (p.Q548*; MAF 0.7%)					no		Found	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	2.746624681	4.95229889	5.938987264	4.706267864	6.388882735	-0.03677844	1.956829098	no	yes	yes	yes	yes	yes	no	0.558915134						
BA2579R	BA2579D	2238	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			53	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	30	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea"	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	49	Dead	168	Dead-Disease	0	8	1	4.7	0.9	40.6	10.4	43.4	0	40	34	3.8	0.73		20.2	7.1	"46,XY[12]"	235	93.5	normal	17	TRUE	"dim variable CD7, dim CD11b, CD13, CD33, CD34, CD58, CD117, and CD123"	TRUE	TRUE	6.8	1.06	FALSE	positive	NA	positive				"DNMT3A (p.R882C; MAF 6%)|FLT3-ITD (MAF 15-20%)|NPM1 (p.W288fs*12; MAF 6%)|TET2 (p.Q548*, MAF 6%)"					no		Found	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	5.87015045	6.655181197	2.739936638	9.650488945	7.06956103	-4.042783597	2.127913771	yes	yes	yes	yes	yes	no	no	0.752382028						
BA2249R	BA2249D	2238	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			53	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	54	63	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	4	"HAM (Cytarabine, Mitoxantrone)|3+7 (Cytarabine, Daunorubicin)|Sorafenib|Hydroxyurea"	4	Induction|Experimental|Re-induction|Maintenance	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	49	Dead	168	Dead-Disease	1.8	48		3.6	6.2	23.2	18.7	17	1.3	29	41	3.6	1		20.9	6.9	"46,XY,t(7;17)(q22;q21)[3]/46,XY,t(2;4)(q33;q25),del(9)(q2?1;q3?2),add(17)(q21)[cp3]/46,XY,t(1;2)(q31;p25),inv(9)(q3?1q34)[2]/46,XY,t(13;14)(q14;q32)[cp2]/46,XY,add(3)(p24)[1]/46,XY[3]"	NA	96.3	normal	21	FALSE	"dimCD7, CD13, dimCD11b, CD33, variable CD34, CD58,  CD117, CD123, and HLA-DR positive"	TRUE	TRUE	6.8	20.77	FALSE	positive	9	positive				DNMT3A (p.R882C; MAF 45%)|FLT3-D835 (p.D835H; MAF 15%)|FLT3-ITD (MAF 78%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.Q548*; MAF 45%)					no		Found	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	2.292743766	2.27522744	5.87456316	4.736573817	6.084907283	-1.960119646	0.142551159	no	no	yes	yes	yes	no	no	0.624850429						
BA2024R	BA2024D	2122	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			48	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	48	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"ADE (Cytarabine, Daunorubicin & Etoposide)"	1	Induction	Unknown	Standard Chemotherapy	7	Standard Chemotherapy	"ADE (Cytarabine, Daunorubicin & Etoposide)"	Induction	7	Dead	33	Dead-Disease	0.2	13		0	0.5	10.2	4.4	84.7	0	84	28	3.9	0.95		42.1	14	"46,XY[20]"	231	89.2	Normal	330	TRUE	"CD33, CD117 positive, negative for CD34 and HLA-DR"	FALSE	TRUE	8.2	6.3	FALSE	positive	NA	positive				FLT3-ITD (MAF 33%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	7.384595872	9.141008059	5.892417064	5.821912698	8.016169321	1.943401745	7.082279016	yes	yes	yes	yes	yes	yes	yes	0.779519797						
BA2271R	BA2271D	2386	Waves1+2	yes	yes	yes	yes	Male	Male	White	HISPANIC	HispNative	1			8	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid leukaemia associated with Down syndrome	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Myeloid leukaemia associated with Down syndrome	8	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	2	"ADE (Cytarabine, Daunorubicin & Etoposide)|Cytarabine"	2	Induction|CNS	Complete Response	Standard Chemotherapy	151	Intrathecal	Cytarabine	CNS	151	Alive	1957	Alive	10.8	70		0	1.8	8.1	13.5	8.1	0	13	25	3.2	0.72	M1	26.8	9.3	"47,XY,+21c[20]"	NA	90.5	RUNX1 (21q22): 89% of cells had three signals for RUNX1 (21q22) consistent with the three copies of chromosome 21 seen on metaphase analysis.	40	TRUE	"dim CD11b, variable CD13, dim variable CD14, CD15, CD38, CD58, dim CD64, and MPO"	FALSE	FALSE	8.2	67.53	TRUE	negative	0	positive				NPM1 (p.W288fs*12; MAF 50%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	3.153795923	3.150065299	0.846900161	4.313658527	6.016643958	0.229044512	7.019839091	yes	no	no	yes	no	yes	yes	0.697811345						
BA3004R	BA3004D	2420	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			76	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"5+2 (Cytarabine, Idarubicin)|Decitabine"	2	Induction|Re-induction	Refractory	Standard Chemotherapy	8	Standard Chemotherapy	"5+2 (Cytarabine, Idarubicin)"	Re-induction	4	Dead	26	Dead-Disease	0	95	54	0	0.9	16.8	3.5	24.8	1.1	23	22	3.5	1.33	M1	31.5	10.3	"46,XX[22]"	244	92.6	Normal	29	FALSE	"dimCD13, CD33, CD45, CD56, dimCD117 and MPO positive"	FALSE	TRUE	7	27.17	TRUE	positive	NA	positive				ASXL1 (p.G966delG; MAF 50%)|DNMT3A (p.R736H; MAF 45%)|FLT3-ITD (MAF 20%)|NPM1 (p.W288fs*12; MAF 35%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.761844554	5.344339074	2.989978183	6.116335963	5.717556877	-1.789188955	2.712388767	no	yes	yes	yes	no	no	no	0.53342152						
BA2662R	BA2662D	2393	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			65	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Other	4	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|Hydroxyurea"	4	Consolidation|Unknown|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1962	Alive	0	74	60	1.9	15.1	21.7	50	11.3	0	23	32	2.6	0.78	M5	21.6	7.2	"46,XX[20]"	905	100.5	Normal	150	TRUE		NA	NA	6.7	84.69	TRUE	positive	NA	positive				CEBPA (p.K298Q; MAF 25%)|DNMT3A (p.R882C; MAF 44%)|FLT3-ITD (MAF 25%)|IDH2 (p.R140Q; MAF 18%)|NPM1 (p.W288fs*12; MAF 46%)					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	1.167678203	2.839957645	1.303983845	2.442337728	6.780749834	-3.504103796	4.017591009	no	no	no	no	yes	no	no	0.722514951						
BA2280R	BA2280D	2044	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			72	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib"	2	Induction|Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	Dead	118	Dead-Disease	0.9	90	78	0	0	2.7	3.6	17.3	1.4	28	23	2.8	0.56	M1	31.7	9.9	"46,XX[20]"	261	98.1	Normal	211	TRUE	"CD13, CD33, CD38, partial CD56, partialCD64, CD117, dimCD123, and MPO"	FALSE	TRUE	6.5	24.01	TRUE	positive	NA	positive				CEBPA (p.E163*; MAF 39%)|FLT3-ITD (MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.611383287	2.874973591	5.584940928	3.130492746	5.582337795	-1.192589773	0.478564734	no	no	yes	no	no	no	no	0.407961548						
BA2277R	BA2277D	2044	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1			72	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	40	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	3	"7+3 (Cytarabine, Idarubicin)|Sorafenib|Ponatinib"	2	Induction|Experimental	Refractory	Standard Chemotherapy	10	Targeted Therapy - Kinase Inhibitor(s)	Ponatinib	Experimental	15	Dead	118	Dead-Disease	0		70	0	1.8	34.8	3.6	0.9	23.2	13	40	3.2	0.55	M1	22.7	7.5	"46,XX[5]"	339	89.7	Normal	32	FALSE		NA	NA	6.4	6.04	FALSE	positive	0.639344262	positive				CEBPA (p.E163*; MAF 40%)|FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 32%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	2.537480043	2.907720138	3.313642911	6.010854323	5.479094529	-1.293321936	-2.361507728	no	no	yes	yes	no	no	no	0.438095364						
BA2512R	BA2512D	2257	Waves1+2	yes	yes	yes	yes	Female	Female			White	3			72	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Other	1	SGN-CD33A	1	Experimental			NA	Targeted Therapy - Other	SGN-CD33A	Experimental	-1	Dead	179	Dead-Disease	NA	41		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA		NA	NA	Normal	NA	NA	"partial CD56, bright CD33, CD13, bright CD64, HLA-DR (Monocytic cells)"	FALSE	TRUE	NA	NA	NA	negative	0	positive				DNMT3A (c.2645G>A; MAF 45.4%)|FLT3-D835 (c.2503G>T (D835Y); MAF 15.5%)|NPM1 (c.860_863dup; MAF 11%)|PTPN11 (c.178G>C; MAF 8.4%)|PTPN11 (c.211T>C; MAF 10%)|TET2 (c.3955-2A>G; MAF 45.4%)					no		Found	FALSE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	1.968574969	2.98706375	3.839579969	3.874387353	7.120403646	-2.578208293	4.054423691	no	no	yes	yes	yes	no	no	0.763614526						
BA2981R	BA2981D	2156	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	6			76	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Unknown	1	Azacitidine	1	Unknown			NA	Unknown	Azacitidine	Unknown	424	Dead	151	Dead-Unknown	NA	86	50	1	NA	14	5	20	NA	32	20	2.9	0.62		24.3	7.8	"48-51,XX,del(4)(q25),del(5)(q11.2),-17,-18,+22,+3-5mar[20]"	NA	84.1		27	TRUE	"POSITIVE FOR DIM CD45, HLADR, CD34, CD117, CD13, CD33, CD43, CD81, CD58. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	5.4	14.3	FALSE	negative	0	negative			TP53 (p.R175H; 91.7%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	3.936308447	5.654858379	5.194869177	2.449261563	6.151013721	0.821801311	6.988215383	yes	yes	yes	no	yes	yes	yes	0.646831661						
BA2483R	BA2483D	2172	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1		KMT2A_re	63	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	44	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	6	"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea"	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	Dead	348	Dead-Disease	1.5	85	38.5	0	0	55	3.5	1.5	0	25	22	3.8	1.3		21.1	7.1	"48,XX,+8,+21[16]/46,XX[4]"	NA	91.3	"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21, as seen on metaphase analysis.  MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) rearrangement. Disruption of MLL was not apparent on banded chromosomes and the partner remains unkn"	18	FALSE	"CD4, partial CD11b, partial CD13, CD33, CD34, CD38,  partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive | CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive"	FALSE	TRUE	7.7	19.76	FALSE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	0.854132266	1.461683326	2.712388767	3.939719808	5.856949802	-0.047664079	4.920026519	no	no	no	yes	no	yes	yes	0.549411065						
BA3002R	BA3002D	2172	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1		KMT2A_re	63	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	58	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Supportive/Palliative Care|Targeted Therapy - Other	6	"7+3 (Cytarabine, Idarubicin)|Cytarabine|Azacitidine|Sorafenib|Decitabine|Hydroxyurea"	5	Hypomethylating/Low Dose Cytarabine|Consolidation|Induction|Experimental|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	-1	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	29	Dead	348	Dead-Disease	0	85		0	0	12.6	0	0	0.2	16	36	3.1	1.57		20.9	7	"48,XX,+8,+21[16]/46,XX[4]"	887	89.7	"RUNX1/RUNX1T1/CEP8: 81% of cells had three signals for all probes, consistent with +8 and +21 MLL: 68% of cells had a split signal pattern consistent with MLL (11q23) "	21	FALSE	"CD4, partial CD11b, partial CD13, CD33, CD34, CD38, partial CD56, CD64, partial CD117, CD123, and dim HLA-DR positive"	FALSE	TRUE	7.3	49.93	TRUE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	0.213349457	0.734433805	2.208582508	2.903579561	5.599245037	0.02648616	4.415323236	no	no	no	no	no	yes	yes	0.552001298						
BA2242R	BA2242D	2507	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			61	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	"Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|MiDAC|Ibrutinib"	5	Consolidation|Induction|Re-induction|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Maintenance	-1	Alive	2027	Alive	0	>95		0	0	89.9	9.3	0.8	0	43	31	2.4	0.5	M1	19.5	6.5		313	92.4	normal	32	TRUE	"partial CD13, CD33, CD38, moderate CD45, CD56, CD58,  CD64, dim CD117, CD123 and MPO+"	FALSE	TRUE	5.8	67.36	TRUE	negative	0	positive				CREBBP (p.R2353Q; MAF 51%)|NPM1 (p.W288fs*12; MAF 46%)|TET2 (p.Q270*; MAF 90%)					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	5.53095273	3.872285406	-0.421061869	3.39251405	6.696930088	-0.752285877	-0.722823053	yes	yes	no	no	yes	yes	no	0.435023573						
BA2846R	BA2846D	2004	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			75	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Rectal Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Supportive/Palliative Care	2	Hydroxyurea|Decitabine	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	4	Dead	17	Dead-Disease	0	90	90	0	0	5.1	0.8	0.9	1	23	51	2.9	0.97	M1	25.3	8.5	"46,XY[20]"	728	91.3	Normal	28	FALSE	"CD33, dim CD38, variable CD56, CD58, dim CD64, CD117, CD123, and MPO positive."	FALSE	TRUE	6.6	62.87	TRUE	negative	0	positive				IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12 (4 nt insertion with frameshift); MAF 17%)|SRSF2 (p.P95L; MAF 37%)		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.470181328	2.21458395	-0.342203265	3.965479708	4.683098974	0.839553071	0.011641161	no	no	no	yes	no	yes	no	0.43069121						
BA2521R	BA2521D	2433	Both	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1			44	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	"Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Hydroxyurea|Busulfan, Cyclophosphamide|7+3 (Cytarabine, Idarubicin) plus Dasatinib "	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Post-Transplant Relapse	Complete Response i	Standard Chemotherapy	28	Standard Chemotherapy	Azacitidine	Post-Transplant Relapse	81	Dead	319	Dead-Disease	0	75	80	0	7.7	10.3	22.2	6.8	0	21	25	2.4	1.25	M5	22.9	7.4	"46,XX[20]"	705	96.2	Normal	42	FALSE	"CD13, CD33, subset CD34, variable CD117, CD123, HLA-DR, and variable MPO positive - Monocytic/blast equivalent immunophenotype: CD11b, CD13, subset CD14, variable CD16, CD33, CD64, dim CD123, and HLA-DR positive"	FALSE	TRUE	6.2	69.84	TRUE	positive	2.333333333	positive				DNMT3A (p.R882H; MAF 48%)|FLT3-ITD (MAF 70%)|NPM1 (p.W288fs*12; MAF 46%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	1.997067626	0.229044512	3.484243087	2.400256357	6.335094336	-1.960119646	1.493354808	no	no	yes	no	yes	no	no	0.625370592						
BA2885R	BA2885D	2139	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			81	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	14	Dead-Disease	0	90	70	0	0.8	6.1	72.2	12.2	0.4	62	50	2.9	4.22	M5	22.8	7.3	"46,XX[20]"	262	90.8	Normal	29	TRUE	"CD11b, variable CD13, variable CD14, CD33, CD56, CD64, dim CD123 and dim HLA-DR positive"	FALSE	TRUE	5.8	97.26	TRUE	negative	0	positive		ASXL1 (p.G645Vfs*58; 16.7%)		ASXL1 (p.W796fs*22; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|TET2 (p.S825fs*1; MAF 49%)					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	3.177838623	3.842193862	2.925454618	1.972594566	6.839193485	-0.346863898	4.241980745	yes	yes	yes	no	yes	yes	no	0.74453358						
BA2775R	BA2775D	2138	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	3			26	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	16	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	647	Alive	NA	35		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[15]"	NA	NA	Normal	NA	NA	"weak  CD13, CD33, partial CD117, and myeloperoxidase"	FALSE	TRUE	NA	NA	NA	negative	0	positive				IDH2 (p.Arg140Gln; MAF 45.9%)|NPM1 (p.Trp288fs; MAF 19.5%)					no		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	1.91542444	2.196776083	-0.725312818	2.428688675	6.436904567	-2.455611746	4.741829846	no	no	no	no	yes	no	yes	0.576069424						
BA2004R	BA2004D	2136	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			77	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	77	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	Azacitidine	1	Hypomethylating/Low Dose Cytarabine			NA	Standard Chemotherapy	Azacitidine	Hypomethylating/Low Dose Cytarabine	253	Dead	341	Dead-Unknown	0.8			2.5	0	15.8	0	70.9	0	62	28	3.3	1.01	M2	24.2	7.9		241	87.7	"EGR-1/ D5S23, D5S721: 58/200 cells (29%) had a 1 red/ 2 green signal pattern, consistent with a deleted 5q. D7S522/CEP 7: 38/200 cells (19%) had a 1 red/ 2 green signal pattern, consistent with a deleted 7q. CBFB: 40/200 cells (20%) had a single signal indicating deleted 16q22. TP53/CEP 17: 12/200 c"	16	FALSE		NA	NA	8	8.29	FALSE	negative	0	negative			TP53 (p.V272_R273insL; MAF 75%)	DNMT3A (p.E285D; MAF 40% )|KDM6A (p.Y215fs*2; MAF 40%)|TP53 (p.V272_R273insL; MAF 75%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	5.050466637	7.036239006	5.044099214	6.963529976	6.669439488	0.452698305	4.516515295	yes	yes	yes	yes	yes	yes	yes	0.807298563						
BA3001R	BA3001D	2344	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			51	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"HiDAC|Hydroxyurea|7+3 (Cytarabine, Idarubicin) plus Sorafenib"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	2	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	1910	Alive	0	95	95	0	0	7.8	0	3.1	0.1	22	12	2.9	0.93	M1	20.6	6.6	"46,XX[20]"	189	112.6	Normal	57	FALSE	"Immunophenotype: CD7, CD13, CD33, CD38, CD117, CD123 and MPO positive"	TRUE	TRUE	6.5	25.02	TRUE	negative	0	positive				CBL (p.R420Q; MAF ~20%)|FLT3 (p.N841K; MAF ~30%)|IDH2 (p.R140Q; MAF ~30%)|NPM1 (p.W288fs*12; MAF ~25%)					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.67574341	1.024968216	0.277265118	2.024179375	3.823850351	-1.330559403	2.419637195	no	no	no	no	no	no	no	0.170897984						
BA2911R	BA2911D	2090	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			24	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	24	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Leukapheresis	y	y	n	y	y	n	3	Standard Chemotherapy|Targeted Therapy - Other|Targeted Therapy - Kinase Inhibitor(s)	6	"AG-120|ATRA (Tretinoin)|HiDAC|3+7 (Cytarabine, Daunorubicin)|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|5+2 (Ara-C, Daunorubicin)"	5	Consolidation|Salvage|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	AG-120	Salvage	77	Dead	861	Dead-Disease	0	N/A	97	0	0	1.9	0	1.9	0.2	14	18	2.7	0.51		19.6	6.2		364	108.3	normal	15	FALSE	"CD13, CD33, CD38, CD58, CD117 and CD123 positive."	FALSE	TRUE	6.4	181.66	TRUE	positive	NA	positive				FLT3 (p.V592G; MAF 6%)|FLT3-ITD ((57 bp in-frame insertion); MAF 3% )|IDH1 (p.W288fs*12; MAF 50%)|NPM1 (p.W288fs*12; MAF 50% )					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.44373455	0.711453578	-0.218006257	1.387451292	4.24387516	-0.610774085	0.792123208	no	no	no	no	no	yes	no	0.178968342						
BA3040R	BA3040D	2183	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	4			69	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	69	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	7	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	7	Dead	238	Dead-Disease	NA	39	11	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"45,XY,add(1)(p13),del(5)(q13q33),add(6)(q13),-7,del(7)(q11.2),der(9)t(1;9)(p13;q22),add(12)(p13),-15,-16,-17,+3mar[19]/43~45,idem,der(3)t(3;17)(p21;q11.2),-17[cp3]"	NA	NA	"COMPLEX DEL(5q)/DEL(7q)/-7 CLONE OBSERVED, CONSISTENT WITH AML"	NA	NA	"Positive (ABNORMAL CD34+ BLAST POPULATION, 29%, EXPRESSINGMYELOPEROXIDASE (VARIABLE), CD34, CD38, CD117, CD33, CD4, HLA-DR,CD13 (PARTIAL), CD56 (dim minor subset), AND CD61 (dim subset))"	FALSE	TRUE	NA	1.6	FALSE	negative	0	negative			TP53 (p.Y220C; 48.0%)|TP53 (p.F113V; 39.4%)						no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	4.089140122	5.241408937	5.212198639	4.08953411	5.333999446	-0.065358812	5.039283443	yes	yes	yes	yes	no	yes	yes	0.587432163						
BA2724R	BA2724D	2041	Waves1+2	yes	yes	yes	yes	Female	Female	White		White	2			67	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	34	Alive	0.8	85	7.7	0	NA	5.1	42.7	40.2	NA	27	41	1.9	0.66		28.7	9.5	"46,XX[20]"	670	102.5	"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	42	TRUE	"CD2(-), CD4(partial dim +), CD7(few dim +), CD11b(-), CD13 (variably +), CD14(-), CD15(partial +), CD16(-), CD19(partial dim +), CD33(variably +), CD34(-), CD36(-), CD38(+), CD45 (moderate +), CD56(-), CD64(partial dim +), CD117(+), HLA-DR(+), MPO(+). (Population #1; 6.5% medium-sized cells) | CD2(dim +), CD4(dim +), CD11b(variably +), CD13(variably +), CD14(partial +), CD15(variably +), CD16(partial +), CD33(slightly bright +), CD34(-), CD36(+), CD38 (variably +), CD45(+), CD64(+), CD117(-), HLA-DR(partial +), MPO(+). (Population #2; 42% medium-sized to large monocytic cells)"	TRUE	TRUE	5.7	56.03	TRUE	negative	0	positive				NPM1 (W288FS*10+; MAF 37.0%)|NRAS (Q61K; MAF 43.0%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	3.926992939	5.266736944	5.075872486	3.406263516	6.964195782	0.47308433	5.614781358	yes	yes	yes	no	yes	yes	yes	0.752506391						
BA2233R	BA2233D	2316	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	4			72	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	CPX-351 (Liposomal Cytarabine + Daunorubicin)|Hydroxyurea	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	CPX-351 (Liposomal Cytarabine + Daunorubicin)	Induction	-1	Alive	95	Alive	NA	97	96	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	"46,XY[5]"	NA	NA	"D5S721, EGR1 del(5q)/monosomy 5, D7Z1, D7S522  del(7q)/monosomy 7, D8Z2 trisomy #8, D20S108, 20qter del(20q)   "	NA	NA	"CD117, MPO,CD38(PARTIAL), CD33(DIM) AND NOT EXPRESSING CD34 AND HLA-DR"	FALSE	TRUE	NA	125.9	TRUE	negative	0	positive				"FLT3 (p.D839G; MAF~45%)|IDH2 (p.R140L; MAF ~50%)|MLL2 (p.V2338I; MAF ~50%)|NPM1 (p.W288fs*12;MAF ~35%)|SRSF2 (p.P95H, MAF~55%)"		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	1.617109534	2.273772977	-0.899929858	3.731965881	4.141343766	-1.039441945	0.332971491	no	no	no	no	no	no	no	0.273197102						
BA2744R	BA2744D	2232	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			76	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	7	Dead	8	Dead-Unknown	0		96	0	0.7	4.7	0	1.3	0.6	23	43	2.3	0.46	M1	31	10.4	"46,XY[20]"	839	93.9	Normal	17	FALSE	"CD13, CD33, CD38, variable CD56, CD58, CD117 and MPO positive"	FALSE	TRUE	5.1	230.05	TRUE	positive	0.176470588	positive				FLT3-ITD (MAF 45%)|NPM1 (p.W288fs*12; MAF 50%)|TET2 (p.W564*; MAF 50%)					no		Found	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.98186111	3.05091544	0.074223775	5.506457351	5.298043939	0.851196224	-0.457686839	yes	no	no	yes	no	yes	no	0.366173683						
BA2301R	BA2301D	2197	Waves1+2	yes	yes	yes	no	Female	Female	White		White	5			42	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	673	Alive	0	90		0	NA	17	NA	20	NA	17	13	3.6	0.98		21.7	7.3	"46,XX[19]"	NA	NA	Normal	71	TRUE	"Positive (\A large blastic population is noted, positive for CD45 and CD64. A small subset of blasts also express CD13 and CD14. The blasts are negative for CD10, CD16, CD19, CD34 and CD117.\\)\\\"""""	FALSE	FALSE	6.6	18.3	FALSE	negative	0	positive				NPM1 (c.859_860insTCTG; p.W288fs)|WT1 (c.933_934ins10; p.R312fs; c.938_939insCGGTC; p.A314fs)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	1.923986914	4.588348156	2.069949345	3.736005732	6.47025473	-1.59483904	4.769590699	no	yes	no	no	yes	no	yes	0.843745468						
BA2133R	BA2133D	2383	Waves1+2	no	no	no	no	Female	Female	White		White	6			73	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	90	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	8	Dead	560	Dead-Unknown	NA			0.5	NA	39.2	7.5	52.5	NA	10	21	4.5	0.87		34.1	10.9		NA	92.4		6	FALSE		NA	NA	7.6	3.8	FALSE	negative	0	positive				IDH2 (p.R140Q; MAF 32%)|JAK2 (p.V617F; MAF 30%)|NPM1 (p.W288Cfs*12; MAF 35%)|SRSF2 (p.R94dup; MAF 31%)|WT1 (p.R440Tfs*14; MAF 29%)		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	5.397803331	9.247041739	2.786952278	5.998072506	8.023245235	1.192150153	4.414601973	yes	yes	yes	yes	yes	yes	yes	0.872616375						
BA2473R	BA2473D	2383	Both	no	no	no	no	Female	Female	White		White	6			73	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	56	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	4	Ruxolitinib|AG-221|Cytarabine|Azacitidine	4	Induction|Experimental|Maintenance|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	90	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	8	Dead	560	Dead-Unknown	NA	5		NA	NA	NA	1	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20] "	NA	NA	This test has not detected clonal abnormalities in the cells analyzed. Subtle structural changes cannot be ruled out due to the limitations of resolution. Small percentage of tumor cells with chromosome abnormalities may not be detected due to the limited number of cells examined. (Cytogenetics)	24	FALSE	"CD34 positive blasts are rare, <1% (Bone Marrow Immunophenotyping)"	FALSE	FALSE	NA	1.8	FALSE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	1.737768256	5.478733315	1.401613392	3.74312437	5.665134154	-2.155980085	5.43585497	no	yes	no	no	no	no	yes	0.473527152						
BA2477R	BA2477D	2219	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			67	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC"	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Mismatched Unrelated Donor	-1	Dead	864	Dead-Other	0	93	94	0	0	1	2.8	1.9	0.1	20	30	2.4	1.23	M4	31.2	10.1	"46,XY[20]"	NA	96.3	Normal	30	TRUE	"partial CD7, CD13, dim CD15, CD33, CD38, CD58, CD117, dim CD123, HLA-DR and partial MPO+. (BM) | dim CD4, CD11b, variable CD13, partial CD14, dim CD15, variable CD16, CD33, CD38, CD58, CD64, CD123 and HLA-DR. (Promonocyte/blast equivalents)"	TRUE	TRUE	NA	125.16	TRUE	negative	0	positive				DNMT3A (p.R882H; MAF 46% )|FLT3 (p.V592D; MAF 43% )|IDH1 (p.R132H; MAF 46%  )|NPM1 (p.W288fs*12 MAF 47% )|SETBP1 (p.K459E; MAF 50% )					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.212748832	0.770833241	-0.662300846	1.679457033	5.68342897	-0.252053019	4.064014872	no	no	no	no	no	yes	no	0.436098683						
BA2244R	BA2244D	2219	Waves1+2	no	no	no	no	Male	Male	White	NON-HISPANIC	White	1			67	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	261	Post-Chemotherapy	Remission	Leukapheresis	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC"	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Mismatched Unrelated Donor	-1	Dead	864	Dead-Other	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	"46,XY,t(4;8)(q21;p23)[2]/46,XY[18]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	positive		ASXL1 (p.G645Vfs*58; 10.0%)							no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	0.639030692	-0.902763299	1.170183876	1.087265128	6.931528555	-3.531597099	1.727517542	no	no	no	no	yes	no	no	0.56321955						
BA3089R	BA3089D	2219	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1			67	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	429	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	5	"AG-120|Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC"	5	Consolidation|Salvage|Induction|Experimental|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Mismatched Unrelated Donor	-1	Dead	864	Dead-Other	0	75	68	1.7	0	17.4	0.9	12.2	0	21	22	3.4	0.9	M4	40.6	13.6	"46,XY[20] "	NA	95.8	Normal	91	TRUE	"CD7, CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+ "	TRUE	TRUE	6.4	20.31	FALSE	negative	0	positive				"DNMT3A (p.R882H; MAF 46%)|FLT3 (p.V592D; MAF 39%)|IDH1 (p.R132H, MAF 39%)|IDH2 (p.R140Q; MAF 39%)|NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.Q61P; MAF 40%)|SETBP1 (p.K459E; MAF 40%)"					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.861265344	2.195311478	-0.19780801	4.845288281	4.866758077	-1.536158945	1.420183931	yes	no	no	yes	no	no	no	0.357895233						
BA2273R	BA2273D	2544	Waves1+2	yes	yes	yes	no	Male	Male			White	6			67	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	2	"Cytarabine|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	Cytarabine	Consolidation	35	Dead	165	Dead-Unknown	NA	80	10	2	NA	68	4	8	NA	8	10	3.9	0.85		21.2	7.2	"46,XY[20]"	NA	110.4	The translocations commonly seen in AML are not detected. Loss of RARA and CBFB genes are detected in 14-39% of cells.	84	FALSE	"These are positive for CD34, CD117, HLADR, CD33, CD13, CD14 and CD11b. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	5.9	0.9	FALSE	negative	0	negative			TP53 (p.Y220C; 42.0%)	BCOR (MAF 49%)|IDH1 (p.R132C MAF 12%)|JAK2 (p.V617F; MAF 43%)|MLL |NF1 (MAF 18%)|TP53 (p.Y220C; MAF 35%)					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	2.360639815	2.685933155	3.915315683	4.815490798	4.53948778	-4.259329304	1.547916899	no	no	yes	yes	no	no	no	0.603377612						
BA2124R	BA2124D	2310	Waves1+2	yes	yes	yes	yes	Male	Male			White	3			67	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|IDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	IDAC	Consolidation	-1	Alive	579	Alive	NA	71.5	56	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA	"CD33, CD38, CD56, CD117, and myeloperoxidase"	FALSE	TRUE	NA	16.24	FALSE	negative	0	positive				NPM1 (p.Trp288fs; MAF 16.4%)|TET2 (p.Leu1081fs; MAF 42.3%)|TET2 (p.Leu1780fs; MAF 46.3%)|ZRSR2 (p.Arg126*; MAF 97.7%)				yes	yes		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.403935493	2.882795628	0.600021705	2.611627168	4.185154904	0.246524714	1.210297225	no	no	no	no	no	yes	no	0.262758871						
BA2400R	BA2400D	2426	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			44	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"HiDAC|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	HiDAC	Consolidation	99	Alive	1856	Alive	0	65	11.2	3.5	0	76.7	0	8.6	0	19	11	2.8	0.53	M2	23.7	7.8		197	100.4	Normal	222	TRUE	"CD13, CD33, CD117, CD123, dim HLA-DR and MPO | CD11b, CD13, CD33, CD117, CD64, CD123, and dim HLA-DR. (Blasts with monocytic differentiation (about 10% of blasts).)"	FALSE	TRUE	6.1	2.41	FALSE	negative	0	positive				FLT3-ITD (MAF 2%)|IDH1 (p.R132H; MAF 44%)|NPM1 (p.W288fs*12; MAF 44%)|PTPN11 (p.R265Q; MAF 3%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.416935615	2.084960335	-1.082918838	4.455039293	5.412822002	-1.99997129	1.862032036	no	no	no	yes	no	no	no	0.514399553						
BA2762R	BA2762D	2061	Waves1+2	yes	yes	yes	yes	Female	Female	White		White	2			22	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	"Fludarabine, Melphalan|Crenolanib|7+3 (Cytarabine, Idarubicin) plus Crenolanib"	3	Allogeneic - Sibling|Induction|Experimental	Complete Response	Standard Chemotherapy	39	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Sibling	-1	Alive	603	Alive	0	63	42	0	NA	32.7	4.4	26.6	NA	27	39	3.1	0.68		19.3	6	"46,XX[20]"	NA	NA	"nuc ish(D5S2064,D5S630,EGR1)x2[199],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1,RUNX1)x2[199],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con3'CBFBx2)[200]"	176	TRUE	"CD2(-), CD4(partial dim +), CD7(variably +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(variably +), CD34(partial+), CD36(-), CD38(variably +), CD45(variably +), CD56(-), CD64(-), CD117(+), HLA-DR(partial +)."	TRUE	TRUE	6.3	22.01	TRUE	positive	0.666666667	positive				FLT3-ITD (K602_W603INSCEYDLK; MAF 33.0%)|NPM1 (K292FS*6+; MFA 35.0%)|TCL1A (E54FS*28; MAF 44.0%)|WT1 (A382FS*4; MAF 40.0%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	1.941731631	4.062012542	0.935170536	3.905948463	5.343262872	0.25032345	4.267009067	no	yes	no	yes	no	yes	no	0.582672285						
BA2813R	BA2813D	2206	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	5			64	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"7+3 (Cytarabine, Idarubicin)|Fludarabine, Cyclophosphamide, Thiotepa, TBI"	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	41	Bone Marrow Transplant	"Fludarabine, Cyclophosphamide, Thiotepa, TBI"	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	636	Alive	0	83	74	0	NA	13	0	13	NA	15	45	4	1.27		25.2	8.7	"46,XY[20]"	NA	NA	Normal	39	FALSE	"Positive (\The large majority of cells (around 90%) are an abnormal population of myeloblasts. The myeloblasts are positive for CD33, CD13, HLA-DR, and CD117, and show uniform aberrant expression of CD7. A subset of the blasts are positive for myeloperoxidase, and a smaller subset shows dim aberrant expression of CD19. The blasts are almost entirely negative for CD34.\\)\\\"""""	TRUE	TRUE	6	53.3	TRUE	positive	0.428571429	positive				DNMT3A (c.2645G>A; p.R882H)|FLT3-ITD (FLT3-ITD 63bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	0.179956005	2.325358651	2.573099734	3.032175147	5.256419896	0.314328185	2.650421025	no	no	no	no	no	yes	no	0.40878348						
BA2211R	BA2211D	2471	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"Azacitidine|7+3 (Cytarabine, Idarubicin) plus Sorafenib"	2	Consolidation|Induction	Complete Response i	Standard Chemotherapy	17	Standard Chemotherapy	Azacitidine	Consolidation	34	Dead	142	Dead-Disease	0	95	92.9	0	0.7	3.6	1.4	1.4	0.1	101	55	3.2	0.83	M1	37	12.4	"46,XX[20]"	697	95.1	normal	42	TRUE	"CD13, CD33, CD38, CD56, CD58, partial CD64, CD117, CD123, and MPO positive"	FALSE	TRUE	6.3	166.91	TRUE	positive	1	positive				FLT3-ITD (MAF 50%)|NPM1 (p.W288fs*12; MAF 45%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.933230346	2.703472537	4.717894908	3.113839381	5.628284641	1.250811855	1.064894854	no	no	yes	no	no	yes	no	0.421283887						
BA2171R	BA2171D	2321	Waves1+2	yes	yes	yes	yes	Female	Female	Unknown	UNKNOWN	White	1			73	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Unknown	Standard Chemotherapy	3	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	3	Dead	4	Dead-Disease	0	90	98.4	0	0	0.8	0	0.8	0.1	18	36	2.9	1.44	M1	25.9	8.2	"46,XX[20]"	NA	90.6	Normal	19	FALSE	"CD13, CD33, CD38, CD58, dim CD64, CD117, CD123, and MPO"	FALSE	TRUE	7.7	122.89	TRUE	positive	0.428571429	positive				DNMT3A (p.R326P; MAF 50%)|FLT3-ITD (MAF 46%)|IDH2 (p.R140Q; MAF 40%)|NPM1 (p.W288fs*12; MAF 40%)					no		Found	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.892973411	2.219669733	2.386926302	2.856433488	6.127736219	-1.205668621	0.53157569	no	no	no	no	yes	no	no	0.407330904						
BA2746R	BA2746D	2522	Waves1+2	yes	yes	yes	yes	Female	Female		HISPANIC	HispNative	5			56	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|GCLAC (GCSF, Clofarabine & Cytarabine)|Fludarabine, Cyclophosphamide, Thiotepa, TBI"	4	Consolidation|Salvage|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	27	Standard Chemotherapy	"GCLAC (GCSF, Clofarabine & Cytarabine)"	Salvage	-1	Dead	323	Dead-Disease	0	1.5	2	0	NA	23	57	13	NA	67	33	3	1.87		29	9.5	"46,XX[19]"	NA	NA	Normal	28	FALSE	"Positive (\Approximately 55% of assayed cells are an abnormal population of immature monocytic cells (consistent with monoblasts and promonocytes). Approximately 30% of assayed cells are mature monocytes. Both the immature and mature monocytic cells show uniform aberrant expression of CD56. A small population of myeloblasts (CD117+/CD34neg) is present, accounting for less than 5% of assayed cells.)\\"	FALSE	FALSE	7.5	58.7	TRUE	"positive\"""""	NA	NA	NA	NA	NA		0.111111111	positive				ASXL1 (c.1954G>A; p.G652S)|DNMT3A (c.2644C>T; p.R882C)|FLT3 (c.2503G>T; p.D835Y)|FLT3-ITD (FLT3-ITD 21 bp insertion)|NPM1 (c.859_860insTCTG; p.W288fs)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	2.101386714	2.772192643	2.622837124	3.943512255	6.506985455	-0.894523655	5.456367319	no	Monocyte_Like		Not_HSC_Like		Promono_Like	cDC_Like	0.738604804
BA2588R	BA2588D	2441	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			59	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	59	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	5	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MEC (Cytarabine, Etoposide, Mitoxantrone)|MiDAC"	3	Consolidation|Induction|Re-induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)"	Re-induction	4	Dead	597	Dead-Disease	0	30	10.5	0	0	19.7	0.9	71.4	0	77	27	3.4	1.01	M2	26.4	8.9	"46,XY[20]"	479	96.4	Normal	101	TRUE	"CD13, CD33, CD117, CD123, and HLA-DR"	FALSE	TRUE	6.4	4.4	FALSE	negative	0	positive				DNMT3A (p.R882C; MAF 40%)|NPM1 (p.W288fs*12 ; MAF 40%)|PTPN11 (p.K70R; MAF 40%)|SOCS1 (p.Q210H ; MAF 55%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	2.945305298	3.897466876	-0.673357481	6.324521891	5.948759191	1.700409312	6.72932018	yes	yes	no	yes	no	yes	yes	0.678833199						
BA2300R	BA2300D	2037	Waves1+2	yes	yes	yes	yes	Male	Female;Male			White	3			79	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	1	Dead-Disease	NA	86	87	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"43-45,X,-Y,del(5)(q22q35),del(7)(q22),+8,-9,add(9)(p13),+11,-13,-14,add(16)(q24),-17,-18,del(20)(q11.2q13.2),+2-3mar[cp21]"	NA	NA	5q31 (EGR1): deletion present  8q22 (RUNX1T1): gain present  11q23 (KMT2A; also known as MLL): gain present 	27	FALSE		NA	NA	NA	70.01	TRUE	negative	0	negative			TP53 (p.X225_splice; 93.2%)	KIT (p.Asp816Val; MAF 44.4%)|TP53 (p.?; MAF 91%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	2.146516301	1.687013274	3.253586287	2.578363439	5.444974816	-3.774925246	6.188149436	no	no	yes	no	no	no	yes	0.470625428						
BA2240R	BA2240D	2181	Waves1+2	yes	yes	yes	yes	Female	Female	White	HISPANIC	HispNative	1			61	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	5	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Sorafenib|Hydroxyurea"	4	Consolidation|Induction|Experimental|Re-induction	Complete Response	Standard Chemotherapy	7	Targeted Therapy - Kinase Inhibitor(s)	Sorafenib	Experimental	61	Dead	263	Dead-Disease	0			0	0	30.8	10.3	0	0.3	195	75	3.6	0.68		25.4	8.2		1033	95.5		49	TRUE		NA	NA	6.7	73.28	TRUE	positive	9	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.475379471	1.712530596	1.419082296	3.58320105	6.143736481	-2.183717161	-1.50723867	no	no	no	no	yes	no	no	0.310445669						
BA2306R		2085	Waves1+2	yes	no	yes	yes	Male	Male	Black		AdmixedBlack	6		RUNX1-RUNX1T1	50	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	n	y	y	n	y	1	Standard Chemotherapy	2	"HiDAC|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	NA	70	91	0	NA	7	2	0	NA	23	25	2.4	0.66		26.6	8.7	"46,XY,t(8;21)(q22;q22)[20]"	NA	94.7		28	TRUE		NA	NA	6.3	71.1	TRUE	negative	0	negative				"ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.341422887	0.777022585	1.144899545	1.891315265	5.53793534	-1.082918838	8.247178934	no	no	no	no	no	no	yes	0.395638552						
BA2842R	BA2842D	2085	Waves1+2	no	no	no	no	Male	Male	Black		Black	6		RUNX1-RUNX1T1	50	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	50	21	Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"HiDAC|3+7 (Cytarabine, Daunorubicin)"	2	Consolidation|Induction	Refractory	Standard Chemotherapy	20	Standard Chemotherapy	HiDAC	Consolidation	182	Alive	424	Alive	NA	8	0	0	NA	12	29	54	NA	19	9	2.3	0.51		22.8	7.5	"46,XY,t(8;21)(q22;q22)[20]"	NA	88.7	RUNX1/RUNX1T1 fusion positive in 6.5% of cells	224	TRUE		NA	NA	5.1	6.8	FALSE	negative	0	negative				"ASXL1 (p.P581R, MAF 46%)|PDGFRB (p.D111N, MAF 52%)|SMC1A (p.R586Q, MAF 96%)"					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	4.452819975	6.099369759	4.777012625	5.239657954	7.140703761	-0.224671623	5.843531338	yes	yes	yes	yes	yes	yes	yes	0.925291573						
BA2726R	BA2726D	2309	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	1			29	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	5	"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|Hydroxyurea|Decitabine|Fludarabine, Cyclophosphamide, TBI |Trametinib"	3	Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	5	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	2	Dead	129	Dead-Disease	0	98		2	1	60	13	24	1.7	393	350	2.5	0.69	M5	27.2	9.4	"47,XX,+8,i(8)(q10),del(9)(q21.2q22.3),der(10)t(1;10)(q11;q22)[cp12]/47,idem,add(17)(p13)[8]"	NA	105.4	Normal	18	TRUE	"CD11b, CD13, CD14, CD33, CD56 and bright CD64+"	FALSE	TRUE	5.4	2.42	FALSE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	7.52879494	6.328233409	4.491279927	5.754917397	6.07014346	-1.921727906	3.499478656	yes	yes	yes	yes	yes	no	no	0.782345315						
BA2228R	BA2228D	2572	Waves1+2	yes	yes	yes	yes	Female	Female	White		White	2			60	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	60	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	5	"HiDAC|AG-221|3+7 (Cytarabine, Daunorubicin)|Azacitidine|MEC (Cytarabine, Etoposide, Mitoxantrone)"	4	Consolidation|Salvage|Induction|Experimental	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	AG-221	Experimental	-1	Dead	259	Dead-Disease	2	2	0	1	NA	12	12	71	NA	27	NA	4.4	0.99		33.5	11.4	"46,XX[20]"	NA	95.4	"nuc ish(D5S2064,D5S630,EGR1)x2[200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1, RUNX1)x2[200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	219	TRUE	The study reveals a minute subset of myeloblasts with mild immunophenotypic variation; the significance of this finding is unclear and it is not diagnostic for recurrent or persistent myeloid neoplasia. (No evidence of disease by flow)	FALSE	FALSE	7.1	5.54	FALSE	negative	0	positive				FLT3 (R311Q; MAF 48%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	3.122684804	6.47025473	6.331419499	6.175982737	7.155572213	1.895537678	6.585177155	yes	yes	yes	yes	yes	yes	yes	0.819104243						
BA2656R	BA2656D	2553	Waves1+2	yes	yes	yes	yes	Male	Male			White	7			NA	FALSE	unknown	unknown	unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	20	2	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	0		NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	3.02765231	1.517595728	1.173829282	1.997067626	4.193320616	0.600021705	1.083150467	yes	no	no	no	no	yes	no	0.337088074						
BA2705R	BA2705D	2100	Waves1+2	yes	yes	yes	no	Male	Male	White		White	5			39	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	40	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	2	"Unknown|GCLAC (GCSF, Clofarabine & Cytarabine)"	2	Induction|Re-induction	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	"GCLAC (GCSF, Clofarabine & Cytarabine)"	Re-induction	-1	Alive	82	Alive	0	41	14	0	NA	5	5	76	NA	12	17	3.6	0.83		29.4	10.2	"46,XY[15]"	NA	NA	Negative	24	FALSE	"Positive (CD7, CD11b, CD13, CD33, dim CD34, CD38, dim CD45, CD117, HLA-DR)"	TRUE	TRUE	5.9	3.6	FALSE	positive	0.923076923	positive				FLT3-ITD (ITD (39bp ins); VAF 39%)|NPM1 (c.859_860insTCTG; p.W288fs)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	TRUE	3.667038503	5.445691048	4.42479494	5.320141831	6.801167204	-0.006757303	4.35795466	yes	yes	yes	yes	yes	yes	no	0.910636788						
BA2764R	BA2764D	2209	Waves1+2	no	no	no	no	Male	Male	White		White	7			77	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	79	0	Post-Chemotherapy	Remission	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Decitabine	Induction	-1	Alive	500	Alive	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA	Translocation between the long arm of chromosome 3 and short arm of chromosome 12.	NA	NA		NA	NA	NA	NA	NA	positive	NA	positive				FLT3-ITD|NPM1					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	TRUE	TRUE	5.271786407	8.614232128	5.884445658	6.138089797	7.900374739	1.526734388	5.762180197	yes	yes	yes	yes	yes	yes	yes	0.831558292						
BA2261R	BA2261D	2528	Waves1+2	yes	yes	yes	yes	Female	Female	White		White	2			62	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	62	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	4	"Vidaza|7+3 (Cytarabine, Idarubicin)|Lenalidomide|Hydroxyurea"	3	Hypomethylating/Low Dose Cytarabine|Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	7	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	198	Dead-Disease	0.8	34	3.3	1.6	NA	14.9	5	68.6	NA	13	11	2.6	0.5		32.4	10.7	"46~47,XX,del(5)(q15q35),i(8)(q10),add(11)(q23),add(17)(p11.2),add(21)(q22),+2~3mar[cp3]/47~49,idem,add(7)(q11.2),-add(11),+11,+14,-20[cp4]/45~49,idem,del(7)(q22q36),-add(11),+11,+14,-20[cp2]/45~48,idem,der(7)del(7)(q22q31)dic(7;20)(q36;q11.2),-add(11),+11,+14["	304	NA	"nuc ish(D5S2064x2,D5S630x2,EGR1x1)[184/200],(D7Z1x2,D7S522x1)[115/200],(D8Z2x2,D20S108x1)[142/200],(RUNX1T1x3,RUNX1x2)[180/200],(5'MLL amp,3'MLL amp)(5'MLL con 3'MLL amp)[66/200],(PML,RARA)x2[197],(5'CBFB,3'CBFB)x2(5'CBFB con 3'CBFBx2)[200]"	36	FALSE	"CD2(-), CD4(-), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(partial +), CD16(-), CD33(+), CD34(+), CD36(-), CD38(partial +), CD45(+),CD56(+), CD64(-), CD117(partial +), HLA-DR(partial +). | In addition, there is a 0.01% population of small cells with the following immunophenotype: CD5(+), CD10(-), CD19(+), CD20(dim+), CD38(-), CD45(+), lambda(dim +), and kappa(-)."	TRUE	TRUE	5.3	8.35	FALSE	negative	0	negative			TP53 (p.R213Dfs*34; 85.5%)	TP53 (R213fs; MAF 34%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	6.427186081	8.244844502	7.164698232	4.972472721	8.369065651	2.322556438	6.832787643	yes	yes	yes	yes	yes	yes	yes	1.02430027						
BA2715R	BA2715D	2192	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	2			81	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	81	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	Dead	97	Dead-Disease	NA	33	8	4	NA	28	24	44	NA	22	20	4.1	1.07		27.5	9.5	"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5]"	333	NA	"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]"	28	TRUE	"CD4(+), CD5(partial +), CD7(partial +), CD11b(-), CD13(+), CD14(-), CD15(predominantly -), CD16(-), CD33(+), CD34(+), CD36(-),CD38(variably +), CD45(variably +), CD56(predominantly -), CD64(partial +), CD117(+), HLA-DR(predominantly + and variable),MPO(-), TdT(-)."	TRUE	TRUE	6.6	2.2	FALSE	negative	0	negative			TP53 (p.R273H; 39.7%)|TP53 (p.L206Wfs*41; 32.4%)	EP300 (Foundation; EP300-ZNF205 fusion)|TP53 (Foundation; L206fs*41; MAFs: 31%)|TP53 (Foundation; R273H; MAFs: 38%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	3.790674813	5.148257346	4.6657703	5.141234257	6.426240855	3.078139365	4.513253679	yes	yes	yes	yes	yes	yes	yes	0.717840027						
BA2116R	BA2116D	2192	Waves1+2	no	no	no	no	Male	Male	White		White	2			81	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	81	41	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	1	Supportive/Palliative Care	2	Vidaza|Decitabine	2	Hypomethylating/Low Dose Cytarabine|Supportive/Palliative Care			NA	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	3	Dead	97	Dead-Disease	0	N/A	70	0	NA	3	1	36	NA	25	33	4.1	1.26		24.1	8.1	"45,XY,add(5)(q11.2),der(6)t(5;6)(p13;p23),der(8)t(8;8)(p23;q11.2),-13,-16,der(22)t(16;22)(q22;q11.2),+r[cp11]/44,idem,-18[cp4]/46,XY[5] "	853	98	"nuc ish(D5S2064x3,D5S630x3,EGR1x1)[97/200],(D7Z1,D7S522)x2[200],(D8Z2,D20S108)x2[200],(RUNX1T1x3,RUNX1x2)[110/200],(5'MLL,3'MLL)x2(5'MLL con 3'MLLx2)[200],(PML,RARA)x2[200],(5'CBFB,3'CBFB)x2(5CBFB con 3CBFB dimx1,5CBFB con 3CBFBx1)[200]"	74	FALSE		NA	NA	NA	39.12	TRUE	negative	0	negative			TP53 (p.R273H; 56.3%)|TP53 (p.L206Wfs*41; 40.7%)						no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	4.637395934	5.464101314	4.802496495	2.888284158	5.42640917	0.128934221	6.520209577	yes	yes	yes	no	no	yes	yes	0.694719695						
BA2269R	BA2269D	2033	Waves1+2	yes	yes	yes	yes	Female	Female		HISPANIC	HispNative	6			34	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	34	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Intrathecal	3	"7+3 (Cytarabine, Idarubicin)|Cytarabine|Etoposide, Mitoxantrone"	3	Unknown|Induction|Re-induction	Refractory	Standard Chemotherapy	35	Intrathecal	Cytarabine	Unknown	6	Dead	157	Dead-Unknown	NA	15		NA	NA	NA	12	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA		426	TRUE		NA	NA	NA	26.4	TRUE	negative	0	negative			TP53 (p.R282Q; 46.6%)	"CSF3R (p.A470V, MAF 51%)|DNMT3A (p.R882C, MAF 51%)|NRAS (p.G13R, MAF 48%)|TP53 (p.R282Q, MAF 51%)"					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	5.529492035	7.687752193	7.719997827	4.047954382	6.806034507	2.739328747	6.272022849	yes	yes	yes	yes	yes	yes	yes	1.065198316						
BA2098R	BA2098D	2414	Waves1+2	yes	yes	yes	yes	Female	Female	White	UNKNOWN	White	1			61	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Idarubicin) plus Sorafenib"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1830	Alive	0	83		1.8	1.8	13.3	63.7	7.9	0.1	69	35	3	0.87	M5	34.7	11.6	"46,XX[20]"	337	95.6	Normal	146	TRUE	"Positive (dim CD4, CD11b, variable CD13, partial CD14, CD33, variable CD56, bright CD64, dim CD123 and HLA-DR-positive, comprising ~75% of WBCs. There is also about 5% of blasts are positive for CD117, CD13, CD33, HLA-DR, CD123, amd CD11b. Lymphocytes account for 13% of WBCs and include 74% T cells, 19% B cells and 7% NK cells. T cells show a CD4:CD8 ratio of 5:1 without aberrant antigen expression.) | Positive (B cells are polytypic by surface light chain expression with a kappa to lambda ratio of 1.2:1.)"	FALSE	TRUE	6.1	44.83	TRUE	negative	0	positive				IDH1 (p.R132H; MAF 37%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G13D; MAF 38%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	1.495560261	3.222269335	0.708403649	3.710231589	6.842210925	-2.113199232	2.867800292	no	no	no	no	yes	no	no	0.762719964						
BA2778R	BA2778D	2083	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			60	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	6	"Fludarabine, Melphalan|Ruxolitinib|7+3 (Cytarabine, Idarubicin)|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|MiDAC|Hydroxyurea"	5	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor|Re-induction|Maintenance	Refractory	Standard Chemotherapy	18	Targeted Therapy - Kinase Inhibitor(s)	Ruxolitinib	Maintenance	496	Alive	1801	Alive	0	75	44	0	0.9	28.7	46.1	24.3	0	18	13	2.9	1.19	M5	26.4	8.8	"46,XX[20]"	222	96.4	Normal	175	TRUE	"Positive (CD11b, variable CD13, CD14, CD33, dim CD56, bright CD64, and HLA-DR+)"	FALSE	TRUE	6.9	34.6	TRUE	negative	0	positive				FBXW7 (p.T15_G16insP; MAF 48%)|NPM1 (p.W288fs*12; MAF 40%)|NRAS (p.G12S; MAF 40%)|TET2 (p.H437fs*7; MAF 42%)					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.137121042	3.473964059	3.012381411	4.499563156	7.202313187	-0.90581406	5.750230366	no	yes	yes	yes	yes	yes	yes	0.867915328						
BA2163R	BA2163D	2129	Waves1+2	yes	yes	yes	no	Male	Male	White	NON-HISPANIC	White	1			67	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Residual Disease	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Fludarabine, Melphalan|Azacitidine|Hydroxyurea|Idarubicin and Cytarabine"	3	Allogeneic - Sibling|Induction|Re-induction	Refractory	Standard Chemotherapy	1932	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Sibling	-1	Dead	452	Dead-Disease	2.6	42.5	54	0.9	0	44.2	2.7	0.9	0	21	15	2	2.62		23.1	7.9	"45,XY,+5,dic(5;8)(q11.2;p12)x2,del(7)(q22q32),-18,del(20)(p11.2)[cp20]"	NA	91.7	"5p/5q: 88/100 (88%) cells had one signal for EGR1 (5q31) and three signals for 5p, consistent with the metaphase karyotype; 5 cells (5%) had one EGR1 signal and four 5p signals, consistent with a previous sideline with three copies of the dicentric 5;8 chromosome.   | BCR: 15/200 (7.5%) cells had three signals for BCR (22q11.2) consistent with a previous sideling that had trisomy 22 (the same sideline with three copies of the dicentric 5;8 chromosome). There was no evidence for BCR/ABL fusion. "	22	TRUE	"Positive (CD7, CD13, dimCD33, CD34, variable CD38, CD56, dim CD58, variable CD117, dimCD123 and dim HLA-DR positive)"	TRUE	TRUE	5.3	1.27	FALSE	negative	0	negative			TP53 (p.K132R; 39.4%)|TP53 (p.X126_splice; 51.3%)	DNMT3A (p.G570E; MAF 44%)|JAK2 (p.V617F; MAF 3%)|TP53 (Intron 4 3' splice site mutation; MAF 42%)|TP53 (p.K132R; MAF 45%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	5.335031781	4.168688371	1.625555128	4.608642877	5.946021508	-1.018860382	3.885475295	yes	yes	no	yes	no	no	no	0.585917738						
BA2820R	BA2820D	2542	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			73	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)|Hydroxyurea"	1	Induction	unknown	Standard Chemotherapy	167	Standard Chemotherapy	"S0919 Trial (Pravastatin, Idarubicin, Cytarabine)"	Induction	21	Dead	28	Dead-Disease	0	88	38	0	1.7	20.9	60.9	1.7	0.1	27	40	3	1.2	M4	33	11.2	"46,XY[20]"	NA	105.8	normal	55	FALSE	"Positive (Myeloid blast immunophenotype: CD13, CD33, dim CD64, CD117, CD123 (+) Monocytic/monoblastic immunophenotype: bright CD11b, CD13, bright CD14, CD33, bright CD64, HLA-DR (+))"	FALSE	TRUE	7.5	58.97	TRUE	positive	1	positive				DNMT3A (p.R882H; MAF 42%)|EP300 (p.N674D; MAF 50%)|EP300 (p.V2140I; MAF 50%)|FLT3-ITD (MAF ~48%)|MLL2 (p.M3398V; MAF 51%)|NPM1 (p.W288fs*12; MAF 43%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	1.072877628	1.452270628	1.830428143	3.985714208	6.35117267	-3.190298081	3.840442769	no	no	no	yes	yes	no	no	0.660487373						
BA2704R	BA2704D	2255	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			61	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	3	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Hydroxyurea	1	Induction	Unknown	Standard Chemotherapy	8	Standard Chemotherapy	Hydroxyurea	Induction	8	Dead	8	Dead-Disease	0	93	85	0.8	0	16.5	0.8	1.6	0.2	19	21	2.7	0.78	M1	21.1	7.1	"46,XX[20]"	360	84.4	Normal	43	TRUE	"partial CD13, CD33, dim/partial CD56, CD58, dim CD117, CD123 and MPO"	FALSE	TRUE	5.7	30.54	TRUE	positive	0.851851852	positive				FLT3-ITD (MAF ~50%)|IDH2 (p.R140Q; MAF ~50%)|NPM1 (p.W288fs*12; MAF ~50%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.570289375	1.727517542	5.500924243	3.757086099	5.575225759	-2.54523938	-0.067402502	no	no	yes	no	no	no	no	0.286521143						
BA3139R	BA3139D	2618	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			30	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	y	Dyskeratosis congenita	y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	31	504	Post-Chemotherapy|Post-Transplant|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine"	4	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"Fludarabine, Cytarabine"	Re-induction	5	Dead	475	Dead-Disease	0	87		0	NA	10.4	3.5	1.7	0.4	23	29	3.3	0.77		23.8	8	"40~42,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18,add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13),+mar[cp12]/40~41,sl,add(2)(q31)[cp7]/46,XY[1] "	532	102.1	"84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously. "	36	FALSE		NA	NA	6.2	19.23	FALSE	negative	0	negative			TP53 (p.M340Cfs*5; 41.0%)|TP53 (p.R273H; 47.8%)	BCL6 (p.C475R; VAF 6%)|TP53 (p.M340fs*5; MAF 42%)|TP53 (p.R273H; MAF 47%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	6.192998322	2.027552303	3.953026894	1.722045083	5.469187797	-3.286356894	2.982452792	yes	no	yes	no	no	no	no	0.409644218						
BA3285R	BA3285D	2618	Waves3+4	no	no	no	no	Male	Male	White	NON-HISPANIC		1			30	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Dyskeratosis congenita	y	n	y	y	n	n	n	n	MYELODYSPLASTIC SYNDROMES	Unknown	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	31	573	Post-Chemotherapy|Post-Transplant|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine|Fludarabine, Cytarabine"	4	Induction|Re-induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"Fludarabine, Cytarabine"	Re-induction	5	Dead	475	Dead-Disease	1.8			1.8	NA	14.7	8.3	0	0	65	64	2.2	0.77		22.9	7.5	"39~41,X,-Y,dic(5;12)(q13;p11.2),del(7)(q22q36),add(9)(q31),add(13)(q22),ins(?;14)(?;q11.2),-15,add(15)(p11.2),del(16)(q11.1),-17,-18.add(19)(q13.4),-20,der(21)t(3;21)(q22.3;q13)[cp16]/46,XY[5] "	NA	90.5	"84.5% of cells were missing a signal for EGR1, consistent with 5q deletion, and as seen previously. "	9	FALSE		NA	NA	5.2	10.63	FALSE	negative	0	negative			TP53 (p.M340Cfs*5; 50.0%)|TP53 (p.R273H; 42.2%)						no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	5.103864345	1.046216879	3.398698076	3.366669274	4.751664549	-4.122159479	2.548688708	yes	no	yes	no	no	no	no	0.420217801						
BA2584R	BA2584D	2422	Waves1+2	yes	yes	yes	yes	Male	Male			White	3		KMT2A_re	42	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"Busulfan, Fludarabine|7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)"	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Sibling	-1	Alive	427	Alive	NA	80		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"45,XY,t(3;17)([21;q11.2),add(4)(q21),add(5)(p15),ins(10;11)(p12;q23q13),der(12;18)(q10;q10)[19]/46,XY[1]"	NA	NA	11q23 rearrangement involving the  KMT2A (MLL) locus in 184/200 (92.0 percent) cells scored | One cell line showed the following clonal abnormalities in 19/20 (95%) cells: an apparent insertion of material form the long arm of chromosome 11 into the short arm of chromosome 10;  a translocation between chromosomes 3 and 17; added material on the long arm of chromosome 4 and on the short arm of chromosome 5; an unbalanced whole arm rearrangement between the long arms of chromosomes 12	NA	NA		NA	NA	NA	NA	NA	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	3.234423629	3.566571456	0.244476134	5.704115252	5.853417339	-2.671580925	0.294138846	yes	yes	no	yes	no	no	no	0.46368912						
BA3079R	BA3079D	2830	Waves3+4	yes	yes	yes	yes	Male	Male				3			68	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Alive	23	Alive	NA	67		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"45,XY,+1,der(1;14)(p10;q10),add(3)(p25),-5,del(12)(p11.2p13)[6]/44,XY,sl,del(7)(q11.2),der(8)del(8)(p21)t(8;17)(q24;q21),-17,+19,-22[cp10]/63<3n>,sdl1,-3,-4,-6,+8,del(8)(p21)x2,+9,+13,-15,-18,-21[cp4]"	NA	NA	"5p15.2 (D5S23): gain present  5q31 (EGR1): deletion present  7cen (D7Z1), 7q31 (D7S486): deletion and monosomy present  | t(8;21)(q22;q22) (RUNX1T1;RUNX1): gain present  11q23 (KMT2A; also known as MLL): gain present  16q22 (CBFB): gain present  17q21 (RARA): gain present  "	NA	NA		NA	NA	NA	NA	NA	negative	0	negative			TP53 (p.N239*; 57.9%)	TP53 (p.Asn239*; MAF 58.4%)|TP53 (p.Ser166_Gln167del; MAF 12%)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	TRUE	4.313273136	4.814802299	2.741167694	5.593630248	5.676959233	-1.453400325	4.572293286	yes	yes	yes	yes	no	no	yes	0.826418928						
BA2450R	BA2450D	2284	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			46	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea"	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	269	Dead-Disease	0			0	0	20.4	0	66.7	1	58	44	3.3	1.04		23.8	8.1		401	88.5	"metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid"	14	FALSE		NA	NA	7.3	6.18	FALSE	positive	0.25	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	3.892320955	5.057913863	6.151013721	4.043120925	6.802992445	-0.166328551	0.068042127	yes	yes	yes	yes	yes	yes	no	0.547614323						
BA2994R	BA2994D	2284	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1			46	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	14	Post-Chemotherapy|Residual Disease	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea"	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	269	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA	"metaphases positive for 45XX monosomy chromosome 17,20/22 metaphases positive for 46XX diploid"	NA	NA		NA	NA	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	2.338146061	1.628561585	6.051520711	2.597407025	6.011722493	1.285270689	0.015882881	no	no	yes	no	no	yes	no	0.3426945						
BA2824R	BA2824D	2284	Waves1+2	no	no	no	no	Female	Female	White	NON-HISPANIC	White	1			46	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	23	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Supportive/Palliative Care	5	"7+3 (Cytarabine, Idarubicin)|Sunitinib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin) plus Sorafenib|Hydroxyurea"	4	Consolidation|Salvage|Induction|Supportive/Palliative Care	Complete Response	Standard Chemotherapy	32	Standard Chemotherapy	Sunitinib	Consolidation	2	Dead	269	Dead-Disease	0	90	90	0	0	5	0	0	0	27	43	1.6	0.93		22.5	7.9		NA	82.1	Positive	43	TRUE	"variable CD7, CD13, dim CD33, partial CD34, CD38,dim CD58, partial and variable CD117 and CD123 positive"	TRUE	TRUE	5.1	18.38	FALSE	positive	0.515151515	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	3.526693218	0.593397427	6.4471016	1.940033158	6.142350741	0.86708053	2.858883093	yes	no	yes	no	yes	yes	no	0.396836438						
BA3099R	BA3099D	2224	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC		1			52	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	383	Post-Chemotherapy|Relapse	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	5	"MiDAC|Idarubicin and Cytarabine|FLAG-IDA plus Midostaurin|Azacitidine, Midostaurin, Ponatinib|7+3 (Cytarabine, Idarubicin) plus Dasatinib "	4	Consolidation|Salvage|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	Idarubicin and Cytarabine	Salvage	3	Dead	559	Dead-Disease	0		78	0	0	14.9	7	10.5	0	40	99	2.3	0.43	M5	25.6	8.5	"46,X,t(X;7)(q21;q32)[20] "	NA	94.1	Normal	5	FALSE	"variable CD7, CD13, CD33, partial CD34, CD38, CD58,  CD117, CD123 and HLA-DR  (Immunophenotypic shift is noted from the prior leukemic blast  population.)"	TRUE	TRUE	5.5	7.66	FALSE	positive	13.28571429	positive				DNMT3A (p.R882C; MAF 46%)|FLT3-ITD (MAF ~90%)|NPM1 (p.W288fs*12; MAF 44%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	1.479667395	1.334643814	2.338146061	3.209378832	5.148973137	-0.497690291	2.006070673	no	no	no	no	no	yes	no	0.434744003						
BA2552R	BA2552D	2203	Waves1+2	yes	yes	yes	no	Female	Female	White	NON-HISPANIC	White	6			67	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	69	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	n	y	y	n	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	6	"AG-120|7+3 (Cytarabine, Idarubicin)|Cytarabine|Decitabine|ME (Etoposide, Mitoxantrone)|Fludarabine, Melphalan, ATG"	6	Consolidation|Salvage|Induction|Experimental|Post-Transplant Relapse|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Cytarabine	Post-Transplant Relapse	3	Dead	944	Dead-Unknown	NA		94	0	NA	3	0	1	NA	18	52	3.2	1.03		24.6	8.6		NA	93.5		28	FALSE		NA	NA	5.7	108.9	TRUE	positive	0.666666667	positive				"IDH1 (p.R132S, MAF 46%)|NPM1 (p.W288Cfs*12, MAF 57%)"					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.836556065	1.619820405	1.767407463	3.034466258	4.292298686	0.643937104	-1.681775566	no	no	no	no	no	yes	no	0.301540609						
BA2456R	BA2456D	2481	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	2			65	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Skin cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Cytarabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Cytarabine	Supportive/Palliative Care	-1	Dead	2	Dead-Unknown	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA	"nuc ish (PML,RARA)x2[199]"	NA	NA		NA	NA	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	3.081970801	4.130497691	2.121525013	5.139762211	6.280519951	-3.589558873	1.343606903	yes	yes	no	yes	yes	no	no	0.803415756						
BA2563R	BA2563D	2493	Waves1+2	yes	yes	yes	yes	Male	Male	White		White	3			61	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|IDAC plus Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Sorafenib"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Matched Unrelated Donor	-1	Alive	398	Alive	NA	86	89	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	57	TRUE		NA	NA	NA	115.15	TRUE	positive	0.063829787	positive				DNMT3A (p.Arg326Cys; MAF 44.5%)|FLT3-ITD (p.Phe594_Asp600dup; MAF 45%)|NPM1 (p.Trp288fs; MAF 20.7%)|TET2 (p.Ala911fs; MAF 40.6%)|TET2 (p.His1036fs; MAF 39.4%)					no		Found	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.395932963	1.128145264	4.683098974	1.616173134	5.618173087	-3.011807357	0.560432478	no	no	yes	no	no	no	no	0.309727655						
BA3164R	BA3164D	2194	Waves3+4	no	no	no	no	Female	Female	Multiracial	HISPANIC		1			46	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	124	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	7	"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate"	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	-1	Dead	360	Dead-Disease	0	85	50	0	0	7.1	4.4	41.6	0.4	25	56	3.7	1		31.9	10.5	"46,XX,t(10;16)(q22;q24)[10]/46,X,t(X;1)(q23;q44),t(10;16)(q22;q24)[3]/46,X,t(X;13)(p21;q14),t(3;22)(q13.2;p11.1),t(5;6)(q31;q24),add(9)(q13),t(10;16)(q22;q24)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[2]/46,sl,der(1)t(1;2)(p13;q11.2),-2, (der(3)t(3;5)(q12;p15),del(6)(q13q23),+22[2]/46,XX[1])"	1199	93	Normal	63	TRUE	"partial CD7, CD13, CD33, partial CD34, CD38,  CD58, CD71, partial CD117, CD123, and HLA-DR +"	TRUE	TRUE	6.6	23.68	TRUE	positive	11.5	positive				DNMT3A (p.R882H; MAF 43%)|FLT3-ITD (Internal tandem duplication (~75 bp; in-frame); MAF 79%)|JAK3 (p.H529R; MAF 50%)|NPM1 (p.W288fs*12; MAF 36%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	3.709785016	1.275802676	6.645188941	3.697153947	5.954796535	0.576990346	0.28485128	yes	no	yes	no	no	yes	no	0.409230908						
BA3235R	BA3235D	2194	Waves3+4	no	no	no	no	Female	Female	Multiracial	HISPANIC		1			46	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	168	Residual Disease|Post-Chemotherapy|Post-Transplant	Residual	Peripheral Blood	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	7	"Bellicum Trial (Flu/Cy/TBI + ATG + Rituximab then BPX-501)|Dasatinib|7+3 (Cytarabine, Idarubicin)|HiDAC|MEC (Cytarabine, Etoposide, Mitoxantrone)|Sorafenib|Methotrexate"	6	Allogeneic - Sibling|Consolidation|Induction|Experimental|CNS|Re-induction	Complete Response i	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Dasatinib	Experimental	-1	Dead	360	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX,t(10;16)(q22;q24)[cp12]/46,sl,t(1;4)(q41;q33),t(7;9)(p15;q32)[5]/46,sl,t(X;1)(q23;q44)[2]/46,sl,der(1)t(1;2)(p32;q32)t(1;15)(q23;q24),der(2)t(1;2)(p32;q32),der(15)t(1;15)(q23;q24)[1]"	NA	NA		NA	NA		NA	NA	NA	NA	NA	positive	15.66666667	positive				FLT3-ITD (ITD; MAF 60%)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	TRUE	FALSE	2.116097354	3.072543248	5.082584874	4.184010337	6.449953852	-0.517131786	4.205597741	no	no	yes	yes	yes	yes	no	0.782124377						
BA2984R	BA2984D	2520	Waves1+2	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC	White	1			81	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	81	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Vidaza, BI836858 (anti-CD33)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Vidaza, BI836858 (anti-CD33)"	Induction	-1	Dead	581	Dead-Disease	0	80	80	0	7	7.8	0	6.9	0.5	31	42	3.2	1.3	M1	25.1	8.8	"46,XY[19]"	665	85.1	Normal	16	FALSE	"dim CD13, CD33, CD38, CD58, dim CD64, CD71, dim CD117 and CD123-positive"	TRUE	TRUE	7.2	33.81	TRUE	negative	0	positive				CSF3R ( p.T640N; MAF: 14%)|EZH2 (p.G709D; MAF: 17%)|EZH2 (p.R684C; MAF: 4%)|IDH2 (p.R140Q; MAF: 46%)|KDM6A (Splice site-Intron 5 3' end mutation; MAF:3%)|NPM1 (p.W288fs*12; MAF: 39%)					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.195311478	1.459629216	0.10465675	3.420105908	4.830238718	-3.647851047	3.510084808	no	no	no	no	no	no	no	0.380753751						
BA2776R	BA2776D	2431	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			61	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Supportive/Palliative Care	1	Hydroxyurea	1	Supportive/Palliative Care			NA	Supportive/Palliative Care	Hydroxyurea	Supportive/Palliative Care	-1	Dead	316	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA	"CD13, CD33, CD38, CD56, CD58, CD117, CD123 and dim MPO positive"	FALSE	TRUE	NA	NA	NA	positive	9	positive				FLT3-ITD (30 bp insertion; MAF 70%)|NPM1 (p.W288fs*12; MAF 45%)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	FALSE	1.530824428	1.067565112	2.071535077	2.019295974	5.292721338	-1.126239505	0.49238161	no	no	no	no	no	no	no	0.224125863						
BA2218R	BA2218D	2282	Waves1+2	yes	yes	yes	yes	Female	Female	White	HISPANIC	HispNative	6			39	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	40	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|ME (Etoposide, Mitoxantrone)|Decitabine"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	39	Standard Chemotherapy	Decitabine	Salvage	69	Dead	433	Dead-Unknown	NA		91	NA	NA	9	NA	NA	NA	21	34	3.8	0.49		29.3	9.9		NA	93.6		66	TRUE		NA	NA	5.8	73	TRUE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.231884909	-1.330559403	-0.286763973	1.782959625	4.517605999	-0.728077925	2.437508634	no	no	no	no	no	yes	no	0.359483197						
BA2135R	BA2135D	2547	Waves1+2	yes	yes	yes	yes	Female	Female			HispNative	6			73	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Decitabine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Decitabine	Supportive/Palliative Care	-1	Alive	122	Alive	NA	71	3	1	NA	68	8	11	NA	11	23	2.9	0.51		24.9	7.8	"46,XX,del(1)(p22),der(15)t(15;?)(q15;?),-17,+mar[19]/46,XX[1]"	NA	110.7	Loss of RARA gene at 17q21 is detected in 69% of cells Gain of MLL gene at 11q23 is detected in 8% of cells.	95	TRUE	"blasts 55% of all events; they are positive for cd34, hla-dr, cd117, cd13, cd33, and negative for cd11b, cd14, cd64, tdt and mpo"	FALSE	FALSE	4.8	63.4	TRUE	negative	0	negative		ASXL1 (p.G646Wfs*12; 32.6%)							no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.420360525	4.243521333	3.820771229	3.806896357	5.570413316	-1.377359964	5.205808118	no	yes	yes	yes	no	no	yes	0.68248863						
BA2914R	BA2914D	2508	Waves1+2	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC	White	1			38	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	38	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	106	Alive	1586	Alive	NA	47		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA	"CD117, dimCD4, heterogeneous CD13, CD33, dimCD64 and  MPO positive  (Myeloid Blast Population) | heterogeneous CD13, bright CD33, dimCD4,  dimCD14, bright CD64 positive  (Monocytes/promonocytes Population)"	FALSE	TRUE	NA	46.27	TRUE	negative	0	positive				DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 25%)|KRAS (p.Q61L; MAF 10%)|NPM1 (p.W288fs*12; MAF 51%)|NRAS (p.G13D; MAF 24%)					no		Found	TRUE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	3.248339325	5.668574383	2.346537472	3.572854403	8.245096155	-1.283519723	7.062347959	yes	yes	no	no	yes	no	yes	0.769979626						
BA2406R	BA2406D	2143	Waves1+2	yes	yes	yes	no	Male	Male	White		White	6			64	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Hodgkin Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	64	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	6	Dead	80	Dead-Unknown	NA	17		NA	NA	NA	5	NA	NA	NA	NA	NA	NA		NA	NA	"42,XY,-3,-7,der(12)t(12;?)(q24.3;?)-17,der(17)t(17;?)(p13;?),-21,der(22)t(22;?)(p11.2:?)[10]/46,XY[10] "	NA	NA		43	TRUE	"NOT DETECTED for the MLL partial tandem duplication (PTD). NOT DETECTED for the FLT3 Internal Tandem Duplication (ITD)-Signal Ratio (SR). NOT DETECTED for the FLT3 TKD Mutation. Pathogenic alterations are DETECTED in the DNMT3A, NF1 and TP53 genes.  (Bone Marrow Immunophenotyping) | positive for CD34, CD117, HLA-DR, CD13, and CD33, negative for monocytic markers CD11b, CD14 and CD64, negative for specific B and T cell markers. (Bone Marrow Immunophenotyping)"	FALSE	TRUE	NA	2.2	FALSE	negative	0	negative			TP53 (p.E204*; 52.3%)	"DNMT3A (c.2635_2651delAACATGAGCCGCTTGGC; p.N879Efs*36c.2656C>T; pQ886*MAF 43%, 36% )|NF1 (c.2192_2199delTCTTGCCC; p.L731Qfs*3  MAF 38%)|TP53 (c.610G>T;p.E204*MAF 51%)"					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	4.688714884	5.507935528	5.190893709	5.470281866	7.093391326	1.436266854	6.208728417	yes	yes	yes	yes	yes	yes	yes	0.848661031						
BA2924R	BA2924D	2475	Both	no	no	no	no	Male	Male	White		White	6			66	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	0	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	HiDAC	Consolidation	63	Alive	300	Alive	NA		8	1	NA	14	19	46	NA	15	22	4.3	0.88		38.3	12.5		NA	97.2		165	TRUE		NA	NA	6.2	9	FALSE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	3.766798496	4.866393511	3.287448061	6.809027973	6.12729526	0.450991498	4.189053376	yes	yes	yes	yes	yes	yes	no	0.719508946						
BA3192R	BA3192D	2475	Waves3+4	no	no	no	no	Male	Male	White			6			66	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	80	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	23	Standard Chemotherapy	HiDAC	Consolidation	63	Alive	300	Alive	NA	90		NA	NA	NA	0	NA	NA	NA	NA	NA	NA		NA	NA	"49,XY,+4,+8,+14[9]/49,sl,del(4)(q21q31.1)[11]"	NA	NA		41	FALSE	"POSITIVE FOR CD117, HLA-DR, CD13, CD33, CD14 AND MPO AND NEGATIVE FOR CD34, CD11B, CD64, CD10 AND TDT. (Bone Marrow Immunophenotype)"	FALSE	TRUE	NA	13	FALSE	positive	NA	positive				DNMT3A (c.2645G>A; p.R882H MAF 42%)|FLT3-ITD|KIT (c.2447A>T; p.D816V MAF 81%)|NPM1 ((NPM1) c.860_863dupTCTG; p.W288Cfs*12  MAF 51%)|SETBP1 (c.3209C>T; p.P1070L MAF 46%)|TET2 (c.3638T>G; p.V1213G MAF 87%)					no		Found	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	0.846900161	0.534938899	1.660015572	2.200430448	5.155284096	0.191709371	-1.042293361	no	no	no	no	no	yes	no	0.362124164						
BA2303R	BA2303D	2570	Both	no	no	no	no	Female	Female			White	3			39	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Fludarabine, TBI"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, TBI"	Allogeneic - Sibling	-1	Alive	296	Alive	NA	70	80	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA		NA	NA	"Large pop. of promonocytes/monoblasts representing approx 57% of total leukocytes and increased atypicalCD117 pos, partial CD34 pos myeloblasts (partial CD7 pos) representing approx 6% of leukocytes consistent w/AMLw/monocytic differentiation."	TRUE	FALSE	NA	190	TRUE	positive	5.666666667	positive				DNMT3A (p.Arg882His; MAF 41.8%)|FLT3 (p.Tyr572Cys; MAF 1.2%)|FLT3 (p.Val581_Arg595dup; MAF 22%)|FLT3-ITD|NPM1 (p.Trp288fs; MAF 21.2%)					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	FALSE	0.433070764	1.4606712	3.418602136	3.077577922	6.450425588	-2.975956175	3.39199853	no	no	yes	no	yes	no	no	0.687144943						
BA2160R	BA2160D	2216	Both	no	no	no	no	Male	Male			White	3			74	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Bladder Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|Azacitidine"	2	Induction|Supportive/Palliative Care	UNKNOWN	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Dead	58	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA	"Large population of CD117pos, CD34 neg, HLA-DR neg myeloblasts, representing approx 68% of leukocytes, consistent w/ residual/recurrent AML."	FALSE	FALSE	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	2.445112797	1.452270628	-1.021805683	3.464588667	5.213971195	-2.584830924	-1.460562837	no	no	no	no	no	no	no	0.320887021						
BA2590R	BA2590D	2131	Both	no	no	no	no	Male	Male			HispNative	5			55	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	"Midostaurin|Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Enasidenib"	3	Induction|Double Umbilical Cord Blood Transplant (DUCBT)|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	44	Dead	282	Dead-Disease	0	88.5	64	0	NA	25	4	7	NA	34	36	3.3	NA		31.3	10.9	"46,XY[19]"	NA	NA	Normal	54	TRUE	"Negative (CD19, CD22, Cyt CD3, CD7, CD56, CD11b, CD13, CD14, CD34, CD64, CD117, TdT) | Positive (CD38, Cyt CD79a, CD15, CD33, MPO) | Dim (CD45, HLA-DR)"	TRUE	TRUE	7.4	24.9	TRUE	positive	1	positive				FLT3 (c.1811_1812insl8; p.E604_P605insYDLKWE; MAF 32%)|IDH1 (c.395G>A; p.R132H; 44%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 42%)|SRSF2 (c.284_307del; p.P95_R102del; MAF 45%)		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	0.463015517	1.323460801	0.502611742	3.938851014	4.472838845	-0.976484324	0.203542587	no	no	no	yes	no	no	no	0.418640065						
BA3410R	BA3410D	2695	Waves3+4	yes	yes	yes	no	Male	Male	White	NON-HISPANIC		8			63	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Supportive/Palliative Care	2	"7+3 (Cytarabine, Idarubicin)|Decitabine"	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	8	Supportive/Palliative Care	Decitabine	Supportive/Palliative Care	67	Dead	250	Dead-Disease	NA		5	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"43-48,XY,add(2)(q11.2),add(3)(p13),add(3)(q29),del(5)(q15q33),der(7)add(7)(p11.2)add(7)(q22),?hsr(8)(q24),+10,+11, add(12)(p11.2),-13,add(14)(p13),add(15)(p12),add(15)(p13),-16,?hsr(16)(q22),-17,-20,+21,add(21)(q22),idic(21)(q22),-22, add(22)(p12),+mar1-5[cp22]/87-88,idem[cp2]"	NA	NA		79	TRUE		NA	NA	NA	1.9	FALSE	negative	0	negative			TP53 (p.R248Q; 58.8%)						no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	6.180746339	7.257903471	5.742443266	5.799143575	7.182352914	1.443763947	6.294106234	yes	yes	yes	yes	yes	yes	yes	0.794990073						
BA3206R	BA3206D	2668	Waves3+4	yes	yes	yes	yes	Female	Female	White	HISPANIC		1		RUNX1-RUNX1T1	35	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	35	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine, Venetoclax"	4	Consolidation|Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"Decitabine, Venetoclax"	Salvage	165	Dead	1220	Dead-Disease	0	60	10	0	0.9	88.7	0.9	9.5	0	34	12	3	0.8	M2	22	7.8	"45,X,-X,t(8;21)(q22;q22)[20] "	334	93.2	"RUNX1T1(8q21.3)/RUNX1(21q22):  64% of cells had an atypical 1r/2g/1f  signal pattern, a fusion pattern consistent with t(8;21) as seen on metaphase analysis.  | All twenty metaphase cells examined were abnormal, with monosomy X and  t(8;21)."	34	FALSE	"CD13, dim CD19, dim CD33, CD34, CD38, CD56, CD58, CD117, dim CD123, HLA-DR and MPO+ "	FALSE	TRUE	7	4.73	FALSE	negative	0	negative				FLT3-ITD (MAF 5%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.469501228	4.702067507	1.517595728	4.596171504	6.51154576	-1.463854919	8.030156765	no	yes	no	yes	yes	no	yes	0.518841133						
BA3306R	BA3306D	2811	Waves3+4	yes	yes	yes	yes	Female	Female	White			5			26	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Fludarabine, Cyclophosphamide, Thiotepa, TBI"	3	Consolidation|Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Cyclophosphamide, Thiotepa, TBI"	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	289	Alive	0	89.5	88	0	NA	7	2	3	NA	10	21	3	NA		23.1	7.6		NA	NA	Normal	19	FALSE	"Dim Positive (CD13, MPO) | Dim Partial positive (CD34) | Variable partial positive (CD117)"	FALSE	FALSE	5.2	138.2	TRUE	positive	19	positive				"FLT3-ITD (ITD, c.l815_1816ins30; p.F605_P606insl0 (MAF 49%))|IDH1 (c.395G>A; p.R132H (MAF 45%))|NPM1 (c.863_864insTCTG; p.W288fs (MAF 43%))"					no		Found	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	1.008641924	2.654167603	4.716819501	2.183881732	4.407287194	1.3401803	1.593428932	no	no	yes	no	no	yes	no	0.441052689						
BA3133R	BA3133D	2747	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			61	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Skin cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Vidaza	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	Vidaza	Induction	-1	Dead	51	Dead-Disease	0	25	26	0	11.5	9.7	7.1	43.4	0.1	23	33	3.6	0.8	M2	22	7	"45,XY,del(5)(q13q33),-7,add(8)(q24.3),add(9)(q34),add(10)(q23),del(17)(p13)  ,add(18)(q23)[3]/47-49,sl,+2-4mar[cp12]/44,sl,-2,add(3)(p21),t(6;11)(p22;q1  4),-add(8)(q24.3),add(8)(p22),-9,add(9)(q33),-10,-13,add(21)(q21),+2mar[8] "	855	116.4	"TP53 (17p13.1):  83% of cells were missing a signal for TP53, consistent with the 17p deletion seen on metaphase analysis.  | RUNX1 (21q22):  15.5% of cells were missing a signal for RUNX1. No  evidence for RUNX1/RUNX1T1 fusion.  | MECOM (3q26.2): 33% of cells had six (6) signals for MECOM. On available  metaphases, the extra MECOM signals hybridized to the small marker  chromosomes. No evidence for MECOM/RPN1 fusion. "	166	TRUE	"CD13, CD33, CD34, CD38, CD58, CD71, CD117,  CD123, HLA-DR + "	TRUE	TRUE	6.7	19.22	FALSE	negative	0	negative	RUNX1 (p.X170_splice; 26.1%)		TP53 (p.Q167*; 91.3%)	BCOR (p.Q1658H; MAF 100%)|RUNX1 (Splice Site; MAF 17%)|SF3B1 (p.K666M; MAF 47%)|SRSF2 (p.R180G; MAF 54%)|TP53 (p.Q167; MAF 65%)	yes	yes			yes	yes	Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	TRUE	FALSE	3.696690741	4.308377901	3.097641081	3.261219191	5.735529047	-0.015069307	5.464844015	yes	yes	yes	no	no	yes	yes	0.639499904						
BA3451R	BA3451D	2780	Waves3+4	yes	yes	yes	yes	Female	Female	White	UNKNOWN		1			47	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	95	Alive	1181	Alive	0	85	70	0.4	0.4	27.1	63.8	5.3	0.1	14	15	2.8	1.39	M5	19.8	6.5	"46,XX[20]"	355	97.5	Normal	48	TRUE	"CD4, CD11b, CD13, CD33, variable CD14, CD38,  dim CD56, CD58, bright CD64, dim CD123, HLA-DR, and partial MPO +"	FALSE	TRUE	7.7	58.66	TRUE	negative	0	positive				KRAS (p.G13D; MAF 36%)|NPM1 (p.W288fs*12; MAF 44%)|TET2 (p.Q897*; MAF 39%)					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	2.039588559	2.110674448	2.512677778	4.604015526	7.337966067	-3.11501734	5.654115006	no	no	no	yes	yes	no	yes	0.749742824						
BA3271R	BA3271D	2792	Waves3+4	yes	yes	yes	yes	Female	Female	White	HISPANIC		1			62	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	6	Dead	23	Dead-Disease	0	81	43	7.5	NA	20.6	16.8	8.4	0.8	21	33	2.3	2.79	M5	26.5	8.6	"46,XX[20]"	487	106.4	Normal	73	TRUE	"dim CD4, dim CD7, CD13, CD33, CD38, CD58, CD117, CD123, HLA-DR, and dim partial MPO (Myeloid Blast Population) | CD4, CD11b, CD13, dim CD14, dim CD15, CD16, CD33, CD38, CD58, CD63, CD123, HLA-DR  (Promonocyte/Monocyte Blast Population)"	TRUE	TRUE	6.5	28.53	TRUE	positive	0.666666667	positive				FLT3-ITD (ITD; MAF 45%)|IDH2 (p.R140Q; MAF 38%)|NPM1 (p.W288fs*12; MAF 41%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.571791266	2.951152346	2.29933994	3.806896357	6.867086307	-1.391022067	1.854913955	no	no	no	yes	yes	no	no	0.58620598						
BA3152R	BA3152D	2758	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			74	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Azacitidine	Supportive/Palliative Care	3	Dead	5	Dead-Disease	0	42	4	0	9.1	3.8	44.7	38.6	0.5	27	23	2.3	1.64	M5	23.8	7.7	"43~44,XY,der(5)t(5;15)(q22;q11.2),add(6)(p23),-15,-16,-17,add(18)(q21),add(  19)(q13.1),-21,+mar1,+mar2[cp20]"	387	93.3	"Approximately 95% of cells had abnormal signal patterns consistent with the metaphase karyotype and reflecting deleted 5q, monosomy 16, monosomy 17, and monosomy 21. "	93	TRUE	"partial CD11b, CD13, partial CD14, CD33, CD34, partial CD64, CD117, HLA-DR and dim MPO (+)"	FALSE	TRUE	6	29.15	TRUE	negative	0	negative			TP53 (p.Y220C; 90.9%)	TP53 (p.Y220C;  MAF 91%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	4.139771589	5.303048469	5.504984843	3.03620368	7.250085084	-1.978278599	6.469282832	yes	yes	yes	no	yes	no	yes	0.686348296						
BA3362R	BA3362D	2655	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			72	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"3+7 (Cytarabine, Daunorubicin)"	1	Induction	Unknown	Standard Chemotherapy	-1	Standard Chemotherapy	"3+7 (Cytarabine, Daunorubicin)"	Induction	-1	Dead	24	Dead-Disease	0	85	75	0	0	14.8	7.8	1.7	0.5	31	63	3.4	0.89	M5	23.7	7.7	"46,XX,der(1)t(1;1)(p36.3;q21),t(8;16)(p11.2;p13.3),add(15)(q24)[20]"	4853	96.7	"In 95/100 cells (95%), three  signals for chromosome 1q25 were observed, and only two signals for 1p36  were observed, consistent with gain of 1q by der(1)t(1;1)"	144	TRUE	"CD4, CD11b, partial CD13, CD33, CD56, bright CD64, partial CD117, CD123, HLA-DR and partial MPO-positive"	FALSE	TRUE	6.6	95.49	TRUE	negative	0	negative			TP53 (p.R175H; 55.0%)	FLT3 (p.D835E; MAF 42%)|TP53 (p.R175H; MAF 43%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	-0.389690037	0.855575139	1.685176012	2.545441967	4.883659381	-3.122130162	5.945200408	no	no	no	no	no	no	yes	0.480384723						
BA3135R	BA3135D	2733	Waves3+4	yes	yes	yes	yes	Male	Male	Black			8			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	7	Alive	48	Alive	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	NA	NA		NA	NA		NA	NA	dim CD56 | dim CD15 | dim CD123	FALSE	FALSE	NA	NA	NA	positive	0.315789474	positive				FLT3-ITD					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	TRUE	1.979844907	2.005229944	2.430680124	3.417574064	4.92208575	-2.429529426	-1.147913254	no	no	no	no	no	no	no	0.417660703						
BA3098R	BA3098D	2630	Waves3+4	yes	yes	yes	yes	Male	Male	White			3		CBFB-MYH11	44	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	44	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)|7+3 (Cytarabine, Idarubicin)|HiDAC"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Fludarabine, Thymoglobulin (Bu/Flu/ATG)"	Allogeneic - Matched Unrelated Donor	-1	Alive	119	Alive	NA	74.8	83	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,der(7)t(7;11)(q22;q13), inv(16)(p13.1q22)[15]/46,XY[5]"	NA	NA	"7cen (D7Z1), 7q31 (D7S486): deletion present | 11q23 (KMT2A; also known as MLL): gain present | 16q22 (CBFB): rearrangement present"	23	FALSE		NA	NA	NA	102.09	TRUE	negative	0	negative				KIT (p.Tyr418_Arg420delinsArgTrpGly; MAF 10%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.994577085	2.040360716	1.15112171	3.165860999	5.890863178	-1.293321936	5.250383209	no	no	no	no	no	no	yes	0.58251511						
BA3203R	BA3203D	2767	Waves3+4	yes	yes	yes	yes	Male	Male	Unknown	HISPANIC		6			62	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	"Acute myeloid leukaemia, NOS"	62	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)"	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	7	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Sibling	6	Dead	310	Dead-Disease	NA	35	39	1	NA	36	2	9	NA	83	69	2.8	0.99		NA	7		NA	102.9	The translocations commonly seen in AML are not detected. 3 copies of RUNX1T1 gene at 8q22 are detected in 56% of cells. Loss of RUNX1 and RARA genes at 21q22 and 17q21 are detected in about 58% of cells Gain of MLL gene at 11q23 are detected in 82% of cells. (Cytogenetics)	50	FALSE	"THESE ARE POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. POSITIVE FOR HLA-DR, CD117, CD34, CD33 AND CD13. (Bone Marrow Immunnophenotype)"	FALSE	TRUE	NA	44.8	TRUE	negative	0	negative			TP53 (p.P153Afs*28; 75.8%)						no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	TRUE	TRUE	3.469063941	5.192706803	4.327458333	4.135925763	6.659580884	0.442049234	6.799311741	yes	yes	yes	yes	yes	yes	yes	0.734974912						
BA3299R	BA3299D	2608	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		6			47	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Busulfan, Fludarabine|HiDAC|3+7 (Cytarabine, Daunorubicin)"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Fludarabine"	Allogeneic - Sibling	11	Alive	263	Alive	NA	70		2.3	NA	18.3	72.7	6.2	NA	17	17	3.1	0.62		NA	9.5	"46,XX[20]"	NA	97.7	"An apparently NORMAL KARYOTYPE was observed in all 20 mitotic cells analyzed. Specifically, there was no significant numerical chromosomal abnormality and no clonal structural aberration of any chromosome detectable within the limits of resolution.  (Cytogenetics)"	237	TRUE	"positive for CD117, HLADR, CD33, CD11b, CD64 and MPO (partial).  (Bone Marrow Immunophenotyping)"	FALSE	TRUE	NA	66.7	TRUE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.953485987	2.88584558	4.608642877	3.418072141	6.516570572	-1.313393676	2.71690838	yes	no	yes	no	yes	no	no	0.840114159						
BA3347R	BA3347D	2708	Waves3+4	yes	yes	yes	yes	Female	Female	White			5			68	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	-1	Alive	233	Alive	0	85	30	3	NA	35	21	11	NA	16	15	2.8	NA	M5	32.4	10.3	"46,XX[20] "	NA	NA	Normal	131	TRUE	"Neagtive (CD10, CD19, CD16, CD14, CD34, CD117) | Bright Positive (CD64)"	FALSE	FALSE	5.2	22	TRUE	negative	0	positive				DNMT3A (c.2311T>C; p.R771X; MAF 40%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 38%)|TET2 (c.2827C>T; p.Q943X; MAF 80%)					no		Found	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	0.043485771	2.46546171	4.327828449	3.757523282	6.170343149	1.210297225	4.07639219	no	no	yes	no	yes	yes	no	0.735247563						
BA3114R	BA3114D	2631	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC		8	mono		75	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Endometrial cancer|Lobular carcinoma in situ	y	n	n	n	y	y	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	75	0	Post-Chemotherapy	Remission	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)"	1	Induction	Unknown	Standard Chemotherapy	4	Standard Chemotherapy	"FLAG (Fludarabine, High-dose Cytarabine, G-CSF)"	Induction	4	Dead	93	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal (Clonal aberrations were not identified in metaphase cells examined by conventional cytogenetic techniques* or for any loci examined by FISH methods.)	NA	NA		NA	NA	NA	NA	NA	negative	0	positive				CEBPA (biallelic)|NPM1|PTPN11|TET2					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	4.886421954	4.950488895	1.977408253	2.322556438	6.415555152	-1.030400299	6.753097394	yes	yes	no	no	yes	no	yes	0.772482471						
BA3109R	BA3109D	2835	Waves3+4	yes	yes	yes	yes	Female	Female	White			2			56	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Residual Disease|Post-Chemotherapy	Residual	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	4	"Azacitidine, Sorafenib|7+3 (Cytarabine, Idarubicin)|HiDAC|Azacitidine, Trametinib"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Azacitidine, Trametinib"	Salvage	-1	Alive	2929	Alive	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX,der(22)t(1;22)(q12;p11.2)[1]/46,XX[19]"	NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	positive	RUNX1 (p.S100Lfs*38; 45.6%)								no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	TRUE	FALSE	NA	TRUE	TRUE	5.395695395	6.667811052	4.630331109	4.147611483	6.870253974	0.219029255	6.267933176	yes	yes	yes	yes	yes	yes	yes	0.869501769						
BA3245R	BA3245D	2829	Waves3+4	yes	yes	yes	yes	Female	Female	White			5			62	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Fallopian Tube Cancer	y	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	62	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Targeted Therapy - Kinase Inhibitor(s)	1	Decitabine	1	Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Supportive/Palliative Care	-1	Alive	53	Alive	0	50.5	53	0	NA	12	3	25	NA	19	19	2.2	NA		NA	8	"47,XX,psu dic(5;7)(q13;p10),r(7)(p12q11.2),+8,der(12)del(12)(p11.2p13)add(12)(q24.1)[2]/ 44,sl,add(3)(q12),-r(7)(p12q11.2),-8,-der(12)del(12)(p11.2p13)add(12)(q24.1),idic(22)(p11.2), +der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[16]/ 45,sdl1,+der(?)(7qter- > 7q11.2::?- > cen- > ?::12q11- > 12qter)[2]"	NA	NA	"5p15.2/ 5q31 (EGR1) (ABNORMAL - Loss of 5q31 sequences) | 7 centromere/ 7q31 (ABNORMAL - Loss of 7q31 sequences, see interpretation) | 8 centromere/ 20q12 (ABNORMAL - Gain of chromosome 8 centromere, Normal 20q12) | RUNX1 (21q22.12)/ RUNX1T1(8q22) (Negative rearrangement, ABNORMAL - Gain of 8q22 sequences)"	30	TRUE	"Negative (CD19, CD22, CD56, CD14, CD15, CD64, MPO) | Positive (CD38, CD7, CD13, CD33, CD34, HLA-DR) | Dim (CD11b, CD45, CD117)"	TRUE	TRUE	NA	18	FALSE	negative	0	negative			TP53 (p.L257Q; 84.5%)	IDH2 (c.419G>A; p.R140Q; MAF 5%)|NRAS (c.!82A>T; p.Q61L; MAF 26%)|TP53 (c.770T>A; p.L257Q; MAF 92%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	4.076001538	5.774883482	4.039910955	3.229168161	5.652987859	2.350741185	5.253852829	yes	yes	yes	no	no	yes	yes	0.714013094						
BA3085R	BA3085D	2785	Waves3+4	yes	yes	yes	no	Female	Female	White	NON-HISPANIC		1		RUNX1-RUNX1T1	14	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	14	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	2	Standard Chemotherapy|Intrathecal	3	"ADE (Cytarabine, Daunorubicin & Etoposide)|HiDAC|Cytarabine"	2	Induction|Intensification	Complete Response	Standard Chemotherapy	17	Standard Chemotherapy	HiDAC	Intensification	9	Alive	1523	Alive	0		60	0	3.5	24.3	6.1	15.7	0	21	26	3.7	0.78		18.5	6.4	"45,X,-X,t(8;21)(q22;q22)[20] "	NA	93.9	"RUNX1T1/RUNX1: 92/100 cells (92%) had a 1red/ 1 green/ 2 yellow fusion signal pattern, reflecting RUNX1T1/RUNX1fusion"	80	TRUE	"dim CD13, dim CD19, CD33, CD34, CD38, CD58, CD117,  CD123, HLA-DR and MPO"	FALSE	TRUE	7.5	13.58	FALSE	negative	0	negative				NRAS (p.G12D; MAF 6%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	3.444616701	3.675402895	0.842405831	3.611530287	6.065110115	1.14352835	7.967445329	yes	yes	no	no	yes	yes	yes	0.520210679						
BA3423R	BA3423D	2605	Waves3+4	yes	yes	yes	yes	Female	Female		HISPANIC		6			49	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Residual Disease|Post-Chemotherapy	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Unknown	Standard Chemotherapy	28	Standard Chemotherapy	HiDAC	Consolidation	114	Alive	345	Alive	NA	90	96	NA	NA	2	1	2	NA	43	32	3.7	0.67		NA	8.7		NA	84.8		78	FALSE	"Positive for CD34, CD117, HLADR, CD33 and CD13.  (Bone Marrow Immunophentyping)"	FALSE	TRUE	NA	19	FALSE	negative	0	positive				FLT3-TKD					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	2.473648115	2.289865922	0.91026955	2.665472463	5.036420551	0.354427733	2.923107349	no	no	no	no	no	yes	no	0.213994934						
BA3173R	BA3173D	2784	Waves3+4	yes	yes	yes	no	Female	Female	Black			6		RUNX1-RUNX1T1	45	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with t(8;21)(q22;q22); RUNX1-RUNX1T1	46	0	Residual Disease	Residual	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	"CLAG-M (Cladribine, Cytarabine, Mitoxantrone, Filgrastim)"	Salvage	4	Dead	457	Dead-Unknown	NA		97	NA	NA	3	NA	NA	NA	151	37	3.5	0.49		22.5	7.7	"46,XX,t(8;21)(q22;q22)[15]/46-47,sl,+6,add(13)(p11.2),add(15)(q26),-16,+19,+22[cp5]"	NA	88.9		23	FALSE		NA	NA	6.5	9.3	FALSE	positive	0.075268817	positive									no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	4.056409867	4.182104012	0.686505344	2.029156318	4.944501719	-0.112757807	3.305398914	yes	yes	no	no	no	yes	no	0.506072665						
BA3171R	BA3171D	2719	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			55	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine|Busulfan, Cyclophosphamide"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	9	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	-1	Dead	402	Dead-Treatment	0	60		0	6.8	19.7	20.5	15.4	1.5	NA	NA	NA	NA	M4	29.8	9.6	"43,XY,dic(5;12)(q11.2;p13),der(7)t(7;13)(q11.2;q12),i(8)(q10),+9,dup(11)(q2  3q23),-13,-15,-16,der(17)t(15;17)(q22;q23),-21,+mar[20]/46,XY[5] "	NA	101.4	"RUNX1T1/RUNX1: 86/100 cells (86%) reflecting the isochromosome 8q and the monosomy 21. No evidence for RUNX1T1/RUNX1fusion | EGR-1/ D5S23, D5S721: 89/100 cells (89%) consistent with missing 5q in the dicentric 5;12 | PML/RARA: Signal patterns were within normal limits with no evidence for  PML/RARA fusion. One metaphase cell shows the PML (15q22) signal on the derivative 17, consistent with the metaphase karyotype | BCR/ABL/ASS: 72/100 cells (72%) consistent the trisomy 9 in the metaphase karyotype. No evidence  for BCR/ABL fusion.  | D7S486/ CEP 7: 79/100 cells (79%) consistent with missing 7q in the derivative 7 | DEK/NUP: 79/100 cells (79%) reflecting the trisomy 9 in the metaphase karyotype. No evidence for  DEK/NUP fusion. | MLL: 61/100 cells (61%) had three intact MLL signals. One metaphase cell  shows two signals on the duplicated 11q. There was no evidence for MLL rearrangement."	21	FALSE	"CD11c, CD13, CD33, CD34, CD38, CD56, CD64, CD117,HLA-DR; negative TdT, CD19 and CD10 (from bmbx 5/3/17)"	FALSE	TRUE	NA	17.99	FALSE	negative	0	negative			TP53 (p.X125_splice; 75.0%)	KRAS (p.G12D; MAF 35%)|TP53 (Splice site (5' splice site mutation in intron 4); MAF 69%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	3.956413745	4.57299501	4.448430503	5.133689563	6.312054448	0.128934221	6.147180299	yes	yes	yes	yes	yes	yes	yes	0.629442968						
BA3277R	BA3277D	2818	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		5			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	-1	Alive	211	Alive	0	66.5	37	2	NA	24	6	31	NA	23	25	2.6	NA	M4	26.3	8.1	"46,XY[20] "	NA	NA	Normal	101	TRUE	"positive (CD38 dim, CD33 dim, CD45 dim, CD117 var, MPO var) | negative (CD10, CD19, CD20, CD22, CD23, Surf Kappa, Surf Lambda, FMC7, CD3, CD5, CD7, CD56, CD13, CD14, CD15, CD34) | PP (CD11b VAR, CD64 VAR, HLA-DR VAR)"	TRUE	TRUE	6	8.6	FALSE	negative	0	positive				IDH2 (c. 419G>A; p.R140Q; MAF 47%)|NPM1 (C.863_864insTCTG; p.W288fs; MAF 34%)|SRSF2 (c. 284C>A; p.P95H; MAF 47%)		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	1.370676648	4.428116689	2.048335989	4.657239738	5.360004718	0.402949581	4.281019838	no	yes	no	yes	no	yes	no	0.592861167						
BA3157R	BA3157D	2614	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			60	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Basal Cell Carcinoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HiDAC|3+7 (Cytarabine, Daunorubicin)|Busulfan, Cyclophosphamide"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Sibling	-1	Alive	1425	Alive	0	87	83	0	0	13.4	0.8	8.3	0.3	125	74	2.3	0.79	M1	26.3	9.2	"46,XY,del(9)(q13q22)[20]"	823	89.5	Normal	146	TRUE	"CD13, CD33, variable CD34, CD38, CD58, CD117,  CD123, HLA-DR, variable MPO"	FALSE	TRUE	6.1	23.32	TRUE	negative	0	positive				NPM1 (p.W288fs*12; MAF 41%)|NRAS (p.G13D; MAF 41%)|SF3B1 (p.T663I; MAF 50%)	yes				yes		Found	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.164885487	-0.152736587	-0.730775878	3.143933558	4.768514002	-2.990147787	1.444850418	no	no	no	no	no	no	no	0.319917645						
BA3433R	BA3433D	2681	Waves3+4	yes	yes	yes	yes	Male	Male				5			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	2	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin) plus Midostaurin"	2	Allogeneic - Sibling|Induction	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Sibling	-1	Alive	215	Alive	0	92	96	0	NA	3	0	1	NA	30	16	3.3	NA	M0	24.8	8.5	"46,XY[20]"	NA	NA	Normal	51	TRUE	"negative (CD19, CD22, CD7, CD11b, CD13, CD14, CD15, CD34, CD64, HLA-DR) | Dim (CD38, CD45) | Positive (CD56, CD33, CD117, MPO)"	TRUE	TRUE	6.5	52.1	TRUE	negative	0	positive				FLT3 (c.1818_1819ins26; p.P606_R607insCREYEYDLKWEFP; MAF 7%)|NPM1 (c.863_864insTCTG; p.W288fs; MAF 45%)|TET2 (C.3379C>t; p.Q1127X; MAF 44%)					no		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	2.17709681	0.18384673	1.420183931	2.158727516	5.039283443	0.26190263	-2.87599727	no	no	no	no	no	yes	no	0.405719183						
BA3450R	BA3450D	2627	Waves3+4	yes	yes	yes	no	Female	Female	White			7			68	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	22	Dead-Unknown	NA	74		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46~47,XX,add(3)(p13),del(5)(q13q33),der(14)t(14;17)(q32;q11.2),del(16)(q22),-17,-22,+2~4mar[cp19]/46,XX[1]"	NA	NA		NA	NA	"positive for CD13, CD33, CD34, CD38, partial HLA-DR, CD117, and a minor population is also positive for MPO"	FALSE	TRUE	NA	NA	NA	negative	0	negative			TP53	JAK2|TP53					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	4.353907806	5.234953808	4.756557293	2.131669073	5.72978047	0.142551159	5.829718495	yes	yes	yes	no	no	yes	yes	0.555790811						
BA3269R	BA3269D	2622	Waves3+4	yes	yes	yes	no	Female	Female	White			5			66	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Targeted Therapy - Kinase Inhibitor(s)	2	AG-221|Azacitidine	1	Supportive/Palliative Care			NA	Standard Chemotherapy	Azacitidine	Supportive/Palliative Care	6	Dead	61	Dead-Disease	0	75	86	0	NA	10	2	2	NA	14	28	2.4	NA	M0	24.3	7.7	"46,XX[19] "	NA	NA	Normal	66	TRUE	"negative (CD19, CD22, Cyt CD79a, Cyt CD3, CD7, CD56, CD14, CD15, CD34, CD64 TdT) | positive (CD38, CD13, CD33, CD117, MPO, HLA-DR) | dim (CD11b, CD45)"	TRUE	TRUE	6.2	70.1	TRUE	negative	0	positive				DNMT3A (c.1903C>G; p.R635G (COSM144550) MAF 44%)|IDH2 (c.419G>A; p.R140Q (COSM41590) MAF 44%)|NPM1 (c.863_864insTCTG; p.W288fs (COSM158604) MAF 37%)					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	2.604590742	3.32910698	3.168114613	3.00083017	5.550257601	-1.709760183	1.765539754	no	no	yes	no	no	no	no	0.560661149						
BA3156R	BA3156D	2702	Waves3+4	yes	yes	yes	no	Male	Male				8			65	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute erythroid leukaemia	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Dead	50	Dead-Disease	NA	25		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M6	NA	NA	"45,XY,del(7)(p13),-9[7]/4 5-47,idem,+13,-15,add(19) (p13.3),+20[cp11]/ 46,XY[2]"	NA	NA	POSITIVE for ABL1 gene locus copy number loss | POSITIVE for PML gene locus copy number loss	NA	NA		NA	NA	NA	NA	NA	negative	0	negative			TP53 (p.R273C; 67.5%)						no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	NA	TRUE	TRUE	3.420105908	3.586470655	2.957075737	3.725172889	6.464310176	-2.528601933	-0.442714222	yes	yes	yes	no	yes	no	no	0.602017933						
BA3226R	BA3226D	2734	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			75	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	75	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	37	Dead-Disease	0	73	79	0	0	11.4	1.8	7.9	0.4	42	41	2.8	0.66	M2	22.9	7.5	"46,XX[20]"	NA	97.9	Normal	45	TRUE	"dim CD11b, CD13, CD33, partial CD34, partial CD38, dim CD45, partial CD64, CD58, partial CD117, CD123 and partial MPO positive"	FALSE	TRUE	6.9	88.2	TRUE	positive	0.960784314	positive				FLT3-ITD (MAF 44%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	3.393553061	2.224894915	4.13786445	2.58046845	5.70373801	0.373939766	4.285915398	yes	no	yes	no	no	yes	no	0.479548651						
BA3421R	BA3421D	2659	Waves3+4	yes	yes	yes	yes	Female	Female	White			5			52	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	52	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Kinase Inhibitor(s)	3	"7+3 (Cytarabine, Idarubicin) plus Midostaurin|Midostaurin|Busulfan, Cyclophosphamide"	3	Allogeneic - Sibling|Induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Kinase Inhibitor(s)	Midostaurin	Maintenance	13	Alive	181	Alive	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA	Normal/Negative Rearrangement	NA	NA		NA	NA	NA	NA	NA	positive	0.724137931	positive				"DNMT3A (MAF 47%)|FLT3-ITD (2 on separate alleles: p.E604_F605insYDLKWE, MAF 19%; p.L601_K602ins18, MAF 9%)|NPM1 (MAF 44%)"					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	TRUE	TRUE	3.618031116	6.014988949	5.256419896	5.425300186	6.933559364	-1.821572113	5.50055254	yes	yes	yes	yes	yes	no	yes	0.993942019						
BA3232R	BA3232D	2714	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			36	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	36	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Other	6	"Azacitidine, Sorafenib|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|SY-1425 (Tamibarotene) plus Daratumumab|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Busulfan, Cyclophosphamide|Cytarabine, Methotrexate"	5	Allogeneic - Sibling|Induction|Experimental|Re-induction|Maintenance	Complete Response	Standard Chemotherapy	-1	Targeted Therapy - Other	SY-1425 (Tamibarotene) plus Daratumumab	Experimental	28	Dead	370	Dead-Disease	0	30	40	0	9.6	13.9	0.9	36.5	0.1	14	25	3.5	0.77	M4	13.3	4.6	"46,XX[20]"	NA	100	Normal	58	TRUE	"dim CD7, partial CD11b, variable CD13, CD33, CD64,  CD117, dim CD123, dim HLA-DR and partial MPO positive"	TRUE	TRUE	6.6	59.05	TRUE	positive	0.265822785	positive				BCOR (p.V89D; MAF 54%)|DNMT3A (p.R882H; MAF 51%)|FLT3-ITD (MAF 15%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12S; MAF 20%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.057901585	4.138984655	1.133368614	2.658017302	6.136398279	0.871276132	7.309488343	no	yes	no	no	yes	yes	yes	0.503060802						
BA3384R	BA3384D	2736	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1		KMT2A_re	39	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	39	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	4	DLI|Standard Chemotherapy|Bone Marrow Transplant|Other	7	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG-IDA (Cytarabine, Filgrastim, Fludarabine, Idarubicin)|Azacitidine|Radiation|Busulfan, Cyclophosphamide"	5	Consolidation|Unknown|Induction|Maintenance|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1512	Alive	0	>90	90	0	0	9.7	28.3	0	0	NA	NA	2.4	0.57	M4	20.5	6.7	"47,XX,del(11)(q23),+21[20]"	540	109.6	"MLL: 97/100 cells (97%) had a 0 red/ 1 green/ 1 yellow signal pattern,  partially deleting the MLL region of 11q23 and consistent with the deleted 11q in the metaphase karyotype. | RUNX1T1/RUNX1: 95/100 cells (95%) had a 2 red/ 3 green signal pattern, consistent with the trisomy 21 in the metaphase karyotype. There was no evidence for RUNX1T1/RUNX1fusion."	12	TRUE	"partial CD11b, dim CD13, CD33, partial CD34, variable CD64, CD117, CD123, HLA-DR+ "	FALSE	TRUE	NA	173.2	TRUE	negative	0	negative	RUNX1 (p.P49T; MAF 69%)			MLL (Possible subclone with partial tandem duplication)|RUNX1 (p.P49T; MAF 69%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	0.842405831	-0.437848975	0.420734247	1.685176012	5.473970121	0.521473783	4.214052862	no	no	no	no	no	yes	no	0.434304162						
BA3427R	BA3427D	2807	Waves3+4	yes	yes	yes	no	Male	Male	Unknown	UNKNOWN		1			67	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	67	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	n	y	y	n	0		0		0				NA	NONE	NONE	NONE	NA	Dead	117	Dead-Disease	1.7	20	7	0	0	80	7	10.4	0	26	17	3.5	0.87		29.3	10	"45,XY,-4,-5,del(6)(p24),add(7)(q21),der(9)t(9;14)(q12;q11.2),-14,-21,+22,ad  d(22)(p11.2)x2,+2mar[20]"	251	96.1	"EGR1/5p:  77% of cells were missing a signal for both probes, consistent  with monosomy, as seen on metaphase analysis.  | D7S486 (7q31): 73% of cells were missing a signal for D7S486 (7q31),  consistent deletion and with the add(7) seen on metaphase analysis. | NUP214 (9q34):  64% of cells were missing a signal for NUP214 (9q34), consistent with deletion due to the der(9) seen on metaphase analysis.  (Also, deletion of 9q34 was observed using the ABL+ASS probe set on a parallel study, GL17-02579.)  | RUNX1 (21q22):  55% of cells had four signals for RUNX1 (21q22); another  28% of cells had three signals. One of the four signals was on what  appeared to be a larger submetacentric chromosome, possibly the larger of  the two marker chromosomes observed on metaphase analysis. "	18	TRUE	"CD13, CD33, variable CD34, CD117, partial HLA-DR"	FALSE	TRUE	7	1.88	FALSE	negative	0	negative			TP53 (p.H179N; 16.9%)|TP53 (p.I195Mfs*13; 9.9%)|TP53 (p.I195Yfs*14; 11.4%)	TP53 (p.H179N; MAF 63%)|TP53 (p.I195fs*52; MAF 39%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	TRUE	4.916854372	6.268811498	1.636402799	7.630415169	7.832683892	-2.039805595	4.36276075	yes	yes	no	yes	yes	no	no	0.893052233						
BA3163R	BA3163D	2638	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1		MLLT3-KMT2A	43	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	43	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	Azacitidine|Mitoxantrone	2	Induction|Supportive/Palliative Care	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	Mitoxantrone	Supportive/Palliative Care	0	Dead	62	Dead-Disease	0	80	55	0.9	2.5	8.5	61	25.4	0.3	198	685	2.7	1.18	M5	34.2	11.4	"46,XX,t(9;11)(p22;q23)[15]/47,idem,+8[2]/46,XX[3]"	5919	99.1	"MLL: 57/100 cells (57%) had the abnormal 1 red/ 1 green/1 yellow signal  pattern, reflecting MLL (11q23) rearrangement, consistent with the 9;11  translocation observed in the metaphase karyotype. | RUNX1T1/RUNX1: 6/200 cells (3%) had a 3 red/ 2 green signal pattern,  reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the trisomy 8  clone observed in the metaphase karyotype. | CEP 8: 5/200 cells (2.5%) had three signals, reflecting an extra  chromosome 8 centromere signal, consistent with the trisomy 8 clone observed in the metaphase karyotype."	120	TRUE	"dim CD4, CD11b, CD13, partial CD14, CD33,  CD38, variable CD56, CD58, CD64, dim CD71, dim CD123, and HLA-DR+"	TRUE	TRUE	5	91.72	TRUE	negative	0	negative				DNMT3A (Splice site mutation (invariant splice donor at end of exon 14; likely pathogenic); MAF 20%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	5.393479498	6.294574842	4.807111451	3.91283292	7.26424109	2.22641256	6.719507651	yes	yes	yes	yes	yes	yes	yes	0.887202762						
BA3158R	BA3158D	2646	Waves3+4	yes	yes	yes	yes	Male	Male				3		RUNX1-RUNX1T1	68	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Non-Hodgkins Lymphoma	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	68	0	Initial Acute Leukemia Diagnosis|Post-Chemotherapy	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	NA		NA		NA				NA				NA	Unknown	0		NA	90.8		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,t(8;21)(q22;q22)[8]46,sl,del(9)(q13q22)[4]/47,sdl,+21[2]/47,sl,+21[4]/46,XY[2] "	NA	NA	"This analysis showed evidence of t(8;21)(q22;q22) (RUNX1T1-RUNX1 translocation) in 196/200 (98.0 percent) cells scored. Of these cells, 20/200 (10.0 percent) showed the translocation accompanied by an additional copy of the RUNX1 locus. "	NA	NA		NA	NA	NA	27.1	TRUE	negative	0	negative									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	4.328596221	2.126420627	0.332971491	2.911844261	5.806944625	-2.713314441	4.994253175	yes	no	no	no	no	no	yes	0.462659595						
BA3436R	BA3436D	2755	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1	mono		23	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	23	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"7+3 (Cytarabine, Idarubicin)|HiDAC|FLAG (Fludarabine, High-dose Cytarabine, G-CSF)|FLAG-IDA, Gemtuzumab|Busulfan, Cyclophosphamide"	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	-1	Alive	1510	Alive	0.9	80		0	0	11.6	0	10.7	0.3	17	7	3	0.68	M1	26.7	8.9	"46,XX[8]"	145	90.8	Normal	54	FALSE	"CD13, CD33, partial CD34, CD38, CD58, dim CD71, CD117,  CD123, and cMPO+ "	TRUE	TRUE	6.9	29.58	TRUE	negative	0	positive				CEBPA (p.A199fs*114; MAF 50%)|EZH2 (p.R288*; MAF46%)|GATA2 (p.A372T; MAF 31%)|NPM1 (p.W288fs*12; MAF 50%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	4.906047114	1.946720599	-0.143707385	1.362836848	4.808852579	0.18384673	1.586439704	yes	no	no	no	no	yes	no	0.223647141						
BA3154R	BA3154D	2768	Waves3+4	yes	yes	yes	yes	Female	Female	White			7			29	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Breast Cancer	y	n	n	n	n	n	n	n	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	"Mixed phenotype acute leukaemia, B/myeloid, NOS"	Adverse	ACUTE LEUKAEMIAS OF AMBIGUOUS LINEAGE	"Mixed phenotype acute leukaemia, B/myeloid, NOS"	29	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	256	Dead-Other	NA	95		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"30~35<1n>,XX,+1,+2,+6,+10,+11,+12,+18,+19,+21,+22[cp6]/46XX[20]"	NA	NA	Negative for 9;22 and MLL	NA	NA	"positive for dim CD2 (aberrant), CD11b (aberrant), CD13, CD33, CD34, CD38, CD117, HLA-DR, and dim nTdT (aberrant)"	FALSE	TRUE	NA	NA	NA	negative	0	negative			TP53 (p.V122Dfs*26; 87.5%)	CREBBP|NF1|TP53					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	TRUE	FALSE	FALSE	NA	FALSE	TRUE	0.939178617	3.205066262	0.672430985	3.136590123	5.899601259	-0.923451509	2.290576585	no	no	no	no	no	yes	no	0.459926707						
BA3162R	BA3162D	2740	Waves3+4	yes	yes	yes	yes	Male	Male	White			2		CBFB-MYH11	20	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11	20	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	-1	Alive	99	Alive	NA	50		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY,inv(16)(p13.1q22)[20]"	NA	NA	Evidence of a CBFB [inv(16)] gene rearrangement in 98% of the cells.	16	FALSE	"CD2(-), CD4(-), CD5(-), CD7(-), CD8(-),CD10(-), CD11b(dim +), CD13(dim +),CD14(dim +), CD15(dim+CD16(-), CD20(-), CD22(-), CD25(dim +), CD33(dim +), CD34(+), CD38(+), CD36(subset +), CD56(-), CD64(subset +), CD79a +)(-), CD123(dim +), MPO(dim +), TdT(-), and surface kappa lambda light chain(-).,"	TRUE	TRUE	NA	68.59	TRUE	negative	0	positive				KIT (Y418_R420>RW; MAF 10.2%)|NRAS (G12s; MAF45.4%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	5.143335632	5.783422865	4.682385721	4.960217595	7.183986361	-1.576683205	6.855214047	yes	yes	yes	yes	yes	no	yes	0.787890389						
BA3352R	BA3352D	2699	Waves3+4	yes	yes	yes	yes	Male	Male	White			2			73	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Refractory	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Dead	22	Dead-Disease	NA	90	94	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA	"CD34(-), CD13(predominantly -), CD33(+), CD38(partial +), CD45(dim +), CD56(variably +), CD64(partial dim +), CD117(+),HLA-DR(-), MPO(+), TdT(-), other myeloid and lymphoid antigens(predominantly -)."	FALSE	TRUE	NA	64.4	TRUE	positive	1.222222222	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	TRUE	6.745019897	3.73776361	2.573099734	2.80605986	5.636295267	0.808663201	1.773838516	yes	yes	no	no	no	yes	no	0.422181896						
BA3084R	BA3084D	2694	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1		KMT2A_re	22	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute myelomonocytic leukaemia	22	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HAM (Cytarabine, Mitoxantrone) + Midostaurin|Busulfan, Cyclophosphamide"	3	Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	-1	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	-1	Dead	328	Dead-Disease	0	92	91	0.9	0	9.8	1.8	0	0.1	22	35	2.5	0.71	M4	27.8	9.5	"46,XY,t(10;11)(p13;q23)[20]"	1186	102.2	"MLL: 88% of cells had a 1g/0r/2f signal pattern, where the lone green signal was small and the green component suggesting a disruption of MLL (11q23) within the green portion of  the probe. This result is consistent with MLL rearrangement and with the t(10;11) seen on metaphase analysis."	95	TRUE	"Immunophenotype 1(15% WBCs): dim CD4, variable CD13, CD33, bright  CD34, CD58, CD64, CD117, CD123, variable MPO  | Immunophenotype 2 (79% WBCs): dim CD4, CD11b, variable CD13, CD33, CD38, CD58, CD64, CD117, CD123"	FALSE	TRUE	7	82.99	TRUE	negative	0	negative				FLT3-D835 (MAF: 31%)|KRAS (p.G12D; MAF 4%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.14745815	1.159882037	-0.988728384	1.447019767	4.756916671	-1.443287764	2.36558501	no	no	no	no	no	no	no	0.295442891						
BA3169R	BA3169D	2662	Waves3+4	yes	yes	yes	yes	Female	Female	White			5		KMT2A_re	88	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Uterine Sarcoma	n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	88	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	5	Dead-Disease	NA	80	24	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XX,+8[4]/47,sl,add(10)(q22)[10]/89~94,sdlx2[cp3]/55,sl,+X,+6,+8,+ 8,+9,+13,+21,+22[2]/46,XX[1]"	NA	NA	MLL (KMT2A) rearrangement in 94% of 200 cells | gain of 8q22 sequence in 94% of 200 cells	NA	NA	"positive for CD11b, dim CD7, CD13, CD14, CD33, CD38, CD15, CD45, CD56, CD64 and HLA-DR"	TRUE	TRUE	NA	23.4	TRUE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	4.10392328	6.120110353	4.860426245	3.759325547	5.671271189	-0.000612478	4.020426385	yes	yes	yes	yes	no	yes	no	0.867938952						
BA3180R	BA3180D	2770	Waves3+4	yes	yes	yes	no	Male	Male	White			5			27	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	27	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	2	Standard Chemotherapy|Bone Marrow Transplant	2	"Fludarabine, Cyclophosphamide, Thiotepa, TBI|7+3 (Cytarabine, Idarubicin) plus Azacitidine"	2	Induction|Double Umbilical Cord Blood Transplant (DUCBT)	Complete Response	Standard Chemotherapy	-1	Bone Marrow Transplant	"Fludarabine, Cyclophosphamide, Thiotepa, TBI"	Double Umbilical Cord Blood Transplant (DUCBT)	-1	Alive	116	Alive	NA		60	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA		NA	NA	NA	NA	NA	positive	0.886792453	positive				FLT3-ITD|IDH2					no		Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	FALSE	1.756346932	2.571135775	0.604875403	2.829756115	5.077654647	0.456125459	2.487808788	no	no	no	no	no	yes	no	0.321984394						
BA3255R	BA3255D	2725	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			55	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	4	"7+3 (Cytarabine, Idarubicin)|HiDAC + Midostaurin|Decitabine, Sorafenib |Busulfan, Cyclophosphamide"	4	Allogeneic - Sibling|Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	"Decitabine, Sorafenib "	Salvage	61	Dead	272	Dead-Disease	0	90	80	0	2.6	9.6	22.6	5.2	0.4	21	25	3	0.9	M0	22.3	7.4	"46,XY[20] "	1037	85.8	Normal	234	TRUE	"dim partial CD4, dim partial CD7, dim CD11b, CD13, CD33,  partial CD34, CD38, CD58, dim CD71, CD117, CD123 and HLA-DR+ "	TRUE	TRUE	7.7	118.21	TRUE	positive	3	positive				DNMT3A (Splice site (start of intron 18; likely pathogenic); MAF 47%)|FLT3-ITD (p.E598delinsDYVDFREYE; MAF 60%)|NPM1 (p.W290fs*10; MAF 45%)|WT1 (p.D464N; MAF 46%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	TRUE	2.430680124	1.891315265	1.637454821	3.533388782	5.605796852	0.340080739	2.521438608	no	no	no	no	no	yes	no	0.606423531						
BA3438R	BA3438D	2834	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1		KMT2A_re	53	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)"	2	Induction|Re-induction	Refractory	Standard Chemotherapy	6	Standard Chemotherapy	"5+2 (Cytarabine, Idarubicin)"	Re-induction	4	Dead	65	Dead-Disease	3.5	95		1.7	NA	69.8	0.9	15.5	4.5	30	24	3.3	0.87	M1	25.1	8.4	"47,XY,der(5)t(5;17)(q12;q12),+8,+15,der(15)t(11;15)(q22;q24)dup(11)(q25q22)  ,del(16)(q22q24),-17,der(20;21)(p10;q10),+mar[16]/46,idem,der(10)t(10;11)(q  25;q23)t(5;11)(q12;q25),-mar[3]/46,XY[1] "	399	88.4	"EGR1: 90% of cells were missing a signal for EGR1 (5q31), consistent with  the der(5) seen on metaphase analysis.  | MLL (11q23):  97% of cells had two normal intact signals and a many other  intact signals per cells, suggesting amplification.  (On available metaphase  cells, there was clustering of amplified fused signals on two chromosomes:  in the first clone, amplified signals clustered on the der(15) and on the  marker chromosome; in the second clone, amplified signals clustered on the  der(15) and on the der(10).) | CBFB (16q22):  94% of cells were missing a signal for CBFB, consistent  with del(16q) as seen on metaphase. | RUNX1/RUNX1T1+CEP8: 92% of cells had three signals for chromosome 8 probes (CEP8 and RUNX1T1) and only one signal for RUNX1 (21q22), consistent with trisomy 8. Results with the RUNX1 probe on chromosome 21 suggest that the interpretation of the chrom results as der(20;21) may be more complicated."	23	TRUE	"CD4, dim CD20, dim CD11b, CD13, CD33, CD34, CD38, CD58,  variable CD64, partial dim CD117, MPO"	FALSE	TRUE	6.8	3.81	FALSE	negative	0	negative			TP53 (p.R248Q; 80.3%)	MLL |TP53 (p.R248Q; MAF 82%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	0.0226043	1.356321008	1.885307826	2.744259442	6.051520711	-2.44012195	2.704174995	no	no	no	no	no	no	no	0.356804108						
BA3431R	BA3431D	2647	Waves3+4	yes	yes	yes	yes	Female	Female	White			7			45	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	45	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	68	Alive	NA	69		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	46[XX]	NA	NA		NA	NA	"positive for CD11b, CD11c, CD14, CD64, CD33, CD38, HLA-DR and partial for CD13, CD15, cMPO"	FALSE	TRUE	NA	NA	NA	negative	0	positive				FLT3-TKD (MAF 1%)|NPM1 (MAF 39%)|PTPN11 (likely pathogenic)					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	2.856998521	3.809409837	3.579365566	4.565501714	6.500544402	-0.067402502	4.462655538	yes	yes	yes	yes	yes	yes	yes	0.891651129						
BA3197R	BA3197D	2738	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			47	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	10	Dead-Disease	0		95	0	0	1.7	0	0	0.1	190	80	3.4	0.83	M1	30.2	10.3		730	93.5	PML/RARA: Negative	22	TRUE	"partial CD13, CD33, CD38, partial CD56, CD58, CD117,  CD123, and MPO positive "	FALSE	TRUE	6.5	134.63	TRUE	positive	0.785714286	positive				FLT3-ITD (p.F605delinsTGSSDNEYFYVDFREYEYDLKWEF; MAF 46%)|IDH1 (p.R132G; MAF 47%)|NOTCH1 (p.E1555V; MAF 51%)|NPM1 (p.W288fs*12; MAF 50%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.339102202	1.400496911	1.567397786	2.697833452	4.803575886	-0.827405877	-0.231575701	no	no	no	no	no	yes	no	0.197818602						
BA3453R	BA3453D	2764	Waves3+4	yes	yes	yes	no	Female	Female	White			5			76	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Targeted Therapy - Kinase Inhibitor(s)	1	Decitabine	1	Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	Decitabine	Supportive/Palliative Care	9	Alive	19	Alive	NA	90	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA		NA	NA	"A large blastic population, positive for CD13, CD15, CD33, CD38, dim CD45, dim CD64, CD117, HLA-DR, and MPO"	FALSE	TRUE	NA	44.4	TRUE	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.609716319	3.042413784	3.555655758	2.284892989	6.277840771	0.821801311	5.215680434	no	no	yes	no	yes	yes	yes	0.654002007						
BA3308R	BA3308D	2772	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			78	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		n	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	78	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Supportive/Palliative Care|Targeted Therapy - Kinase Inhibitor(s)	4	AG-221|Imatinib|Midostaurin|Interferon	3	Salvage|Maintenance|Supportive/Palliative Care			NA	Targeted Therapy - Kinase Inhibitor(s)	AG-221	Salvage	191	Dead	319	Dead-Disease	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"47,XY,del(6)(q13),+8[8]/47,idem,-8,+13[2]/46,XY,del(13)(q14q22),del(20)(q11.2)[6]/46,XY[4] "	NA	NA	"RUNX1T1: 22/200 cells (11%) had a 3 red/ 2 green signal  pattern, reflecting an extra RUNX1T1 (8q21.3) signal, consistent with the  trisomy 8 clone observed in the metaphase karyotype | RUNX1: 18/200 cells (9%) had a 2  red/ 3 green signal pattern, reflecting an extra RUNX1 (21q22) signal. The  extra chromosome 21 material was not apparent in the G-banded karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion. | CEP8:  29/200 (14.5%) cells  scored with the CEP 8 probe had three signals, consistent with trisomy 8.  | D20S108/20p subtel: 6/200 cells (3%) had a 1 red/ 2 green signal pattern,  consistent with the deleted 20q in the metaphase karyotype. "	NA	NA		NA	NA	NA	NA	NA	negative	0	negative	RUNX1 (p.R162S; 84.5%)	ASXL1 (p.G646Wfs*12; 34.3%)	TP53 (p.X187_splice; 9.3%)	IDH2 (p.R140Q; MAF 45%)|KRAS (p.Q61R; MAF 5%)|NOTCH1 (p.P2412L; MAF 57%)|RUNX1 (p.R162S; MAF 74%)|SRSF2 (p.P95H; MAF 54%)|TP53 (Splice site; MAF 9%)		yes			yes	yes	Found	TRUE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	TRUE	TRUE	FALSE	NA	FALSE	FALSE	1.242680414	2.195311478	0.581773503	4.111448431	4.940687389	-2.221671142	2.265641923	no	no	no	yes	no	no	no	0.394652128						
BA3186R	BA3186D	2743	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			68	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	n	n	y	y	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	70	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Supportive/Palliative Care	3	"Fludarabine, Melphalan|Azacitidine|MiDAC"	3	Symptom Control|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor			NA	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	980	Dead-Disease	0	79	56	0	0	14.6	4.5	8.2	2.6	31	58	2.9	0.69		33.5	11.8	"45,XY,add(3)(p22),-7,t(8;22)(q11.2;q11.2),add(11)(q23),-13,-15,-16,  der(17)t(7;17)(q11.2;p11.2),+3mar[cp3]/44~46,sl+der(8)t(8;21)(q11.2;q11.2),  -18[cp15]/44,sl,-add(3)(p22),+10,+13,+15,-18,-3mar[2] "	3293	92.5	"MLL: 97/100 cells (97%) had the variant abnormal 0 red/ 1 green/1 yellow  signal pattern, reflecting MLL (11q23) rearrangement and previously  observed.  | TP53/CEP 17: 99/100 cells (99%) had a 1 red/ 2 green signal pattern,  reflecting TP53 deletion, previously observed and consistent with the  derivative 17 in the metaphase karyotype. | RUNX1T1/RUNX1: 93/100 cells (93%) had a 2-3 red/ 3-4 green signal pattern,  reflecting an extra copies of RUNX1T1 and RUNX1. There was no evidence for  RUNX1T1/RUNX1 fusion.  | CBFB: 96/100 cells (96%) had a single intact signal, reflecting CBFB  (16q22) loss and consistent with the monosomy 16 in the metaphase  karyotype.  | D7S486/ CEP 7: 99/100 cells (99%) had a 2 red/ 1 green signal pattern,  indicating loss of a chromosome 7 centromere signal with 7q material  attached to the derivative 17 in the metaphase karyotype.  | CEP 8: 66/100 cells (66%) had three signals, consistent with the clone  having an extra copy of the derivative 8. "	28	FALSE	"dim CD4, dim CD7, dim CD33, CD34, dim CD56, CD58, dim  CD123, CD117 and HLA-DR positive"	TRUE	TRUE	NA	49.48	TRUE	negative	0	negative			TP53 (p.R248W; 71.9%)	JAK2 (p.V617F; MAF 88%)|SF3B1 (p.G740V; MAF 41%)|TET2 (p.E692fs*8; MAF 40%)|TP53 (p.R248W; MAF 78%)	yes				yes	yes	Found	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	7.458669758	3.139900593	6.882992955	2.202007581	5.176998147	1.694555777	0.878502133	yes	no	yes	no	no	yes	no	0.524183573						
BA3280R	BA3280D	2648	Waves3+4	yes	yes	yes	no	Male	Male	White			5	N/A		51	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	51	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	n	y	y	n	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	-1	Alive	82	Alive	NA	80	85	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA		NA	NA	"positive for CD117, CD13, CD33, and HLA-DR. Roughly half of the blasts were positive for CD34, roughly half of the blasts showed aberrant dim expression of CD7, and roughly half of the cells showed aberrant dim expression of CD19."	TRUE	TRUE	NA	NA	NA	positive	0.136363636	positive				ASXL1|CEBPA|FLT3-ITD|NPM1|NRAS|PTPN11|STAG2					no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	FALSE	FALSE	TRUE	NA	FALSE	TRUE	1.177475595	3.042413784	0.23878428	3.972999486	5.596625022	0.725196498	0.643937104	no	no	no	yes	no	yes	no	0.402182799						
BA3318R	BA3318D	2593	Waves3+4	yes	yes	yes	yes	Female	Female				2			83	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Alive	13	Alive	NA	80		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX,-15,+dic(1;15)(p11;p11)[10]/47,idem,+11[10]"	NA	NA	67.5% of cells had an extra copy of MLL(11q23)	78	TRUE		NA	NA	NA	14.17	FALSE	negative	0	negative				IDH2 (p.172Arg>Lys)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	2.041877603	2.194521977	3.468562018	3.355942775	5.512416769	-3.034003292	1.953482863	no	no	yes	no	no	no	no	0.541050329						
BA3332R	BA3332D	2748	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		7			26	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	26	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin"	1	Induction	Complete Response	Standard Chemotherapy	8	Standard Chemotherapy	"7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin"	Induction	8	Alive	720	Alive	NA	41		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX"	NA	NA	Normal	NA	NA	"CD117(+) myeloid precursors comprise 26%of total events and are positive for dim CD7, CD13, CD33, CD38, CD117, HLA-DR, and cyMPO. They are negative for CD34. "	TRUE	TRUE	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	1.811757206	3.142212496	-0.130727984	3.324007032	5.582337795	-0.758732188	6.118052395	no	no	no	no	no	yes	yes	0.380901091						
BA3328R	BA3328D	2741	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|HiDAC|7+3 (Cytarabine, Idarubicin) plus Midostaurin"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	167	Dead-Treatment	0	95	86	0	32	13	0	6	0.8	15	25	3.5	0.98	M1	25.2	8.5	"46,XX[15]"	563	93	Normal	60	FALSE	"dim CD13, CD33, CD38, partial CD56, CD58, CD64, dim CD117, CD123 and MPO+"	FALSE	TRUE	7.4	59.23	TRUE	positive	0.754385965	positive				DNMT3A (p.R326L; MAF 47%)|FLT3-ITD (MAF 43%; mutant allelic ratio 0.74)|IDH2 (p.R140Q; MAF 47%)|NPM1 (p.W288fs*12; MAF 48%)					no		Found	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.477098644	3.399225424	2.324649572	4.644857775	6.062989253	-0.824696888	3.589444817	no	no	no	yes	yes	yes	no	0.562756241						
BA3142R	BA3142D	2612	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			54	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	54	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Other	3	"7+3 (Cytarabine, Idarubicin)|Decitabine, MGB453|MEC (Cytarabine, Etoposide, Mitoxantrone)"	3	Salvage|Induction|Re-induction	Refractory	Standard Chemotherapy	-1	Other	"Decitabine, MGB453"	Salvage	56	Dead	214	Dead-Disease	0		65	1.8	0.9	41.7	1.7	14.8	0	71	50	3.7	1.13	M1	22.6	8.1	"43,XY,add(5)(q11.2),add(9)(q12),add(10)(p11.2),-12,idic(12)(p11.2),t(14;14)  (q31;q32),-16,-17,add(17)(q21),add(19)(p13),-20,add(21)(p11.2),+mar[19]/46,  XY[1] "	185	89.7		23	FALSE	"CD13, dim CD33, CD34, CD38, CD117, dim CD123,  HLA-DR positive "	FALSE	TRUE	7.6	8.94	FALSE	negative	0	negative			TP53 (p.V216M; 78.5%)	TP53 (p.V216M; MAF 57%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	2.196033715	3.679910928	1.493354808	3.898748141	4.911936986	-2.099328339	2.724935193	no	yes	no	yes	no	no	no	0.48110755						
BA3333R	BA3333D	2746	Waves3+4	yes	yes	yes	yes	Male	Male	White			5			NA	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	n	n	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NA	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	2	Dead-Disease	NA	93		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XY[20]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	positive				FLT3-TKD (I836del; VAF 8%)|GATA2 (T358A;16%)|NPM1 (W288Cfs*12; VAF 46%)|SRSF2 (P95L; VAF 41%)|TET2 (A1344E; VAF 52%)|TET2 (R1440Tfs*38; VAF 47%)		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	2.907121591	2.949393646	0.253940584	2.671935251	4.851961831	-0.112757807	-0.43050765	yes	no	no	no	no	yes	no	0.404754753						
BA3225R	BA3225D	2658	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			65	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	65	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	1	"7+3 (Cytarabine, Idarubicin)"	1	Induction	UNKNOWN	Standard Chemotherapy	4	Standard Chemotherapy	"7+3 (Cytarabine, Idarubicin)"	Induction	4	Dead	16	Dead-Disease	NA	85		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M5	NA	NA		NA	NA	Normal	NA	NA	"Monocytic blast immunophenotype (75%):  CD11b, CD13, CD14, CD33, CD38, CD58, CD64, dim CD117, CD123, and dim HLA-DR+. | Myeloid blast immunophenotype (13%): dim CD13, CD33, CD38, CD58 dim CD117, dim CD123 and MPO+.           | Monoclonal plasma cell population immunophenotype (approximately10% involvement): CD138 and kappa+. "	FALSE	TRUE	NA	NA	NA	negative	0	positive				"GNA13 (p.T365S; MAF 46%)|NPM1 (p.W288fs*12; MAF 43%)|PHF6 (c.730-2A>G, Acceptor-splice-site mutation in intron 6; MAF 89%)|TET2 (c.3594+1G>T, Donor-splice-site mutation in intron 3; MAF 46%)|TET2 (p.D1242fs*11; MAF 42%)"					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	4.752010161	2.861265344	3.813035578	1.516603718	7.091190411	-2.613288524	0.645555631	yes	no	yes	no	yes	no	no	0.752104841						
BA3183R	BA3183D	2798	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			64	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	n		y	n	n	n	y	y	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	64	0	Post-Chemotherapy|Residual Disease	Residual	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	5	"Fludarabine, Melphalan|5+2 (Cytarabine, Idarubicin)|7+3 (Cytarabine, Idarubicin)|Azacitidine|Decitabine"	4	Consolidation|Induction|Supportive/Palliative Care|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	5	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	337	Dead-Treatment	0	51	65	0.9	NA	12.3	3.5	15.8	0.1	20	13	2.6	1.2		24.4	8.2	"46,XY[20]"	NA	103	Normal	46	TRUE	"CD13, CD33, CD38, CD58, CD117, CD123, partial MPO+"	FALSE	TRUE	6.5	15.38	FALSE	negative	0	positive				"ATM (p.H1136R; MAF 45%)|DNMT3A (p.R882H; MAF 46%)|IDH1 (p.R132H; MAF 27%)|IDH2 (p.D314V (Low allele frequency, subclonal), MAF 2%)|IDH2 (p.R140Q; MAF 18%)|KRAS (p.G12A; MAF 3%)|NPM1 (p.W288fs*12; MAF 49%)|U2AF1 (p.D208E; MAF 46%)"			yes		yes		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	0.872750258	1.397328316	-0.334928321	2.422475967	5.908410754	-0.49525152	5.319397189	no	no	no	no	no	yes	yes	0.383597965						
BA3397R	BA3397D	2674	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			79	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	y	Prostate Cancer	y	y	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	54	Dead-Disease	0	60	74	0	NA	10.7	22.9	9	0.4	22	27	2.2	1.36	M2	27.9	9.2	"44,XY,-3,-5,dic(10;12)(q26;p13),add(11)(p15),-17,+mar[20] "	219	97.9	"ETV6 (12p13): 93.5% of cells were missing a signal for ETV6, consistent with 12p deletion resulting from dic(10;12).  | CEP17: 98.5% of cells were missing a signal for CEP17, consistent with monosomy 17.  | PML/RARA: 189/200 cells (94.5%) were missing a signal for RARA (17q21.2)."	92	TRUE	"CD13, CD33, CD34, variable CD38, CD117, CD123, HLA-DR, partial MPO"	FALSE	TRUE	6.3	13.72	FALSE	negative	0	negative			TP53 (p.L194R; 86.6%)	TP53 (p.L194R; MAF 80%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	2.562577463	2.964675357	3.816959788	2.224894915	5.936506688	-0.067402502	5.706431736	no	no	yes	no	no	yes	yes	0.423309082						
BA3311R	BA3311D	2720	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			74	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	y	Prostate Cancer	y	y	y	y	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Therapy-related myeloid neoplasms	74	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	Unknown	Standard Chemotherapy	6	Standard Chemotherapy	Azacitidine	Induction	6	Dead	24	Dead-Disease	NA	21	8	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M2	NA	NA	"48,XY,+11,+13[17]/46,XY[3]"	NA	NA	"MLL (11q23):  161/200 cells (80.5%) had three intact signals for MLL, consistent with the trisomy 11 seen on metaphase analysis. "	NA	NA	"CD13, CD33, CD34, variable CD38, partial CD64, CD117, dim CD123, HLA-DR, partial TdT. "	FALSE	TRUE	NA	NA	NA	negative	0	negative				CBLB (p.V581M; MAF 52%)|DNMT3A (p.V877fs*4; MAF 40%)|MLL (Partial tandem duplication (exon 9/exon 3) )|NRAS (p.G12D; MAF 14%)|U2AF1 (p.S34F; MAF 43%)|WT1 (p.R353fs*15; MAF 26%)|WT1 (p.S364*; MAF 25%)			yes		yes		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	FALSE	6.518633362	7.086715234	4.125761549	4.502099476	8.040607806	-0.286763973	6.330027942	yes	yes	yes	yes	yes	yes	yes	0.822026286						
BA3422R	BA3422D	2636	Waves3+4	yes	yes	yes	yes	Female	Female	Black			5			72	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	72	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	-1	Alive	521	Alive	NA	97		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[20]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	negative	0	positive				GATA2 (A372T; VAF 48%)|NPM1 (W288Cfs*12; VAF 39%)|TET2 ( E843*; VAF 47%)|TET2 (T1726Lfs*19; VAF 51%)					no		Found	FALSE	TRUE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	FALSE	TRUE	1.20914253	1.586439704	-0.423494402	1.998665413	3.696690741	-0.311019674	-1.500222088	no	no	no	no	no	yes	no	0.298116815						
BA3415R	BA3415D	2825	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			79	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	79	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	14	Dead-Disease	0	65	15	0	NA	25.2	0.9	24.3	1.7	NA	NA	NA	NA	M2	23.9	8.3	"49~50,XX,+X,-3,del(5)(q13q33),der(7)t(3;7)(q11.2;q21),+8,-9,  del(17)(p11.2),+18,+21,der(21)t(9;21)(q22;q22)X2,+22,+1~2mar[cp20]"	NA	92.6	"EGR-1/ D5S23, D5S721:  97/100 cells (97%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | CEP 8:  179/200 cells (89.5%) had three signals, consistent with the trisomy 8 in the metaphase karyotype.  | RUNX1T1/RUNX1:  92/100 cells (92%) had a 3 red/ 3 green signal pattern, reflecting the extra copies of chromosome 8 and chromosome 21 in the metaphase karyotype.  There was no evidence for RUNX1T1/RUNX1 fusion.  | BCR/ABL:  95/100 cells (95%) had a 3 red/ 2-3 green signal pattern, reflecting the extra copies of chromosome 9q and chromosome 22 in the metaphase karyotype.  There was no evidence for BCR/ABL fusion. | DEK/NUP214:  184/200 cells (92%) had a 3 red/ 2 green signal pattern, reflecting an extra copy of NUP214 (9q34),consistent with the extra chromosome 9q material in the metaphase karyotype.  There was no evidence for DEK/NUP214 fusion.  | TP53/CEP 17:  93/100 cells (93%) had a 1 red/ 2 green signal pattern, reflecting TP53 deletion and consistent with the deleted chromosome 17 short arm in the metaphase karyotype. "	31	FALSE	"partial CD7, CD13, CD33, CD34, CD38, CD56,  CD117, HLA-DR, MPO"	TRUE	TRUE	NA	11.5	FALSE	negative	0	negative			TP53 (p.R196*; 89.6%)	CBL (p.L209V; MAF 92%)|FLT3 (p.L198F; MAF 52%)|TP53 (p.R196*; MAF 80%)					no		Found	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	3.284332729	4.443717515	2.60644037	2.242712282	5.14613707	1.316669546	5.397803331	yes	yes	no	no	no	yes	yes	0.455513403						
BA3270R	BA3270D	2814	Waves3+4	yes	yes	yes	yes	Female	Female	White	DECLINED		1			47	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	7	Standard Chemotherapy	HiDAC	Consolidation	100	Alive	432	Alive	0	18	9	0	NA	13.3	16.8	46	0.6	16	23	2.7	0.7		23.4	7.4	"46,XX[20"	470	98.7	Normal	189	TRUE		NA	NA	6.1	65.11	TRUE	negative	0	positive				DNMT3A (p.R882C; MAF 46%)|NPM1 (p.W288fs*12; MAF 48%)|NRAS (p.G12D; MAF 46%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	1.156033745	6.356703151	2.608418792	3.697153947	7.410087978	0.648604039	7.190649758	no	yes	no	no	yes	yes	yes	0.6998325						
BA3324R	BA3324D	2625	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			60	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	60	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"Decitabine, MGB453|7+3 (Cytarabine, Idarubicin) plus Sorafenib"	2	Induction|Re-induction	Complete Response	Standard Chemotherapy	15	Standard Chemotherapy	"Decitabine, MGB453"	Re-induction	84	Dead	200	Dead-Disease	0	85	72	0.9	NA	14.6	32.8	4.3	0.1	12	37	2.5	1.2	M1	27.5	9.1	"46,XY,del(5)(q13q34),add(7)(q11.2),+11,add(12)(p13),-16, add(17)(p11.2)[cp17]/46,idem,add(4)(q35)[4] "	1498	107.4	"EGR-1/ D5S23, D5S721:  193/200 cells (96.5%) had a 1 red/ 2 green signal pattern, indicating a deleted 5q, consistent with the metaphase karyotype.  | D7S522/ CEP 7:  191/200 cells (95.5%) had a 1 red/ 2 green signal pattern, indicating deleted 7q, consistent with the metaphase karyotype.  | MLL:  150/200 cells (75%) had three intact signals, consistent with the trisomy 11 in the metaphase karyotype. An additional 18 cells (9%) had four intact MLL signals.  There was no evidence for MLL rearrangement.  | CBFB:  195/200 cells (97.5%) had a single intact signal, consistent with the monosomy 16 in the metaphase karyotype.  There was no evidence for CBFB rearrangement. "	133	TRUE	"variable CD4, dim CD7, dim CD11b, CD13, variable CD14, variable CD15, CD33, variable CD34, CD38, dim CD56, partial CD64, CD117, HLA-DR, MPO positive."	TRUE	TRUE	7.1	62.69	TRUE	negative	0	negative			TP53 (p.L194R; 88.3%)	PTPN11 (p.S502P; MAF 34%)|TP53 (p.L194R; MAF 87%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	3.616243408	3.465532596	3.495979988	2.803035574	6.644646271	-1.054173263	6.61700352	yes	no	yes	no	yes	no	yes	0.59568343						
BA3335R	BA3335D	2602	Waves3+4	yes	yes	yes	yes	Female	Female	White			5			56	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	FavorableOrIntermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	56	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	1	"Venetoclax (ABT-199), Azacitidine"	1	Induction	Refractory	Standard Chemotherapy	30	Standard Chemotherapy	"Venetoclax (ABT-199), Azacitidine"	Induction	30	Alive	514	Alive	NA	80		NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA	"46,XX[22]"	NA	NA	Normal	NA	NA		NA	NA	NA	NA	NA	positive	NA	positive				DNMT3A (P38SRfs*22; VAF 22%)|FLT3-ITD|GATA2 (T354_T355 insF; VAF 15%)					no		Found	FALSE	FALSE	TRUE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	TRUE	2.550005513	5.277244153	1.821369594	3.163668633	5.616270358	-1.784790142	0.49238161	no	yes	no	no	no	no	no	0.5416015						
BA3297R	BA3297D	2657	Waves3+4	yes	yes	yes	yes	Female	Female	Asian	NON-HISPANIC		1			46	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	46	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	-1	Standard Chemotherapy	HiDAC	Consolidation	102	Alive	1159	Alive	0	81	84	0	NA	12.1	16.1	8.9	0.2	45	29	2.9	0.41	M2	30	9.9	"46,XX[20] "	NA	95.2	Normal	220	TRUE	"dim CD13, CD33, CD38, CD117 and MPO+"	FALSE	TRUE	7.4	61.13	TRUE	negative	0	positive				IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 40%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	1.180017992	2.018354671	-0.303521767	3.645217725	5.792001118	-4.288398574	2.244244934	no	no	no	no	no	no	no	0.46852274						
BA3227R	BA3227D	2650	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			70	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	70	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	4	"MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate|Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	3	Allogeneic - Sibling|Consolidation|Induction	Refractory	Standard Chemotherapy	6	Bone Marrow Transplant	"Bu/Flu/TBI (Busulfan, Fludarabine, Total Body Irradiation)"	Allogeneic - Sibling	-1	Alive	1188	Alive	0	95	96	0	NA	2.7	0	0	0.2	163	68	3.1	0.78	M1	16.8	5.6	"46,XX[20]"	469	106.3	Normal	45	TRUE	"dim CD13, CD33, CD38, CD117, and MPO +"	FALSE	TRUE	7.6	159.73	TRUE	positive	0.149425287	positive				ATM (p.K1454N; VAF 49%)|BCL6 (p.A321V; VAF 49%)|FLT3-ITD (Allelic ratio: 0.32)|IDH2 (p.R140Q; VAF 49%)|NOTCH2 (p.P2377L; VAF 48%)|NPM1 (p.W288fs*12; VAF 69%)|NRAS (p.A59T; VAS 3%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	2.357223898	0.497480704	-1.170291732	2.484498674	4.014407252	-3.311376794	-1.290112818	no	no	no	no	no	no	no	0.146730412						
BA3293R	BA3293D	2685	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			53	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	y	Cervical Cancer	y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	55	0	Relapse|Post-Chemotherapy|Post-Transplant	Relapse	Leukapheresis	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Busulfan, Cyclophosphamide"	3	Consolidation|Induction|Allogeneic - Mismatched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Mismatched Unrelated Donor	-1	Dead	835	Dead-Disease	NA		90	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M4	27.2	8.8	"46,XX[20]"	NA	97.5		34	TRUE	"variable CD11b, CD13, CD33, dim CD123, partial HLA-DR, dim/partial MPO"	FALSE	TRUE	NA	43.57	TRUE	positive	11.5	positive									no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.254618437	0.764705649	8.042424664	2.640801758	5.128770175	-2.455611746	0.824641148	no	no	yes	no	no	no	no	0.403691638						
BA3315R	BA3315D	2812	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			57	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with myelodysplasia-related changes	57	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	1	Standard Chemotherapy	3	"7+3 (Cytarabine, Idarubicin)|HiDAC|Decitabine"	3	Salvage|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	Decitabine	Salvage	0	Dead	127	Dead-Disease	0	83	12	0.9	NA	69.9	0.9	8.8	7.1	72	49	3.2	0.9	M1	21.5	6.9	"69~82<3n>,X,-X,+4,+8,+8,+8,+8,+8,+8,-9,+10,-12,-15,-17,+18,+20,+21,+22,+1~2mar[cp13]/47~48,X,-X,+4,+6,+8,+8,-9,-16,-17,+mar[cp3]/92,XXXX[2]/46,XX[2]"	1498	89.2	BCR/ABL: 38% of cells had three signals for BCR and another 18% of cells had three signals for BCR and for ABL/ASS.  | PML/RARA: 6% of cells had three signals for both probes. 	32	TRUE	"MPO, CD33, CD43, CD45, and CD117 positive"	FALSE	TRUE	6.1	3.65	FALSE	negative	0	negative			TP53 (p.V143M; 44.0%)	BCL6 (p.R459C; VAF 44%)|IDH2 (p.R172K; VAF 14%)|NRAS (p.Q61K; VAF 12%)|TP53 (p.V143M; VAF 32%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	2.407234345	4.069250368	1.038589712	5.152070504	7.000109985	-1.620833694	4.784670382	no	yes	no	yes	yes	no	yes	0.568342023						
BA3386R	BA3386D	2654	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			63	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	4	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal|Targeted Therapy - Kinase Inhibitor(s)	5	"Fludarabine, Melphalan|Gilteritinib or Placebo|MIDAC, Midostaurin|7+3 (Cytarabine, Idarubicin) plus Midostaurin|Methotrexate"	5	Consolidation|Induction|CNS|Maintenance|Allogeneic - Matched Unrelated Donor	Refractory	Standard Chemotherapy	6	Targeted Therapy - Kinase Inhibitor(s)	Gilteritinib or Placebo	Maintenance	734	Alive	1046	Alive	NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	M1	27.9	9.2	"46,XX[20]"	NA	87.2		135	TRUE	"dim CD7, partial CD11b, dim CD13, variable CD25, CD33, partial CD34, CD117, HLA-DR, and MPO positive"	TRUE	TRUE	NA	40.36	TRUE	positive	32.33333333	positive				DNMT3A (p.G543C; VAF 49%)|FLT3-ITD (VAF 76%; VAR 13.3)|NPM1 (p.W288fs*12; VAF 45%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	3.602616205	0.252190376	5.292327329	0.395932963	6.041929479	0.295993387	-1.057221694	yes	no	yes	no	no	yes	no	0.292318333						
BA3176R	BA3176D	2765	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			53	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	53	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	3	"HiDAC|Vyxeos (Daunorubicin, Cytarabine - liposomal)|MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin"	3	Consolidation|Salvage|Induction	Complete Response	Standard Chemotherapy	4	Standard Chemotherapy	"MEC (Cytarabine, Etoposide, Mitoxantrone) plus Midostaurin"	Salvage	-1	Dead	326	Dead-Disease	0	34	0	0.5	NA	46.5	2.7	50.3	0	10	11	3.3	0.63	M2	23.4	8.2	"47,XX,+4[3]/46,XX[17] "	NA	104.9	Normal	40	FALSE	"dim CD7, CD13, CD33, CD38, CD117 and HLA-DR+"	TRUE	TRUE	7	1.87	FALSE	negative	0	positive				DNMT3A (p.N879D; VAF 37%)|NPM1 (p.W288fs*12; VAF 28%)|PTPN11 (p.A461T; VAF 3%)|RAD21 (p.E534*; VAF 4%)|SMC1A (p.R496H; VAF 31%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.902424558	4.69576436	0.962688765	3.854289573	5.958911233	0.028593421	7.296871226	no	yes	no	yes	no	yes	yes	0.413632945						
BA3258R	BA3258D	2739	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			66	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	66	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	5	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate"	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1130	Alive	0.2	90		0	NA	8.1	85.9	4	0.1	30	25	2.8	1.17	M5	30.8	10.1	"46,XX[20]"	363	86.8	Normal	130	TRUE	"partial CD7 and CD9, CD11b, dim CD13, CD14, CD15, CD33, CD38, partial CD56, CD64, HLA-DR+"	TRUE	TRUE	6.1	145.55	TRUE	negative	0	positive				DNMT3A (p.N797D; VAF 46%)|IDH2 (p.R140Q; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.Q61P; VAF 47%)					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	0.230814198	2.736165519	2.246470288	2.726861855	6.977312527	-2.618821697	2.948830076	no	no	no	no	yes	no	no	0.709772116						
BA3446R	BA3446D	2739	Waves3+4	no	no	no	no	Female	Female	White	NON-HISPANIC		1			66	TRUE	TRUE	FALSE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	67	366	Relapse|Post-Chemotherapy	Relapse	Peripheral Blood	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Intrathecal	5	"Fludarabine, Melphalan|7+3 (Cytarabine, Idarubicin)|MiDAC|HiDAC, Mitoxantrone, CPI-613|Methotrexate"	4	Consolidation|Induction|Re-induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Alive	1130	Alive	0	26		0	NA	7.9	21.1	22.8	0.1	35	39	2.7	0.66	M5	33.8	10.6	"46,XX,del(14)(q21q31)[20] "	775	90.1	Normal	14	FALSE	"Myeloid blasts: CD13, CD33, CD38, CD117, HLA-DR. | Blasts with monocytic features: CD11b, dim CD13, CD15, CD33, CD38, CD64, HLA-DR  "	FALSE	TRUE	5.7	39.23	TRUE	negative	0	positive				BCOR (p.E1093K; VAF 48%)|DNMT3A (p.N797D; VAF 46%)|FAT4 (p.D1836N; VAF 41%)|IDH2 (p.R140Q; VAF 47%)|KMT2D (p.P647T; VAF 67%)|NPM1 (p.W288fs*12; VAF 43%)|NRAS (p.Q61P; VAF 46%)|RBBP6 (p.P1416A; VAF 51%)					no		Found	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	0.962688765	3.40936163	0.986902066	2.294287283	6.606345231	-0.534916744	6.172970101	no	no	no	no	yes	yes	yes	0.641676721						
BA3390R	BA3390D	2744	Waves3+4	yes	yes	yes	yes	Male	Male				3			NA	FALSE	unknown	unknown	unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NA	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	0		NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA		NA	NA	NA	NA	NA	negative	0	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	FALSE	NA	TRUE	TRUE	2.316535318	3.763673587	3.450030757	3.538263063	7.146870014	-4.03086008	3.573747573	no	yes	yes	no	yes	no	no	0.847366757						
BA3136R	BA3136D	2649	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1		KMT2A_re	47	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	Adverse	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	Acute monoblastic and monocytic leukaemia 	47	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|HiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	HiDAC	Consolidation	133	Alive	529	Alive	0	95	60	0	NA	18.5	0	3.4	0.2	100	142	2.2	0.92	M5	23.7	8.2	"46,XY,t(10;11)(p12;q23)[8]/45,sl,-Y[12]"	3738	100.9	"86/100 cells (86%) had the abnormal 1 red/ 1 green/1 yellow signal pattern, reflecting MLL (11q23) rearrangement and consistent with the 10;11 translocation observed in the metaphase karyotype. "	32	TRUE	"dim CD4, CD9, CD11b, CD15, CD33, CD38, partial CD56, CD64, partial CD117, and partial HLA-DR+"	FALSE	TRUE	6.7	12.35	FALSE	negative	0	negative				FLT3 (p.I836del; VAF 3% (in frame deletion in the tyrosine kinase domain))|MLL (Partial tandem duplication (exon 11/3 breakpoint) )					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	4.179789841	2.326749366	-0.926284489	4.507864603	7.181545546	-3.993048051	6.366952257	yes	no	no	yes	yes	no	yes	0.529049778						
BA3234R	BA3234D	2688	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			75	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	75	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	1	Azacitidine	1	Induction	UNKNOWN	Standard Chemotherapy	8	Standard Chemotherapy	Azacitidine	Induction	8	Dead	91	Dead-Disease	0	80		0	NA	4.4	77.4	11.3	0.1	52	29	2.4	2.78	M5	31.4	10.1	"46,XY[20]"	747	99.1	Normal	39	TRUE	"Monocytic population (about 80%) : dim CD4, dim CD9, CD11b, partial CD13,  partial CD14, CD15, subset CD16, CD33, CD38, CD56, CD64, and HLA-DR. | Myeloid blasts phenotype (8%): CD33, CD56, CD117, HLA-DR, and MPO"	FALSE	TRUE	5.9	84.29	TRUE	negative	0	positive				NPM1 (p.W288fs*12; VAF 24%)|SRSF2 (p.P95R; VAF 48%)|TET2 (p.R506*; VAF 95%)		yes			yes		Found	FALSE	TRUE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	TRUE	2.261333777	4.308013345	3.732390207	1.685176012	7.065966362	-0.722823053	2.736165519	no	yes	yes	no	yes	yes	no	0.768492021						
BA3454R	BA3454D	2679	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			82	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	14	Dead-Disease	0	50	50	0	NA	11	5	35	0.3	22	35	3.2	0.8	M2	29.4	9.4	"46,XX[20] "	574	98	Normal	71	TRUE	"CD13, CD33, CD117, and MPO"	FALSE	TRUE	5.9	87.73	TRUE	positive	0.960784314	positive				DNMT3A (p.R882C; VAF 48%)|FLT3-ITD (VAF 44%; Allelic ratio 0.77)|NPM1 (p.W288fs*12; VAF 48%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.262913855	1.539016813	6.188149436	3.515946526	5.985890216	-0.816169203	1.13465748	no	no	yes	no	no	yes	no	0.439347493						
BA3083R	BA3083D	2692	Waves3+4	yes	yes	yes	yes	Female	Female				3			NA	FALSE	unknown	unknown	unknown	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	NonInitial	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	57	0	Unknown	Unknown	Peripheral Blood	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Unknown	0		NA			NA	NA	NA	NA	NA	NA	NA	NA	NA	NA		NA	NA		NA	NA		NA	NA		NA	NA	NA	NA	NA	positive	5.666666667	positive									no		Found	FALSE	FALSE	FALSE	FALSE	NA	FALSE	FALSE	FALSE	FALSE	TRUE	NA	FALSE	FALSE	1.36067003	3.333737476	3.184847938	1.560156281	6.924992481	-0.180095332	6.459912266	no	no	yes	no	yes	yes	yes	0.520927318						
BA3266R	BA3266D	2672	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			83	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	83	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	28	Dead-Disease	0.9	75	52	0	NA	9.4	14.5	27.3	0.2	19	24	2.7	0.77	M2	20.5	6.5	"46,XX[20]"	333	95.8		273	TRUE	"dim CD4, CD7, partial CD9, CD13, CD25, CD33, partial CD34, CD38, CD117, CD123, HLA-DR and MPO-positive"	TRUE	TRUE	7	44.85	TRUE	positive	0.587301587	positive				BRAF (p.S87N; VAF 52%)|DNMT3A (p.R882C; VAF 47%)|FLT3-ITD (Allelic ratio: 0.464; VAF 31.7%)|IDH1 (p.R132H; VAF 32%)|IDH2 (p.R140Q; VAF 3%)|NPM1 (p.W288fs*12; VAF 42%)					no		Found	TRUE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.930534563	3.132660267	-0.069657965	3.39814496	5.947571694	-0.649189872	4.088367032	no	no	no	no	no	yes	no	0.533318595						
BA3119R	BA3119D	2778	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			61	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	61	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	1	Standard Chemotherapy	2	"7+3 (Cytarabine, Idarubicin)|MiDAC"	2	Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Standard Chemotherapy	MiDAC	Consolidation	101	Alive	784	Alive	0.8	90	65	0	NA	30.2	3.1	6.2	5.3	21	13	3.4	0.5	M1	31.3	10.8	"46,XX[20] "	NA	95.7	Normal	104	TRUE	"CD33, CD38, CD117, MPO positive"	FALSE	TRUE	7.7	4.68	FALSE	negative	0	positive				ASXL1 (p.L1395V; VAF 50%)|IDH1 (p.R132H; VAF 45%)|KMT2D (p.R3167W; VAF 48%)|NPM1 (p.W288fs*12; VAF 48%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	1.923986914	1.637454821	-1.173606791	3.678995048	3.865404352	-2.52260439	-1.030400299	no	no	no	no	no	no	no	0.154983267						
BA3219R	BA3219D	2731	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			73	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	73	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Leukapheresis	y	y	y	y	y	y	1	Standard Chemotherapy	1	Cytarabine	1	Induction	Refractory	Standard Chemotherapy	1	Standard Chemotherapy	Cytarabine	Induction	1	Dead	4	Dead-Disease	0.4	90		0.4	NA	13.9	80	1.8	0.1	130	186	2.1	6.6	M5	17.8	6	"46,XY[15]"	1072	89.4	Normal	35	TRUE	"dim CD9, CD11b, variable CD13, partial CD14, dim CD15, dim CD16, CD33, CD38, dim CD56, CD64, CD123, and HLA-DR"	FALSE	TRUE	6.3	104.23	TRUE	negative	0	positive				CCND1 (p.R245W; VAF 48%)|DNMT3A (p.P633R; VAF 46%)|NPM1 (p.W288fs*12; VAF 46%)|NRAS (p.G13D; VAF 6%)|PTPN11 (p.T73I; VAF 33%)|TET2 (p.N926fs*28; VAF 16%)					no		Found	FALSE	TRUE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	2.398131803	3.109368232	2.3905136	4.262866018	6.373585661	-3.458680576	0.609653767	no	no	no	yes	yes	no	no	0.760460879						
BA3310R	BA3310D	2716	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			82	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		n	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	82	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	0		0		0				NA	NONE	NONE	NONE	NA	Dead	17	Dead-Disease	0	90	70	0	NA	1.7	0	16.7	0.2	11	38	1.9	0.7	M1	25.7	7.8	"46,XY[20]"	421	88.6	Normal	23	TRUE	"dim CD13, CD33, CD117 and MPO"	FALSE	TRUE	6.4	44.35	TRUE	negative	0	positive				CBL (p.G838V; VAF 48%)|CREBBP (p.N1615S; VAF 48%)|FLT3 (p.D839G; VAF 6%)|FLT3 (p.N676K; VAF 2%)|FLT3-ITD (Allelic ratio 0.01)|IDH2 (p.R140Q; VAF 46%)|KIT (p.D816V; VAF 4%)|KMT2D (p.F4579S; VAF 49%)|NPM1 (p.W288fs*12; VAF 46%)|SRSF2 (p.P95_R102del; VAF 45%)		yes			yes		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	2.583768981	4.769951631	0.483801055	2.236016563	4.343078332	-1.296592903	2.455968127	no	yes	no	no	no	no	no	0.299014644						
BA3200R	BA3200D	2665	Waves3+4	yes	yes	yes	yes	Female	Female	Asian	NON-HISPANIC		1			76	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	76	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Targeted Therapy - Other	2	"SY-1425 (Tamibarotene) plus Azacitidine|Ruxolitinib, Venetoclax"	2	Salvage|Induction	Complete Response i	Targeted Therapy - Other	357	Standard Chemotherapy	"Ruxolitinib, Venetoclax"	Salvage	37	Dead	425	Dead-Disease	NA		predominant	NA	NA	NA	NA	NA	0.1	NA	NA	NA	0.56	M1	21.8	7.3	"46,XX[8]"	411	97.3	Normal	10	FALSE	"CD33, CD38, CD56, CD117, and cMPO positive"	FALSE	TRUE	NA	97.67	TRUE	negative	0	positive				NPM1 (p.W288fs*12; VAF 50%)|PHF6 (p.R274*; VAF 45%)|PRDM1 (p.P467L; VAF 48%)|TET2 (p.H1382R; VAF 50%)|TET2 (p.K1720*; VAF 48%)					no		Found	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	3.081389854	1.744206884	-0.874344283	3.848664311	4.56407532	-3.254984414	-2.077222414	yes	no	no	yes	no	no	no	0.228363118						
BA3146R	BA3146D	2776	Waves3+4	yes	yes	yes	yes	Male	Male	White	NON-HISPANIC		1			42	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	42	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HIDAC + Gemtuzumab Ozogamicin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide"	3	Allogeneic - Sibling|Consolidation|Induction	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Sibling	-1	Dead	140	Dead-Treatment	0	70		1	NA	22	30	5	0	NA	NA	NA	0.95	M2	23.6	8	"46,XY[20]"	1811	98.7	Normal	18	TRUE	"CD7, CD13, CD25, CD33, partial CD34, CD117, dim CD123, HLA-DR, and MPO."	TRUE	TRUE	NA	22.79	TRUE	positive	0.176470588	positive				DNMT3A (p.R882H; VAF 45%)|FLT3-ITD (allelic ratio 0.85; VAF 45.9%)|NPM1 (p.W288fs*12; VAF 69%)					no		Found	FALSE	FALSE	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.696432296	1.01268719	1.038589712	2.717494698	6.111189099	-0.725312818	1.507099664	no	no	no	no	yes	yes	no	0.531728016						
BA3376R	BA3376D	2781	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1	N/A		58	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	58	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	3	Standard Chemotherapy|Bone Marrow Transplant|Targeted Therapy - Other	4	"Gilteritinib or Placebo|HiDAC + Midostaurin|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin|Busulfan, Cyclophosphamide"	4	Allogeneic - Sibling|Consolidation|Induction|Maintenance	Complete Response	Standard Chemotherapy	6	Targeted Therapy - Other	Gilteritinib or Placebo	Maintenance	-1	Alive	803	Alive	0.9	91		0	NA	4.3	1.7	1.7	0.2	49	90	2.8	0.69	M1	19.7	6.5	"46,XX[20]"	1122	98	Normal	26	TRUE	"CD11b, CD13, CD33, variable CD34, CD38, CD117, CD123, and MPO positive"	FALSE	TRUE	6.9	145	TRUE	positive	1.040816327	positive				CEBPA (p.G242S; VAF 47%)|FLT3-ITD (allelic ratio 1.03; VAF 51%)|NPM1 (p.W290fs*10; VAF 49%)|SYNE1 (p.A2715G; VAF 50%)					no		Found	FALSE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.535019163	1.095167045	4.127338634	1.78469624	5.63016664	0.495809485	2.007637126	no	no	yes	no	no	yes	no	0.407669798						
BA3375R	BA3375D	2749	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			63	TRUE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Intermediate	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	63	1	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Peripheral Blood	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"Fludarabine, Melphalan|MiDAC|7+3 (Cytarabine, Daunorubicin) plus Gemtuzumab Ozogamicin plus Midostaurin"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	7	Bone Marrow Transplant	"Fludarabine, Melphalan"	Allogeneic - Matched Unrelated Donor	-1	Dead	171	Dead-Treatment	0.8	95	85	0.8	NA	9.2	2.3	4.6	0.3	NA	NA	NA	0.64	M1	26.9	8.8		476	94.1	Normal	30	TRUE	"dim CD13, CD33, CD117 and MPO-positive"	FALSE	TRUE	NA	62.54	TRUE	positive	0.754385965	positive				CHD2 (p.P1353L; VAF 50%)|CHEK2 (p.T410fs*15; VAF 51%)|FLT3 (p.N676K; VAF 4%)|FLT3-ITD (p.F594delinsLPSDNEYFYVDF (33-nucleotide internal tandem duplication); allelic ratio 0.85; VAF 46%)|IDH1 (p.R132S; VAF 47%)|KMT2A (p.F798L; VAF 49%)|NPM1 (p.W288fs*12; VAF 48%)|PLCG2 (p.Y206F; VAF 50%)					no		Found	TRUE	FALSE	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.062011926	2.168790458	1.653275016	3.846960485	5.611759574	-0.991836124	1.894709615	no	no	no	yes	no	no	no	0.358042922						
BA3385R	BA3385D	2594	Waves3+4	yes	yes	yes	yes	Female	Female	White	NON-HISPANIC		1			50	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	n		y	n	n	n	n	n	n	n	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	Favorable	ACUTE MYELOID LEUKAEMIA (AML) AND RELATED PRECURSOR NEOPLASMS	AML with mutated NPM1	50	0	Initial Acute Leukemia Diagnosis	Initial Diagnosis	Bone Marrow Aspirate	y	y	y	y	y	y	2	Standard Chemotherapy|Bone Marrow Transplant	3	"HiDAC|7+3 (Cytarabine, Daunorubicin) plus Crenolanib|Busulfan, Cyclophosphamide"	3	Consolidation|Induction|Allogeneic - Matched Unrelated Donor	Complete Response	Standard Chemotherapy	6	Bone Marrow Transplant	"Busulfan, Cyclophosphamide"	Allogeneic - Matched Unrelated Donor	-1	Dead	264	Dead-Disease	0	88		0	NA	23.5	48.7	9.5	0.1	20	14	2.9	0.65	M4	20.5	6.8	"46,XX[20]"	409	97.2	Normal	29	FALSE	"Myeloid blasts immunophenotype:  CD7, partial CD13, CD33, partial CD34, CD117, HLA-DR and MPO | Monoblasts immunophenotype: dim CD4, CD11b, partial CD13, CD14, CD15, bright CD33, CD64, HLA-DR"	TRUE	TRUE	6.9	31.8	TRUE	positive	0.492537313	positive				DNMT3A (p.S714C; VAF 43%)|FLT3-ITD (p.E596delinsQVTGSSDNEYFYVDFRE (48-nucleotide internal tandem duplication); VAR 0.79; VAF 44%)|NPM1 (p.W288fs*12; VAF 44%)|WT1 (p.S381fs*4; VAF 43%)					no		Found	FALSE	FALSE	TRUE	FALSE	FALSE	FALSE	FALSE	FALSE	FALSE	TRUE	TRUE	FALSE	FALSE	1.907788417	3.923280222	2.454556883	4.1566116	6.478138032	-1.036537236	5.731709462	no	yes	no	yes	yes	no	yes	0.58740853						